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Abstract 
Atherosclerosis, a chronic inflammatory disorder of the vasculature, is one of 
the major causes of cardiovascular disease and is responsible for most deaths in 
western societies. The disease is characterised by a number of steps that occur 
during the lifespan of an individual, including fatty streak formation, development of 
complex lesions containing a fibrous cap, and thinning and rupture of such plaques 
leading to thrombosis and clinical complications of this disease. Macrophages play 
key roles during all stages of this disease such as foam cell formation, amplification of 
the inflammatory response and control of plaque stability. The actions of 
macrophages during this disease are regulated by cytokines present in atherosclerotic 
lesions such as interferon-γ (IFN-γ), tumour necrosis factor-like protein 1A (TL1A) and 
interleukin-17 (IL-17). 
 Statins are widely used for the primary and secondary prevention of 
atherosclerosis and its complications because of their ability to inhibit cholesterol 
biosynthesis and, thereby, plasma levels of pro-atherogenic low density lipoprotein. 
However, statins have actions beyond lowering cholesterol levels, the so-called 
pleiotropic effects, and includes acting in an anti-inflammatory manner. Unfortunately, 
the anti-inflammatory effects of statins are not fully understood and therefore formed 
the focus of studies in this thesis using a combination of human macrophage THP-1 
cell line, primary cultures of human monocyte-derived macrophages and mouse 
RAW264.7 macrophage cell line. 
 Simvastatin generally acted in an anti-inflammatory manner in macrophages in 
relation to the expression of several pro-atherogenic genes, such as monocyte 
chemoattractant proein-1 (MCP-1) and intercellular adhesion molecule-1 (ICAM-
1),regulated by IFN-γ, TL1A or IL-17. Such an anti-inflammatory action also extended 
to another statin, Atorvastatin. The inhibitory action of Simvastatin on IFN-γ induced 
expression of MCP-1 and ICAM-1 was reversed, at least in part, by intermediates of 
the 3-hydroxy-3-methyl-glutaryl coenzyme A pathway such as farnesyl pyrophosphate 
and geranylgeranyl pyrophosphate. This suggested a potential role for monomeric G-
proteins that require such intermediates for activation. In addition, Simvastatin 
inhibited the phosphorylation-mediated activation of signal transducer and activator of 
transcription-1 (STAT1), a key transcription factor in IFN-γ signalling, on tyrosine 701 
and serine 727 in response to the cytokine. The effect of Simvastatin on MAP Kinase 
(MAPK) pathways in macrophages was also analysed. The statin attenuated the IFN-
γ induced activation of p38 MAPK and extracellular signal activated kinase (ERK)-1/2. 
Simvastatin also affected the constituve expression of many components of the MAPK 
pathways (e.g. ERK-1/2) along with downstream genes involved in atherosclerosis 
(e.g. ATP-binding cassette transporters-A1 and-G1). 
 The effect of Simvastatin on lipid profile of THP-1 and RAW264.7 
macrophages was also investigated. Simvastatin does not affect total polar lipids and 
triacylglycerol. The statin also had no significant effect on fatty acid distribution into 
polar lipids and triacylglycerol. 
 The studies presented in this thesis provide insights into the actions, and 
potential mechanisms, underlying the anti-inflammatory effects of statins on human 
macrophages along with their effects on lipid profiles. Such studies are essential given 
the widespread use of statins and a need to gain a deeper understanding of their 
actions. 
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1.1 Atherosclerosis an overview 
  Coronary artery disease (CAD), also known as coronary heart disease (CHD), 
is a condition where narrowing of the coronary arteries takes place (Allender et al., 
2008). Atherosclerosis is the principal cause of CAD and mainly affects the large and 
medium arteries (Lusis et al., 2004). This disease is commonly described as 
hardening of the arteries; the word atherosclerosis comes from the Greek words 
“athero” (meaning gruel or paste) and “sclerosis” (hardness). In the UK, CHD is the 
most common cause of mortality and accounts for about 45% of all cardiovascular 
disease death (National Statistic, 2012). 
Atherosclerosis starts in the early life of an individual due to the various risk 
factors detailed in section 1.2, and progresses during the lifetime of that 
individual(Berenson, 2002). It is considered as a progressive disease that is 
characterised by lipid accumulation and inflammation within the walls of the arteries 
(see Figure 1.1 for the structure of a normal artery) (Lusis, 2000).  
1.2 Risk factors 
Epidemiological studies show that there are several risk factors for atherosclerosis 
(Table 1.1). The most common risk factors include genetic background, lipid 
metabolism disorders, particularly high plasma cholesterol levels, hypertension and 
diabetes mellitus (Lusis et al., 2004). Raised blood cholesterol plays a key role in 
developing CHD and is responsible for over 60% of such cases. For example, a large 
case control study reported that around 40% of heart attack cases are due to elevated 
blood cholesterol and those with high cholesterol are three times greater at risk of the 
disease than those with normal blood cholesterol (Yusuf et al., 2004). 
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Figure 1. 1: Structure of a normal large artery. 
A large artery consists of three morphologically distinct layers. The intima, the innermost layer, 
is bounded by a monolayer of endothelial cells on the luminal side and a sheet of elastic fibres, 
the internal elastic lamina, on the peripheral side. The normal intima is a very thin region (size 
is enhanced in this figure for illustration) and consists of extracellular connective tissue matrix, 
primarily proteoglycans and collagen. The media, the middle layer, consists of smooth muscle 
cells (SMCs). The adventitia, the outer layer, consists of connective tissues with interspersed 
fibroblasts and SMCs (Adapted from Lusis, 2000). 
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Very low density lipoproteins (VLDL) are of two types according to its particle’s size: 
small VLDLs and large VLDL. Small VLDLs has the ability to enter the arterial wall 
and reaches the intima layer while large VLDLs does not (Carmena et al., 2004). 
Compelling evidence suggests that small VLDLs are independently associated with 
atherosclerosis (Libby et al., 2011). 
1.3 Pathophysiology of atherosclerosis 
Activation of endothelial cells (ECs) by the various risk factors is a main 
initiating event in atherosclerosis. From all the risk factors, the accumulation of LDL in 
the subendothelial matrix is the major cause of activation (Lusis, 2000). Once 
activated, the ECs secrete various chemoattractant molecules and express many 
adhesion molecules on the cell surface. The immune cells, particularly monocytes and 
T-lymphocytes in the blood stream, are then attracted towards the activation/injury 
site in response to such chemoattractants and begin to produce fatty streaks in these 
locations (Li and Glass, 2002). Overall, the progression of atherosclerosis can be 
subdivided into four major stages: early fatty streak development; early fibroatheroma; 
advancing atheroma; and complex lesion development (Insull, 2009). The different 
stages of atherosclerosis are described below in more details (Figure 1.3). 
1.4 Early fatty streak development 
Early fatty streak development arises during childhood and adolescence (Insull, 
2009). The first step usually begins when LDL particles migrate from the blood to the 
internal intima of arteries. However, the mechanism by which LDL initiates 
atherogenesis is not fully understood. Nevertheless, there is increasing evidence from 
biomedical and animal studies that suggest that the LDL particles must be modified 
before it can become pathogenic (Grundy, 1993). It is believed that modified LDL 
plays a major role in atherosclerosis pathogenesis particularly the formation of foam 
cells (Ross, 1999). In addition, modified LDL activates ECs, which leads to initiation of 
an inflammatory response.  
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Table 1.1: The genetic and environmental risk factors for atherosclerosis 
(adapted from (Lusis, 2000). 
Genetic Risk Factors Environmental risk factors 
 Elevated LDL and VLDL 
 Reduced levels of high density 
lipoprotein (HDL) 
 Elevated blood pressure 
 Elevated levels of homocysteine 
 Family history 
 Diabetes and obesity 
 Elevated levels of haemostatic 
factors 
 Depression 
 Gender (male) 
 Systemic inflammation 
 Metabolic syndrome 
 
 High fat diet 
 Smoking 
 Lack of exercise 
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The ECs then express adhesion molecules and secrete chemokines, chemoattracting 
cytokines, which then attract monocytes, lymphocytes, mast cells and neutrophils in 
the blood stream into the arterial wall (Li and Glass, 2002). 
The migration process of immune cells such as monocytes is aided by the 
expression of chemokines by ECs such as monocyte chemoattractant protein-1 
(MCP-1), macrophage colony-stimulating factor (M-CSF), migratory inflammatory 
protein-1 (MIP-1), tumour necrosis factor- (TNF-α) and transforming growth factor- 
(TGF-) (Li and Glass, 2002).  MCP-1 is a key factor in the pathogenesis of 
atherosclerosis and is produced by atheromatic cells such as ECs, smooth muscle 
cells (SMCs) and macrophages (Sheikine and Hansson, 2004; Boisvert, 2004). MCP-
1 has been found to cause a rapid progression of atherosclerosis in 
hypercholesterolaemic mice (Namiki et al., 2002). Additionally, a number of studies 
have shown that MCP-1 also induces the expression of genes that are thought to play 
a role in controlling plaque instability (e.g. matrix metalloproteinases (MMP) ) and 
stimulate acute thrombosis (e.g. tissue factor) (Schecter et al., 1997; Yamamoto et al., 
2000). Furthermore, a study by Inoue and colleagues (2002) on apolipoprotein-E 
(apoE)-knockout mice (a widely used mouse model of the disease) confirmed the 
involvement of MCP-1 in advanced lesion complications. Deficiency of MCP-1 
reduces lesion development in such mice (Ni et al., 2001). Monocytes are attracted by 
adhesion molecules on the surface of the ECs such as P- and E-selectins, which 
interact with L-selectin molecules on the surface of monocytes(Bobryshev, 2006). The 
interaction between the selectins causes the monocytes to roll across the endothelial 
surface, which enables molecules such as Vascular cell adhesion molecule-1 (VCAM-
1) and Inter-cellular adhesion molecule-1 (ICAM-1) to initiate binding with integrins. 
Integrin binding causes a higher level of adhesion to the endothelium so that the 
migration of monocytes through the endothelial layer to the intima can begin (Figure 
1.2). 
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Once the monocytes have passed through the endothelial layer and are present 
in the intima of the blood vessels, they differentiate into macrophages and begin to 
form foam cells by taking up oxidised LDL from the subendothelial environment. 
Monocyte-derived macrophages have a multifunctional role in the development and 
progression of atherosclerotic lesions (Weber et al., 2008). In humans, around 40% of 
the atherosclerotic plaque expresses macrophage markers (Quehenberger, 2005; 
Hansson and Libby, 2006). A study by Smith and co-authors (1995) showed that 
apoE-knockout mice lacking macrophages have very little atherosclerosis despite the 
presence of high levels of cholesterol in the blood.  
Macrophages are associated with scavenger receptors, such as CD36, lectin-
type oxidised low-density lipoprotein receptor 1 (LOX-1), scavenger receptor A (SR-A) 
and SR-B1, which internalise oxLDL leading to foam-cell formation, a rate-limiting 
step in atherosclerosis (Nicoletti et al., 1999; Quehenberger, 2005). After the uptake 
of oxLDL, endosomes loaded with ligand-bound scavenger receptors transfer 
cholesterol esters to lysosomes for intercellular breakdown. In addition, scavenger 
receptors can mediate the uptake of modified antigens for presentation to antigen-
specific T cells and thereby initiate an adaptive immune response (Janeway and 
Medzhitov, 2002). The induced expression of inflammatory cytokines, chemokines 
and co-stimulatory molecules in macrophages provide an additional antigen-specific 
stimuli and co-stimulatory molecules activate antigen-specific T cells (Glass  and 
Witztum, 2001; Li and Glass, 2002). Therefore, macrophages act as an important link 
between innate and adaptive immunity involved in atherogenesis. 
1.5 Early fibroatheroma 
This occurs in early adulthood of individuals and is characterised by fibrous 
plaque lesions (Burke et al., 2001; Stary, 2003). It results from a series of biochemical 
changes that occur inside the arterial wall. These events or changes include an 
increase in the amount of foam cells deposited within the plaque, accumulation of 
natural killer cells in the arteries, progressive increase in the lipid binding capacity of 
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extracellular proteoglycans as a consequence of increased synthesis and secretion by 
smooth muscle cells (SMCs), and death of macrophages and SMCs (Insull, 2009). 
Consequently, there is an increase in the level of inflammatory activities, which will 
subsequently lead to structural changes of the intimal layer leading to an enlarged 
pool of lipid-rich necrotic cores dominating 30 % to 50 % of arterial wall volume 
(Figure 1.3) (Ross, 1999; Insull, 2009). 
1.6 Advanced atheroma 
Unlike fibroatheroma, advanced atheromas typically occur in the mid of fifth 
decade of individual’s life and is characterised by a development of a thin cap 
fibroatheroma (TCFA) that is susceptible to rupture (Virmani et al., 2000; Cheruvu et 
al., 2007; Moreno et al., 2006). This lesion is usually labelled as a vulnerable plaque 
and  is associated with life threatening thrombosis due to a high risk of rupture (Insull, 
2009). This happens when the fibrous cap transforms into a thin cap as a result of 
decreased extracellular matrix (ECM) synthesis by the reduced number of SMCs 
within the cap and degradation of the matrix by proteases produced by the infiltrating 
macrophages (Thim et al., 2008). Thin-cap atheroma and ruptured plaques are 
responsible for about 1.2% to 1.6% of the coronary arteries events. Most of these 
lesions mainly occur in the proximal branches of the major coronary arteries, and the 
majority of them are clustered within ≤ 2 adjacent 20-mm artery segments (Cheruvu et 
al. ,2007). 
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Figure 1.2: Mechanisms contributing to the recruitment of monocytes to the 
artery wall and foam cell formation. 
LDL is subject to oxidative modification in the subendothelial space, progressing from mmLDL 
to extensive oxLDL. Monocytes attach to EC that have been induced to express cell adhesion 
molecules by mmLDL and inflammatory cytokines. Adherent monocytes migrate into the intima 
where they differentiate into macrophages. Uptake of oxLDL via macrophage scavenger 
receptors, such as SR-A and CD36, leads to foam cell formation.  
Abbreviations: mmLDL, minimally modified low density lipoprotein; oxLDL, Oxidised low 
density lipoprotein; SR-A: Scavenger receptor A; ICAM-1, Intercellular adhesion molecule-1; 
VCAM 1, vascular cell adhesion molecule-1; MCP-1, Monocyte chemoattractant protein-1; 
CCR2, Chemokine receptor-2, M-CSF, Macrophage colony stimulating factor. Taken from 
(Glass and Witztum, 2001). 
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1.7 Complex lesion development 
In this stage, there is a continuous rupture of thin fibrous caps that are usually 
clinically silent. The ruptured areas are replaced by fibrous tissues, collagen fibres 
and ECM that may re-rupture in the future (Lusis et al., 2004). This process of rupture, 
calcium deposition, thrombosis and healing may recur up to four times at the same 
site resulting in the formation of multiple layers of healing tissue inside the arterial wall 
(Insull, 2009). The exact mechanism of plaque rupture is not fully understood. 
However, the cytokine IFN-γ is thought to promote plaque instability by cap thinning, 
production of inflammatory cytokines and proteases, particularly matrix 
metalloproteinases (e.g. MMP-1, 2, 3, 9). All these decrease collagen synthesis and 
cause the accumulation of injured or apoptotic cells within the necrotic core (Harvey 
and Ramji, 2005). The increasing size of some plaques is sufficient to block the artery 
and cause serious events such lethal ischemia. This has been found to be the case in 
60% of patients who have had sudden cardiac death (Burke et al., 2001). 
1.8 Role of monocytes and macrophages in atherosclerosis 
 Monocytes and macrophages are present at all stages of lesion development 
and make up to about 60-70% of cells in the advanced plaque (Ross, 1993). 
Monocytes and macrophages have multifunctional roles in the progression of the 
atherosclerotic lesion (Takahashi et al., 2002). Monocytes are recruited to the 
inflammation site to infiltrate the artery wall where they differentiate into macrophages 
in response to stimulation by M-CSF (Watanabe et al., 1995). Initially this acts as a 
protective mechanism as it causes the removal of the damaging agents such as ox 
LDL. However, uncontrolled uptake of modified lipoproteins by macrophages 
ultimately leads to foam cell formation and atherogenesis (Glass and Witztum, 2001).  
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Figure 1.3: Characteristic stages of atherosclerotic lesions 
The lipid-rich macrophages (foam cells) and T-lymphocytes accumulate inside the intima layer 
with modified LDL stimulating pro-inflammatory responses that provoke innate immunity in the 
intima that leads to fatty streak formation. This is the precursor of more advanced lesions 
characterised by the complex aggregation of lipid-rich necrotic debris and SMCs. Such early 
atheromas typically have a fibrous cap consisting of a necrotic core enclosed by SMCs and 
ECM. The condition develops into a more complex lesion, the fibrous plaque which could be 
either stable or vulnerable depending on the components. The rupture of the vulnerable plaque 
could initiate thrombosis, ultimately leading to acute myocardial infarction or stroke taken from 
(Lusis et al., 2004). 
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1.9 Macrophage foam cell formation: 
Uptake of oxLDL by macrophages is mediated primarily through scavenger 
receptors expressed on the macrophage surface, particularly, SR-A and CD36 
(Suzuki et al., 1997; Yamada et al., 1998). The LDL receptor (LDL-R) will also initially 
contribute to lipid loading by binding to native LDL and mmLDL. However, LDL-R 
expression is downregulated by the sterol regulatory element–binding proteins 
(SREBP) pathway as cholesterol accumulates in the cells (negative feedback), while 
scavenger receptors continue to take up increasing amounts of modified lipoproteins 
in an uncontrolled manner (Goldstein et al., 2002). The mmLDL has also been found 
to induce macropinocytosis, another mechanism for LDL uptake, which has the ability 
to potentiate the uptake of both native and oxLDL thereby contributing to foam cell 
formation (Kruth et al., 2002). For example, macropinocytosis has been found to be 
involved in the internalisation of both oxLDL and acetylated LDL (AcLDL) by human 
macrophages (Michael et al., 2013). Interestingly, the authors of this study found that 
inhibition of macropinocytosis using cytochalasin-D increased the expression of SR-A 
and CD36, which may indicate a potential compensatory mechanism to maintain 
modified LDL uptake and cholesterol levels in the absence of the macropinocytosis 
pathway. Additionally, they found that macropinocytosis is regulated by cytokines 
such as IFN-γ, TL1A, IL-17A and TGF-β (Michael et al., 2013), thereby demonstrating 
the importance of macropinocytosis in the control of foam cell formation.  
As macrophage levels of cholesterol increase, efflux mechanisms may also 
maintain homeostasis for a short period, largely through a process known as reverse 
cholesterol transport (RCT). RCT is a process responsible for cholesterol 
transportation from peripheral tissues to the liver and then via bile for clearance 
through the faeces (Oram and Yokoyama, 1996). One of the primary components of 
this system is the ATP-binding cassette transporter A1 (ABCA1), which mediates 
transfer of cholesterol from the cell to high density lipoprotein (HDL), a role that 
makes HDL highly atheroprotective (Tall et al., 2000).  
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 Cellular cholesterol is eliminated by HDL and its components via several 
mechanisms (Oram and Yokoyama, 1996). The RCT pathways (Figure 1.4) act as a 
natural defence mechanism for atherosclerosis by removing accumulated cholesterol 
from the arterial wall and excreting it via the liver.  ApoA-I is secreted from the liver 
and the intestine and loaded with cholesterol and phospholipids by members of 
superfamily of ATP‐binding cassette transporters (ABCs), ABCA1 and ABCG1. Liver 
ABCA1 initiates HDL particle formation and macrophage ABCA1 protects the arteries 
from atherosclerosis. Additionally, HDL phospholipids passively absorb cholesterol                                                                                    
that has diffused from the plasma membrane into the aqueous phase, which is  
facilitated by the interaction of HDL particles with SRBI (Oram and Heinecke, 2005).  
Several studies using cultured cells or specific animal models have shown that ABCA
1 is an effective atheroprotective agent and a major determinant of plasma HDL levels
 (Aiello et al., 2003; Oram and Heinecke, 2005; Wang and Tall, 2003; Singaraja et al., 
2003).  In support for an anti-atherogenic role for ABCA1, ApoE null mice transplanted 
with ABCA1-deficient bone marrow cells show significantly more atherosclerosis than 
those given wild–type bone marrow (Aiello et al., 2002). In addition to ABCA1, 
ABCG1 is highly expressed in tissue macrophages and liver cells and is recognised 
to facilitate cholesterol transport from macrophages to HDL particles (Out et al., 
2007).      
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Figure 1.4: Reverse cholesterol transport 
HDL has a major role in the reverse cholesterol transport pathway. Lipid-poor apo A-I is 
secreted by the liver and rapidly acquires cholesterol via the hepatocyte ABCA1 transporter 
and promotes cholesterol efflux from macrophages. Free cholesterol is esterified to cholesteryl 
esters by LCAT to form mature HDL, which transfers its cholesterol to apo B-containing 
lipoproteins, such as VLDL and LDL, via CETP-mediated transfer. This cholesterol is 
subsequently taken up by the liver via the LDL receptor. PLTP transfers phospholipids from 
triglyceride-rich lipoproteins to HDL, which promotes HDL remodeling. Hepatic cholesterol can 
be excreted into the bile after conversion to bile acid or expelled directly into the bile as 
cholesterol. Bile and its components are either reabsorbed by the intestine or ultimately 
excreted in feces. HDL can be remodeled by lipases, such as endothelial lipase and hepatic 
lipase, which hydrolyze HDL phospholipids and HDL triglycerides, respectively. The kidneys 
are an important site of apo A-I catabolism. Abbreviations: ABC, ATP-binding cassette; apo A-
I, apolipoprotein A-I; CETP, cholesteryl ester transport protein; LCAT, lecithin–cholesterol 
acyltransferase; LDLR, LDL receptor; PLTP, phospholipid transfer protein; SRB1, scavenger 
receptor class B member 1. (Adapted from Navab et al., 2011).                                                                                                                 
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Ultimately, when the concentration of modified LDL is high (above 5mmol/L), 
macrophages fail to maintain an adequate cholesterol balance. The majority of 
cholesterol in the foam cells exists in the form of cholesterol esters. In the absence of 
a suitable acceptor such as HDL, free intracellular cholesterol is esterified by the 
enzyme acyl coenzyme acylcholestrol transferase (ACAT) (Li and Glass, 2002). It was 
originally thought that knocking out the ACAT-1 gene would be beneficial to 
atherosclerosis but ApoE null mice with this deletion exhibited progression of 
atherosclerosis to a similar extent to those without it (Fazio et al., 2001) Although the 
lesions had reduced cholesterol content, deposits of this sterol were found elsewhere 
including the brain (Fazio et al., 2001). It is therefore possible that other atherogenic 
effects are being affected by the deletion of the ACAT-1 gene. 
Phagocytosis of apoptotic cells by macrophages leads to further accumulation 
of lipids within atherosclerotic lesions (Glass and Witztum, 2001). As the disease 
progresses, the fatty streaks begins to mature into plaques. The lesions are usually 
covered with a fibrous cap made up of SMCs and ECM. The fibrous cap encloses a 
lipid-rich necrotic core of the lesion; the lipid core of the lesion is formed as the lesion 
grows. The cells in the middle of the plaque are unable to obtain sufficient nutrients 
and therefore undergo necrosis (Newby and Zaltsman, 1999). 
Increased macrophage density has long been known to correlate with unstable 
atherosclerotic plaques (Lendon et al., 1991). Indeed, macrophages have now been 
shown to contribute to the instability of the plaque in several ways. Firstly, as 
macrophage foam cells undergo apoptosis themselves, their contents contribute to 
the necrotic core (Li and Glass, 2002). Macrophages have also been shown to 
release pro-thrombotic molecules, such as tissue factor (TF) and complement 
proteins (e.g. complement C3b) into the necrotic core to increase the thrombogenic 
potential of the plaque (Takahashi et al., 2002; Linton and Fazio, 2003). In addition, 
the proteolytic enzymes, including matrix metalloproteinases (e.g. MMP-2, MMP-9) 
produced by macrophages, act to weaken the fibrous cap and so lead to eventual 
plaque rupture (Newby, 2008).  
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 Cytokines secreted by macrophages such as IL-2, IFN-γ and TNF-α play 
crucial roles in the development of atherosclerotic lesions (Ait-Oufella et al., 2011). 
These cytokines regulate the recruitment of inflammatory cells to the lesion through: 
chemotaxis; modulation of expression of cell adhesion molecules by ECs, SMCs and 
macrophages; and the regulation of cell proliferation and migration in the atheroma. 
Cytokines also modulate plaque stability by regulating the expression of effectors of 
ECM turnover, and thrombosis through the regulation of genes involved in coagulation 
cascades (Daugherty et al., 2005; Tedgui and Mallat, 2006; Mehra et al., 2005). IFN-γ 
is considered as one of the key cytokines that exerts its crucial role at all stages of 
lesion development. 
1.10 Inflammatory mediators and nuclear receptors 
Cells in the vessel wall secrete many inflammatory mediators that influence 
macrophage function. However, secretion of inflammatory mediators by damaged 
macrophages themselves plays a crucial role in plaque progression (Lusis et al., 
2004). Cytokines (e.g. TGF-β, TNF-α, IL-1), chemokines (e.g. MCP-1, MCP1-β) and 
growth factors (e.g. platelet derived growth factor (PDGF) and Insulin–like growth 
factor-1 (IGF-1) produced by macrophages have numerous effects on gene 
expression in surrounding cells and contribute to the continued recruitment of 
inflammatory cells into the plaque and further uptake of lipoproteins (Burke-Gaffney et 
al., 2002). Macrophages also produce proteolytic enzymes, including MMP-2, MMP-9 
and collagenase that act to weaken the fibrous cap and result in eventual plaque 
rupture (Galis et al., 1994). In addition, the nuclear receptors, peroxisome 
proliferators-activated receptors (PPARs) and liver X receptors (LXRs) are emerging 
as crucial regulators of inflammation that are involved in the pathogenesis of 
atherosclerosis. 
1.10.1  Nuclear receptors 
The nuclear receptor superfamily of proteins regulate the expression of genes 
involved in diverse processes such as development, reproduction and metabolism 
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(Robinson-Rechavi, 2003). The nuclear receptors have a highly conserved modular 
structure organised into functional domains. Most members consist of an N-terminal 
region that often contains a ligand-independent activation function (AF-1), a DNA-
binding domain (DBD) containing two zinc fingers, a C-terminal ligand-binding domain 
(LBD) that interacts with small lipophilic molecules, and a ligand-dependent 
transcriptional activation function (AF-2)  (Mangelsdorf and Evans, 1995). 
1.1.1 Peroxisome proliferator-activated receptors (PPARs) 
The PPARs bind to their recognition sequences in the regulatory regions of 
target genes as heterodimers with the 9-cis-retinoic acid receptors (retinoid X 
receptor; RXRs). PPARs play important roles in the regulation of metabolic pathways, 
including those of lipid biosynthesis and glucose metabolism, as well as the control of 
cell differentiation, proliferation and apoptosis pathways (Moraes et al., 2006). They 
are ligand-activated transcription factors involved in the transcriptional regulation of 
key genes in metabolic processes such as lipid metabolism, adipogenesis and insulin 
sensitivity. More recent work implicates all three PPAR isotypes, PPAR , PPAR  and 
PPAR  (also known as PPARß or PPARß/  ) in inflammatory and atherosclerotic 
pathways (Brown and Plutzky, 2007). 
PPARα is expressed predominantly in the liver, kidney and heart, and is 
primarily involved in fatty acid oxidation (Schoonjans et al., 1996). Activation of PPAR 
α has also been demonstrated to reduce macrophage triglyceride accumulation and 
promote intracellular cholesterol distribution to plasma membrane which consequently 
enhances its efflux to HDL (Chinetti-Gbaguidi et al., 2005).  
PPARδ is the most abundant isoform and ubiquitously expressed, and has a 
role in the development of atherosclerosis (Azhar, 2010). In a mouse model system, 
activation of PPARδ reduced the expression of MCP-1, ICAM-1 and inflammatory 
cytokines, and decreased the development of atherosclerosis (Graham et al., 2005). 
Similar to PPARα, activation of PPARδ in macrophages promotes cholesterol efflux 
and fatty acid catabolism alongside attenuation of inflammatory cytokine expression 
(Graham et al., 2005; Lee et al., 2006).  Activators of PPAR α (fibrates) and γ 
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(thiazolidinediones) have been used clinically for a number of years in the treatment 
of hyperlipidaemia and to improve insulin sensitivity in diabetes (Kliewer et al., 2001). 
More recently, PPAR activation has been found to confer additional benefits on 
endothelial function, inflammation and thrombosis, suggesting that PPAR agonists 
may be good candidates for the treatment of cardiovascular disease (Robinson and 
Grieve, 2009). In this regard, it has been demonstrated that PPAR activators are 
capable of reducing blood pressure and attenuating the development of 
atherosclerosis and cardiac hypertrophy (Robinson and Grieve, 2009). PPAR α also 
has pleiotropic effects in the cardiovascular system, including anti-inflammatory and 
anti-atherosclerotic properties (Marx et al., 2000; Lee et al., 2006) . PPARα activation 
inhibits vascular smooth muscle pro-inflammatory responses and attenuates the 
development of atherosclerosis in mouse model systems (Zahradka et al., 2003). 
Additionally, PPARδ ligands have been shown to attenuate the pathogenesis of 
atherosclerosis by improving endothelial cell proliferation and survival whilst 
decreasing endothelial cell inflammation and vascular SMC proliferation (Hamblin et 
al., 2009). 
Mice lacking both PPARα and ApoE have been found to develop reduced 
atherosclerosis despite having elevated triglyceride and LDL levels (Tordjman et al., 
2001). Furthermore, total cholesterol, HDL cholesterol, and apoAI and apoAII levels 
were higher in PPARα null mice compared with wild-type controls. PPARα ligand 
fenofibrate has been shown to attenuate the development of atherosclerotic lesions, 
with more pronounced effect noted in ApoE−/−mice overexpressing human apoA-I 
(Brown and Plutzky, 2007). Additionally, administration of the PPARα ligand 
fenofibrate to ApoE−/− mice resulted in decreased total cholesterol and reduced 
atherosclerosis (Duez et al., 2002).  
PPARγ appears to be highly expressed during atherosclerotic lesion formation 
thereby suggesting that increased PPARγ expression may be a vascular 
compensatory response (Marx et al., 1998; Ricote et al., 1998; Tontonoz et al., 1998). 
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Also, ligand-activated PPARγ decreases the inflammatory response in cardiovascular 
cells, particularly in ECs (Hamblin et al., 2009). 
The anti-inflammatory effect of PPAR ligands is further confirmed by the findings 
that the expression of key pro-inflammatory cytokines, such as TNF-α, IFN-γ, IL-1 and 
-8, as well as the cytokines involved in immuno-modulation such as IL-2 and -4 is 
inhibited by various types of ligands for all three PPAR isoforms in macrophages and 
SMCs (Jiang et al., 1998; Takano et al., 2000; Ryoo et al., 2004; Ding et al., 2006; 
Piraino et al., 2006). Repression of IFN-γ expression by fenofibrate has also been 
confirmed in IL-10-deficient mice (Lee et al., 2007). 
T lymphocytes and SMCs play an important role in atherosclerotic lesion 
formation and complication (Hansson, 2001). After the recruitment into the arterial 
wall, T cells undergo differentiation into CD4+Th1 cells following stimulation by 
various antigens including oxLDL. Th1 cell predominantly secrete pro-inflammatory 
cytokines such as IFN-γ, TNF-α and IL-12, which can subsequently activate other 
cellular participants in atherosclerosis (Binder et al., 2002). PPAR-α and –γ activation 
reduces the T cell production of IFN-γ, TNF-α, IL-2 and IL-4, thus possibly modulating 
multiple levels of distal responses to these cytokines during atherogenesis (Jones et 
al., 2002; Marx et al., 2002). 
In general, PPAR activators reduce the risk of atherosclerosis, decrease the 
progression of atherosclerotic plaques, and reduce the incidence of mortality from 
cardiovascular disease (Ehrenborg and Skogsberg, 2013). 
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1.10.2 1.10.2            Liver x receptors (LXRs) 
The LXRs are nuclear receptors that are activated by endogenous oxysterols, 
oxidised derivatives of cholesterol. There are two isoforms of LXR, LXR (NR1H3) 
and LXR (NR1H2). Both LXR and LXR regulate gene expression by binding to 
regulatory DNA sequences in target genes as heterodimers with isoforms of RXR, 
RXR (NR2B1), RXR (NR2B2) or RXR (NR2B3). LXRs act as cholesterol sensors 
as when cellular oxysterols accumulate as a result of increasing concentrations of 
cholesterol, they induce the transcription of genes that protect cells from cholesterol 
overload such as ABCA1 and ABCG1 (Zhao and Wright, 2010). 
The two LXRs identified, LXR and LXR, share a high degree of amino acid 
similarity (78% in their DNA- and ligand-binding domains) but differ in their tissue 
distribution. LXR was first identified in the liver (hence the name liver X receptor) but 
is also expressed in other metabolically active tissues/cell types such as the kidney, 
intestine, adipose tissue, and macrophages. In contrast, LXR is ubiquitously 
expressed (Millatt et al., 2003). 
LXRs regulate the expression of many genes associated with cholesterol 
absorption, transport, efflux and excretion, and as such control whole body cholesterol 
homeostasis. The activation of LXRs results in improved RCT and increased 
circulating HDL levels (Laffitte et al., 2003; Cao et al., 2002). It has also been shown 
that treatment with LXR agonists attenuates the development of atherosclerosis and 
inhibits cholesterol absorption in mouse models, suggesting therefore that synthetic 
LXR agonists may be promising anti-atherosclerotic agents (Hong and Tontonoz, 
2014).  
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1.11 Diagnosis of atherosclerosis and therapeutic approaches 
There are no precise diagnostic tests for atherosclerosis but cardiologists tend 
to determine plasma levels of serum biomarkers like C-reactive protein (CRP) 
(Corrado et al., 2010). Serum levels of CRP have been found to be up to 1000-fold 
higher than normal levels in individuals with advanced atherosclerosis (Paffen and 
DeMaat, 2006). There are also some other markers for chronic heart disease that 
includes TNF-α and IL-6 (Rodondi et al., 2010). In addition, physicians use other 
means to diagnose atherosclerosis including chest X-ray, electrocardiogram (ECG or 
EKG), computed tomography (CT scan), angiography, analysis of risk factors, such as 
plasma LDL cholesterol and triglycerides, and family history. 
Optimal management of atherosclerosis reduces the risk of fatal and non-fatal 
cardiovascular events. In addition, monitoring atherosclerosis risk factors including 
blood pressure, smoking and hypercholesterolemia, is crucial in minimising the risk of 
cardiovascular disease (Lewis, 2009). A combination of lifestyle and therapeutic 
approaches are used to limit atherosclerosis. Dietary changes, such as reduced 
intake of saturated fats and increased intake of polyunsaturated fatty acids, increased 
levels of exercise and stopping smoking all help to reduce inflammation in arteries 
and limit the development of atherosclerosis (Leon and Sanchez, 2001). Both animal 
and human studies have shown that high intake of fish and unsaturated fatty acids, 
especially omega 3 fatty acids (n-3 FA), reduce chronic heart disease (De Caterina et 
al., 2000). 
Targeting hyperlipidaemia represents another approach. HMG-CoA reductase is 
the rate limiting enzyme in the biosynthesis of cholesterol and it catalyses the 
conversion of HMG-CoA to mevalonic acid. Inhibition of this enzyme via statins 
reduces hepatic cholesterol synthesis and increases LDL receptor levels, which 
causes the clearance of LDL from the plasma (Wang et al., 2008). The action of 
statins is discussed later in more detail. 
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There is strong evidence to support that controlling hypertension protects 
against the development of atherosclerosis. Drugs for hypertension are prescribed 
alone or in combination with others depending on the severity and presence of other 
diseases (James et al., 2014). There is a strong agreement that the treatment of 
hypertension should be stratified according to age and ethnicity (James et al., 2014). 
There are several categories of medications for lowering blood pressure depending 
on their site of action, though in most cases it is not fully understood on how they 
work. The most common drugs include aspirin, beta-blockers, thiazide, calcium 
channel blockers (CCB) and angiotensin-converting enzyme (ACE) inhibitors.  ACE 
inhibitors are drugs that block the production of   angiotensin II.  This is a hormone in 
the body that has a vital role in the cardiovascular system with its main function being 
to narrow blood vessels (vasoconstriction) resulting in high blood pressure. Blocking 
angiotensin II with ACE inhibitors reduces blood pressure and prevents such 
narrowing of arteries (Sweitzer, 2003). 
1.11.1 Statins 
Statins are potent inhibitors of cholesterol biosynthesis (Figure 1.5). Originally 
discovered in the 1970s, statins were found to potently inhibit HMG-COA, a key 
enzyme in cholesterol biosynthesis (Ridker et al., 2009). Statins can be divided into 
two categories: natural or fungally derived analogues (e.g. Lovastatin, Simvastatin 
and Pravastatin; type I statins) and synthetic analogues (e.g. Atorvastatin, Fluvastatin 
and Rosuvastatin; type II statins). The natural statins share similar chemical 
structures, while the synthetic statins vary considerably from each other and from the 
natural statins (Figure 1.6) (Igel et al., 2002; Davidson et al., 2004). Statins can also 
be classified according to their properties as either lipophilic or hydrophilic. Lipophilic 
statins include lovastatin, simvastatin, atorvastatin and fluvastatin whereas pravastatin 
and rosuvastatin are more hydrophilic (Garcia, 2003). 
The chemical structure of statins is constituted by two components (Figure 1.6), 
the pharmacophore, which is a dihydroxyheptanoic acid segment, and its moiety 
composed of a ring system with different substituents. The pharmacophore works 
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through inhibition of the HMG-CoA reductase enzyme in a competitive, dose-
dependent, and reversible manner. The stereoselectivity of the HMG-CoA reductase 
enzyme dictates the stereochemistry of statins, which present two chiral carbon 
atoms, C3 and C5, on their pharmacophore to the enzyme. The moiety of the 
pharmacophore, according to the chemical modified ring systems and the nature of 
the substituents, generates the different structures of statins. The ring system is a 
complex hydrophobic structure, covalently linked to the pharmacophore, that is 
involved in the binding interactions with the HMG-CoA reductase. The binding 
interactions of the ring have the ability to reduce the competition for the binding site 
between the statin and the endogenous HMG-CoA substrate. Subsequently, 
maintaining the statin closed to the enzyme prevents the possibility of statin 
displacement by the endogenous substrate. The ring's structure can be a partially 
reduced naphthalene (lovastatin, simvastatin, pravastatin), a pyrrole (atorvastatin), an 
indole (fluvastatin), a pyrimidine (rosuvastatin), a pyridine (cerivastatin), or a quinoline 
(pitavastatin). The substituents on the rings define the solubility of the statins along 
with many of their pharmacological properties (Gazzerro et al.,2012). 
The evidence for a protective role of statins in cardiovascular disease emerges 
from many clinical trials. For example, in a large randomised double blind study using 
carotid intima-media thickness (CIMT) as a surrogate marker of atherosclerosis in 876 
patients with hypercholesterolaemia, patients were either treated with Rosuvastatin 
(40 mg/day) or received placebo treatment for 2 years. The Rosuvastatin group 
showed no evidence of atherosclerosis progression as measured by CIMT compared 
with the placebo treated group, which had a significant CIMT progression (Crouse et 
al., 2007). In addition to inhibiting atherosclerosis progression, there were significantly 
greater reductions in LDL-C levels and increases in HDL-C levels in Rosuvastatin 
group than the placebo controls. Similarly, another multicentre study of 349 patients 
with high plasma cholesterol levels carried out serial intravascular ultrasound (IVUS) 
to examine the effect of intensive Rosuvastatin (40mg daily) therapy on the 
progression of coronary atheroma (Nissen et al., 2006). After two years, the results of 
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this study showed reductions in LDL-C levels, increases in HDL-C levels, and a 
significant regression of atherosclerosis measured by IVUS. However, this study 
lacked a control group to ascertain the maximum efficacy of their regimen.  The same 
research group also conducted a double blind multicentre study in patients with CHD 
comparing Pravastatin (40 mg) to Atorvastatin (80 mg) (Nissen et al., 2006). Patients 
on 80 mg of Atorvastatin experienced significant reductions in LDL-C levels and 
atheroma volume compared with patients on 40 mg of Pravastatin. Progression of 
coronary atherosclerosis was inhibited in the Atorvastatin group, but not in those 
receiving Pravastatin.  
The effect of statins is not just limited to LDL-C, but also extends to levels of 
HDL-C, which play a significant role in the prevention of atherogenesis and reduction 
of cardiovascular events (Nicholls et al., 2007; Puri et al., 2014). The combined 
analysis of four randomised controlled trials of nearly 1500 patients with coronary 
atherosclerosis that underwent serial IVUS showed that statin treatment induced a 
mean increase of 7.5% (p < 0.01 vs baseline) in HDL-C (Nicholls et al., 2007).  
The beneficial effects of statin therapy on CHD and atherosclerosis progression 
are not just attributable to their effects on lipid profiles, but possibly as a consequence 
of their anti-inflammatory properties (Puri et al., 2014). Statin therapy either with 
Pravastatin (40 mg/day) or with Atorvastatin (80 mg/day) for 18 months was 
associated with a 22% reduction in CRP levels in a post hoc analysis of 502 patients 
with CHD (Nissen et al., 2006). The reduction in CRP levels was significantly 
associated with decrease in both total atheroma volume and percent atheroma 
volume (p = 0.02 and 0.01, respectively). Statins-mediated changes in CRP and the 
rate of atheroma progression were beyond their lipid-lowering effect. Despite many 
such advances, the anti-inflammatory effect of statin therapy is still controversial and 
further studies are required. 
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1.12 Actions of statins 
1.12.1 Inhibition of cholesterol biosynthesis 
Cholesterol is synthesised from acetyl Co-A via several steps as summarised in 
Figure 1.5. HMG-COA reductase is the rate-limiting enzyme in cholesterol 
biosynthesis. Statins are analogues of HMG-CoA so act as competitive inhibitors of 
the enzyme. In addition to direct inhibition of cholesterol synthesis, statins reduce 
plasma cholesterol levels by up-regulating the expression of LDL receptors, thereby 
aiding the clearance of this lipoprotein from the plasma (Wang et al., 2008). 
Statins usually target hepatocytes and inhibit HMG-COA reuctase, the enzyme 
that converts HMG-CoA into mevalonic acid, a cholesterol precursor. The action of 
statins is not just limited to competing with the normal substrate for the enzymes 
active site. They alter the conformation of the enzyme when they bind to its active 
site. This prevents HMG-COA from attaining a functional structure. The change in 
conformation at the active site makes these drugs very effective and specific, binding 
of statins to HMG-COA is reversible and their affinity for the enzyme is in the 
nanomolar range as compared to the natural substrate, which has micromolar affinity 
(Corsini et al.,1999). 
The pharmacokinetic properties of statins are orchestrated by several factors, 
including their active or lactone form, their lipophilic/hydrophilic properties, and their 
absorption and metabolism. Statins are administrated orally as active hydroxy acids, 
except for lovastatin and simvastatin, which are administrated as lactone pro-drugs 
and then hydrolyzed to hydroxy acid form (Corsini et al.,1999). 
1.12.2 Inhibition of small G protein activation 
When statins inhibit the synthesis of mevalonate, they also prevent the 
production of important isoprenoid intermediates such as farnesyl pyrophosphate 
(FFP). The action of many proteins in signalling cascades is dependent on post-
translational modification by isoprenylation. These intermediates act as important lipid 
attachment molecules for the γ subunit of heterotrimeric G proteins and small G 
proteins, such as Ras, Rho, and Rac (Seabra, 1998; Maltese, 1990). 
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The attachment of these lipids also known as isoprenylation is essential for the 
activation and intracellular transport of these proteins. They act as molecular switches 
controlling multiple pathways and cell functions such as maintenance of cell shape, 
motility, factor secretion, differentiation, and proliferation (Zhou and Liao, 2010). 
Inactive GDP-bound Ras, Rho, and Rac are located in the cytoplasm. After 
isoprenylation, these small G proteins are translocated to the membrane and 
converted to active GTP-bound forms (Figure 1.7).  
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Figure 1.4: Cholesterol biosynthesis. 
Cholesterol biosynthesis is a complex process involving more than 30 enzymes. A simplified 
version is shown here, which highlights the step inhibited by statins, and shows the chemical 
structures of the starting substrate (HMG-CoA) and product (mevalonate) of this step, taken 
from (Tobert, 2003). 
 
 
 
 28 
 
 
 
Figure 1.5: Molecular configurations of the natural (fungally derived) and 
synthetic statins. Taken from (Davidson and Toth, 2004). 
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Figure 1.6: Biological actions of isoprenoids and cholesterol. 
This diagram of the cholesterol biosynthesis pathway shows the effects of inhibition of 
HMG-CoA reductase by statins. Decrease in isoprenylation of signalling molecules 
such as Ras, Rho and Rac leads to modulation of various signalling pathways. BMP-
2, bone morphogenetic protein-2; eNOS, endothelial nitric oxide synthase; t-PA, 
tissue- type plasminogen activator; ET-1, endothelin-1; PAI-1, plasminogen activator 
inhibitor-1. Taken from (Liao, 2002). 
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1.12.3 Other effects of Statins 
Statins have anti-inflammatory activity, such as reducing levels of inflammatory 
biomarkers like CRP (Nissen et al., 2006; Puri et al., 2014). Statins have also been 
shown to decrease the expression of macrophage CD36, a recognised receptor for 
oxidized LDL (Fuhrman et al., 2002). Statins inhibit the uptake of oxidised LDL by 
CD36, scavenger receptor A and also attenuate macrophage oxidative properties 
(Plenge et al., 2002). Other anti-inflammatory activities include inhibition of endothelial 
adhesion molecule expression, impairment of monocyte recruitment and T-cell 
activation and repression of smooth muscle cell proliferation (Jain and Ridker, 2005). 
Statins can also increase lipoprotein fluidity, which may reduce the susceptibility of 
lipids to oxidation. For example, Rosuvastatin has been shown to increase the surface 
and core fluidity of ApoB-containing lipoproteins (Rosenson, 2004). Simvastatin also 
inhibits LDL oxidation by activated HMDM, and the metabolites of Atorvastatin have 
been shown to have potent antioxidant effects (Aviram et al., 1998).  These 
physiological effects of statins on atherosclerosis pathogenesis contribute to reduced 
foam cell formation.  
Immune mechanisms play a role in atherogenesis. Increasing evidence 
suggests that statins may modulate immune response and that use of statins may 
have applicability in organ transplantation and other conditions requiring 
immunosuppression. Pravastatin treatment, added to standard antirejection 
medications (cyclosporine, prednisone, and azathioprine) after cardiac transplant, has 
been reported to significantly reduce the frequency of rejection (3 versus 14; p=0.005) 
and increase survival (94% versus 78%; p=0.025) at 12 months compared with 
control patients (Kobashigawa et al.,1995). Furthermore, statins modulate platelet 
function. Although the underlying mechanism remains unknown, statins inhibit 
fibrinogen expression and thrombin formation in vitro and reduce platelet aggregation 
and deposition in diseased vessels in vivo (Dangas et al.,2000; Mayer et al.,1992). 
Reduced expression of cyclooxygenase 2 (COX-2), thromboxane A2 (TxA2), or TxB2 
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and enhanced synthesis of prostacyclin caused by statin treatment may contribute to 
diminished platelet activation (Schönbeck and Libby, 2004). 
Statins are among the most important cardiovascular therapies developed and 
have revolutionised the treatment of atherothrombotic disease. Although they are 
highly effective lipid-lowering agents, clinical and experimental observations strongly 
suggest that inhibition of inflammation also contributes to the beneficial effects of 
these medications.  
1.12.4 Role of Atorvastatin in atherosclerosis 
From the various statins, Atorvastatin is the only one that produces a metabolite 
that has the capability to inhibit HMG-CoA reductase equivalent to that of the parent 
molecule (Poli, 2007). Both Atorvastatin and its metabolite are principally eliminated 
through biliary excretion with only small amounts cleared in the urine (Neuvonen et 
al., 2006). The clearance half-life of Atorvastatin is approximately 14 hours, which is 
considerably longer than most other statins (with the exception of Rosuvastatin). The 
half-life of HMG-CoA reductase inhibition by Atorvastatin is around 20–30 hours as a 
result of the action of its active metabolites (Poli, 2007). This long half-life has a 
significant impact on medication administration schedule as Atorvastatin can be taken 
at any time during the day in contrast to other statins that are taken at night because 
of their shorter half-life.   
In patients with primary hypercholesterolaemia, Atorvastatin has proven to be more 
successful in reducing total cholesterol, LDL-C and triglyceride levels when compared 
with same doses of Simvastatin, Lovastatin, Fluvastatin and Pravastatin (Jones et al., 
1998). Nevertheless, statins also improve the endothelial function by increasing nitric 
oxide bioavailability (Anderson 1999). The endothelium is the single layer of 
endothelial cells lining the lumen of the blood vessels. The location of the endothelium 
provides mechanical and metabolical advantages as it separates the vascular wall 
from the circulation and the blood components (Lerman and Zeiher, 2005). 
Endothelial dysfunction is a term that covers diminished production/availability of nitric 
oxide (NO) and/or an imbalance in the relative contribution of endothelium-derived 
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relaxing and contracting factors (Hadi et al., 2005). Endothelial dysfunction is 
characterized by a reduction of the bioavailability of NO, and/or an increase in 
endothelium-derived contracting factors (Lerman and Burnett 1992). This imbalance 
leads to an impairment of endothelium-dependent vasodilation, which is the functional 
characteristic of endothelial dysfunction. In addition to impaired endothelium-
dependent vasodilation, endothelial dysfunction also comprises a specific state of 
endothelial activation, which is characterised by a proinflammatory, proliferative, and 
procoagulatory states that favour all stages of atherogenesis (Anderson 1999). 
In the majority of comparative clinical trials, Atorvastatin in dosages of 10 and 
20 mg/day has shown to be equivalent to or even better than that of dosages of 20 
and 40 mg/day of these other statins (Malhotra and Goa, 2001). Atorvastatin has also 
been found to produce a significant improvement in endothelial function as early as 
two weeks after beginning the treatment compared with dietary therapy alone 
(P<0.001), as well as at four and eight weeks (Marchesi et al., 2000). This study also 
provided evidence that Atorvastatin may exert beneficial effects on endothelial 
dysfunction that are independent of the degree of lowering of plasma cholesterol 
levels. Atorvastatin also has an anti-atherogenic effect in a primary prevention setting, 
not just by decreasing lipid levels, but also by suppressing the oxidation of LDL (Sezer 
et al., 2011). In the Atorvastatin versus Simvastatin on Atherosclerosis Progression 
(ASAP) study, aggressive statin therapy (Atorvastatin 80 mg) reduced CRP levels to a 
greater extent than conventional therapy (Simvastatin 40 mg) thus indicating a potent 
anti-inflammatory activity of Atorvastatin (van et al., 2002). 
1.13 Cytokines 
Cytokines are small, nonstructural proteins with molecular weights ranging from 
8000 to 40,000 daltons. They were originally called lymphokines and monokines to 
refer them back to their cellular origins, lymphocytes and monocytes respectively 
(Balkwill and Burke, 1989). Lately, it has become obvious that the term “cytokine” is 
the best description since the majority of the nucleated cells have the ability to 
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synthesise these proteins and, in turn, respond to them. There is no amino acid 
sequence motif or three dimensional structure that is common to all cytokines 
identified so far; rather, the biological activities of the cytokines allow the researchers 
to classify them and put them in different categories (Dinarello, 2000).  
Cytokines consist of around 50 secreted factors that are involved in intercellular 
communication and regulation of fundamental biological processes. Cytokines have 
been grouped into several families over the years and some of the families include: 
the interleukins; interferons; tumour necrosis factors; transforming growth factors; 
colony stimulating factors; and chemokines. Cytokines are especially important for 
regulating the immune responses and have major regulatory functions in both innate 
and adaptive immunity (Tedgui and Mallat, 2006). 
 Atherosclerosis is considered as a state of chronic inflammation within the 
vascular wall. A variety of cytokines are released at different stages of the disease 
and these have been studied and reviewed in relation to them being pro- or anti-
atherogenic (Tedgui and Mallat, 2006). The cytokines are capable of mediating their 
actions by interacting with specific receptors on the cell surface. The receptor 
interaction triggers downstream effects via signal transduction pathways. The 
transduction cascades ultimately leads to transcriptional control within the cell that 
can bring about changes in their functions and properties (Singh and Ramji, 2006).  
High levels of pro-inflammatory cytokines are observed in atherosclerotic 
lesions (Harvey and Ramji, 2005). Pro-inflammatory cytokines include TNF-, IFN-, 
IL-1, IL-17 and IL-12. Anti-inflammatory cytokines include IL-10, IL-4, IL-33 and TGF-
. Macrophages are the major source of cytokines in the atherosclerotic lesion 
alongside vascular cells and infiltrating T- lymphocytes (Figure 1.8) (Tedgui and 
Mallat, 2006).  
Cytokines are also often classified as class I or class II cytokines according to 
the structural homology of their receptors. Most interleukins (ILs), CSFs, and 
interferons (IFNs) belong to one of the two classifications. Many such cytokines 
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mediate their effects through the Janus kinase-signal transducers and activators of 
transcription (JAK-STAT) pathway. Three other major cytokine families include the IL-
1 family (including IL-1 , IL-1 , IL-1ra, and IL-18), TNF family, and TGF-  superfamily. 
IL-1 and TNF family members activate the nuclear factor- B (NF- B) and mitogen-
activated protein (MAP) kinase signalling pathways while TGF-  superfamily members 
activate signalling proteins of the Smad family (Tedgui and Mallat,2006). 
Most ILs, CSFs and IFNs mediate their effects through the JAK-STAT pathway. 
Cytokine binding induces receptor dimerisation and recruitment of members of the 
JAK family, which in turn cross-phosphorylate each other and the cytoplasmic 
domains of the receptors on tyrosine residues (JAK activation). This provides docking 
sites for the latent transcription factors STATs. After docking, these transcription 
factors become phosphorylated; they dimerise before entering the nucleus to initiate 
transcription of target genes (Ihle, 2001). 
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Figure 1.7: Cytokines involved in atherogenesis. 
Cytokines involved in atherogenesis and their cellular source and targets. (1) LDL particles 
penetrate the endothelial cell layer and are oxidized in the intima (oxLDL). Pro-inflammatory 
lipids are released from oxLDL and induce expression of cytokines in EC (e.g. IL-1, MIF, M-
CSF, and GM-CSF) and SMCs (M-CSF). MIF and M-CSF can function as a chemotactic factor 
for monocytes and T-cells. GM-CSF is a major regulator of dendritic cell differentiation and 
involved in lesional dendritic cell accumulation. (3) TNF-α and MIF are involved in the 
autocrine activation of macrophages thereby amplifying inflammation. IL-12 and IL-18 formed 
by macrophages and IL-4 (e.g. from NKT) promote the differentiation of native T-cells into TH1-
cells and TH2-cells, respectively. IL-12 and IL-18 are potent inducers of IFN-γ. (4) TH1-cells can 
further activate macrophages (inflammatory cascade) whereas TH2-cells produce anti-
inflammatory mediators (e.g. IL-4, IL-10, and IL-13) with opposite effect on macrophages, T-
cells and EC. IL-4 (TH2-associated) impair the development of TH1-cells from pre-TH-cells (not 
shown). Vice versa, IFN-γ inhibits TH2-cell development. Also, TH2-derived IL-4 and IL-13 are 
potent stimulators of antibody production (on B-cells, not shown), IL-5 is involved in B-cell 
differentiation and eosinophilic inflammation. (5) Macrophages are further stimulated by T-cell 
derived IFN-γ as well as IL-1 and TNF-α (also from other sources) together resulting in an 
amplification of the inflammatory response. (6) SMCs are targets for many of the macrophage- 
and T-cell-derived cytokines and participate in this self-perpetuating inflammatory cycle by 
producing and secreting a range of pro-inflammatory factors among which are IL-1, TNF-α, 
and IFN-γ.(Kleemann et al. 2008) 
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1.14 Proinflammatory cytokines 
1.14.1 TNF- 
TNF-α is a pleiotropic cytokine that exerts strong pro-inflammatory effects in 
atherosclerosis and other metabolic and inflammatory disorders, such as obesity and 
insulin resistance, which are also risk factors for cardiovascular diseases (Staiger and 
Häring, 2005). TNF-α is primarily produced by monocytes and macrophages. The 
involvement of TNF-α in the pathogenesis of atherosclerosis is supported by its 
presence in human atherosclerotic plaques (Barath et al., 1990; Tipping and Hancock, 
1993). Furthermore, circulating TNF-α levels are associated with increased risk of 
recurrent myocardial infarction, atherosclerotic thickening of carotid intima-media, 
disturbances in triglyceride and glucose homeostasis, and age-related atherosclerosis 
(Schreyer et al., 1996). Blocking of TNF-  activity or disruption of its expression 
diminishes the development of atherosclerosis in ApoE–/– mice (Brånén et al., 2004; 
Ohta et al., 2005). 
1.14.2 TL1A 
TL1A (TNFSF15/VEGI) is a recently identified member of the tumour necrosis 
factor superfamily (TNFSF) that is primarily expressed by ECs and other immune cells 
(Cavallini et al., 2013). It is a ligand for the death domain-containing receptor DR3 
(TNFRSF12). DR3 was initially found to have a role in atherogenesis as it stimulated 
the expression of matrix degrading enzymes including MMP-9 (Kang et al., 2005). 
Immunohistochemical staining of human carotid atherosclerotic plaques revealed a 
high-level expression level of  TL1A in regions rich in macrophage/foam cells (Kang et 
al., 2005). DR3 has been demonstrated to change the function of immune cells and to 
drive several inflammatory-driven diseases such as inflammatory bowel disease and 
arthritis (Meylan et al., 2008; Croft, 2009). Both TL1A and DR3 have been found to be 
involved in the development of atherosclerosis (McLaren et al., 2010a). It was found 
that TL1A enhanced macrophage foam cell formation in vitro by increasing 
 37 
 
AcLDL/oxLDL uptake and intracellular cholesteryl ester content whilst also reducing 
cholesterol efflux from human macrophages (McLaren et al., 2010a). 
1.14.3 IL-17 
The IL-17 family encompasses six members (IL-17A to F) (van et al., 2009). 
All members of the IL-17 family share a similar protein structure characterised by four 
highly conserved cysteine residues, but they have no sequence similarity to any other 
known cytokines (Huang et al., 2004; Gaffen et al., 2006). IL-17E, more commonly 
called IL-25, has different biologic functions, but shares structural features with other 
IL-17 family members (Lee et al., 2001; Fort et al., 2001). IL-17A and IL-17F (which 
are 55% homologous) are both produced by Th17 cells and are the most 
characterised family members to date. The IL-17A and IL-17F genes are located next 
to each other on chromosome six, suggesting the genes encoding IL-17A and IL-17F 
are the result of a duplication event (Langrish et al., 2005; Harrington et al., 2005). 
The receptor for IL-17A (IL-17RA) is a type I transmembrane protein and consists of a 
293 amino acids long extracellular domain and a relatively long intracellular domain 
consisting of 525 amino acids (van et al., 2009). The IL-17A receptor is ubiquitously 
expressed with particularly high levels in haematopoietic tissues. This expression 
pattern is curious, as the main responses to IL-17A occur in epithelial, endothelial and 
fibroblast cells (Gaffen, 2009). Another function of IL-17RA might be to limit signalling 
by receptor-mediated internalisation of the ligand (Gaffen, 2009). It has been noticed 
that surface expression of IL-17RA is rapidly reduced following IL-17 binding. This 
helps internalising IL-17A and clearing it from the inflammatory environment 
(Lindemann et al., 2008). IL-17A activates a highly pro-inflammatory programme of 
gene expression, typical of that induced by innate immune receptors such as IL-1R 
and Toll- like receptors (TLRs) (Park et al., 2005). Similar to these receptors, IL-17A 
activates NF-κB, a hallmark transcription factor associated with inflammation. IL-17A 
has pleiotropic activities, including induction of the production of TNF- , IL-1β and 
MCP-1 as well as adhesion molecules like ICAM-1 (Erbel et al., 2009). The best-
characterised member is IL-17A or IL-17 as it is the founding member of the family 
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(van et al., 2009). IL-17 is generally classified as a pro-inflammatory cytokine (Erbel et 
al., 2009). It is involved in the early activation of the immune system and plays a vital 
role in bridging the innate immune response with the adaptive immune response (van 
Es et al., 2009). 
The role of IL-17 in atherosclerosis development remains contentious. IL-
17A is elevated in patients with CHD, which have raised expression in cells of 
atherosclerotic plaque (Hashmi and Zeng, 2006; Simon et al., 2013). IL-17A induces 
the expression of many pro-atherosclerotic mediators, including TNF-α, IL-1β, and 
MMP-1 by a range of cells involved in atherosclerosis (Shibata et al., 2014; Erbel et 
al., 2009; Eid et al., 2009). The evidence in in vivo mouse studies has been 
inconsistent. A number of studies have shown that mice with disrupted IL-17A 
signalling have reduced atherosclerosis (van Es et al., 2009; Erbel et al., 2009). In 
contrast, a study by Taleb and colleagues (2009) showed that neutralisation of  IL-
17A in chimeric LDLr-/-SOCS3-/- mice accelerated atherosclerosis and did not reduce 
atherosclerosis in LDLr-/-SOCS3+/+ mice. This inconsistency is possibly due to 
differences in mouse genetic background but also suggests that the role of IL-17A is 
multifaceted and requires further validation in vivo. 
1.14.4 Interferon-γ 
The human interferon (IFN) family is categorised into two major types. Type I 
consists of IFN-α, IFN-β, IFN-ε, IFN-κ, IFN-ω and IFN-ν and type II consists of only 
IFN-γ (Pestka, 2007). Type I IFNs share a common structure and are synthesised by 
most cell types (McLaren and Ramji, 2009). On the other hand, type II IFN has a 
single member with a different molecular structure from the type I IFNs and functions 
through a separate receptor (IFN-γR). IFN-γ is secreted mainly by natural killer (NK) 
cells and activated T-lymphocytes but can also be produced by 
monocytes/macrophages, B cells and dendritic cells (Mire-Sluis and Thorpe 1998; 
Schroder et al., 2004). The biological properties of IFN-γ are discussed in detail in the 
following sections. 
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1.14.5 Structure of IFN-γ 
Human IFN-γ has a molecular weight of approximately 17 kDa and consists of 
two self-associated anti-parallel α-subunits with no β-sheet (Pestka, 2007). As 
addressed below in more detail, IFN-γ is considered to play an important role in the 
pathogenesis of atherosclerosis. However, in vitro cell culture studies have suggested 
that the role of IFN- is more complicated since it acts in both a pro- and anti-
atherogenic manner (McLaren and Ramji, 2009). For example, IFN- has some anti-
foam cell actions such as suppression of macrophage lipoprotein lipase (LPL) 
expression (McLaren and Ramji, 2009). Also, it has been shown in some studies to 
reduce the expression of SR-A and CD36 specifically in macrophages, and due to this 
effect, the cytokine had been attributed to a reduction of macrophage foam cell 
formation in one study  (Geng and Hansson, 1992). However, the majority of 
subsequent studies have shown that IFN-γ promotes macrophage foam cell formation 
despite decrease in the expression of LPL and CD36 genes (McLaren and Ramji, 
2009).  
1.14.6 The roles of IFN-γ in atherosclerosis 
IFN-γ is multifunctional and has antiviral activity along with a variety of 
immuno-modulatory and inflammatory roles. IFN-γ plays a significant role in inhibition 
of viral infections through intervening and prevention of several stages of viral protein 
synthesis and replication (Wei et al., 2009).  A number of studies have shown that 
mice deficient in IFN-γ or IFN-γR had a greater susceptibility to bacterial and viral 
infection (Dalton et al., 1993; van den Broek et al., 1995). IFN-γ demonstrates its 
activity on immune system and inflammation predominantly through several 
mechanisms including stimulation of antigen presentation by inducing the expression 
of Class I and II major histocompatibility complex (MHC) molecules on the surface of 
macrophages and T-lymphocytes, antigen processing, and promoting differentiation of 
naive T helper (Th0) cells towards a Th1 phenotype. Additionally, IFN-γ activates 
antigen-presenting cells (APCs) (e.g. macrophages) and T-lymphocytes by inducing 
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the production of reactive oxygen intermediates and hydrogen peroxides. These 
augment the apoptosis of cells containing intracellular parasites, stimulate cytokine 
production in target cells and cause recruitment of white blood cells to the 
inflammation site through increased expression of chemokines and adhesion 
molecules in both leukocytes and endothelial cells (Boehm et al., 1997; Stark et al., 
1998; Schroder et al., 2004).  Furthermore, IFN-γ regulates the cellular state, mainly 
by influencing the rate of proliferation, differentiation and apoptosis. Inhibition of cell 
growth is modulated by IFN-γ through the expression of certain genes linked to the 
cell cycle (e.g. Fas), and can either induce or suppress apoptosis depending on the 
cell type or state of differentiation (Dai et al., 1998; Boehm et al., 1997; Stark et al., 
1998; Schroder et al., 2004).  
The important role of IFN-γ in immunity and inflammation imply that the 
cytokine is likely to have a key role in disorders associated with a chronic 
inflammatory reaction.  Indeed, a number of studies have suggested an association 
between the differential expression of IFN-γ with the pathology of a number of 
inflammatory diseases including rheumatoid arthritis, glomerulosclerosis and 
pancreatitis (Cañete et al., 2000; Kitching et al., 1999; Uehara et al., 2003). In 
particular, IFN-γ demonstrates major roles in atherosclerosis and its pathogenesis 
through  the regulation of several processes in the disease (McLaren and Ramji, 
2009; Harvey and Ramji, 2005). IFN-γ stimulates a variety of immune cellular 
responses, including the regulation of antigen presentation, control of Th1/Th2 
adaptive immune response, immune cell activation and cytokine secretion (Mallat and 
Tedgui, 2004; Gattoni et al., 2006; Schoenborn et al., 2007). Consequently, these 
responses act alongside IFN-γ-mediated regulation of other cellular activities, such as 
proliferation, differentiation and apoptosis, which participate in the complex nature of 
atherosclerosis (Stark et al., 1998). Although this cytokine can display anti-
inflammatory properties IFN-γ predominantly exerts pro-inflammatory and pro-
atherogenic roles throughout disease development, ranging from early lesion 
formation (foam cell), to the more mature and advanced lesion progression 
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(atheroma), to clinical complication of atherosclerotic plaques (plaque stability), as 
detailed below (Mühl and Pfeilschifter, 2003). 
1.14.7 Recruitment of immune cells to the lesion   
The recruitment of monocytes / macrophages and T-lymphocytes to the site of 
inflammation is a critical early step in atherogenesis (Lusis, 2000).  IFN-γ has been 
shown to up-regulate the expression of several chemokines and adhesion molecules, 
including MCP-1, MIP-1α and –β and ICAM-1 (Boisvert, 2004). IFN- has also been 
shown to have an effect on ECs in atherosclerosis; for example, the expression of the 
monocyte adhesion molecule VCAM-1 is induced by IFN- (Gupta et al., 1997). This 
cytokine also stimulates the expression of ICAM-1 and VCAM-1 on endothelial cells 
and SMCs (Chung et al., 2002; Li et al., 1993). IFN-γ also stimulates the activation of 
macrophages (Nathan et al., 1983). The activation of CD4+ T-cells (Th1) is also 
facilitated by IFN-γ by increased expression of MHC class II molecules on the surface 
of ECs, macrophages and SMCs (Jonasson et al. 1985; Mach et al., 1996). 
1.14.8 Cholesterol accumulation in foam cells 
Scavenger receptors such as SR-A and CD36 are responsible for the uptake 
of modified LDL (Kunjathoor et al., 2002). As mentioned earlier, a study showed that 
IFN-γ inhibited the expression of SR-A and CD-36 especially in macrophages (Geng 
and Hansson,1992). Also, IFN-γ supressed macrophage  LPL expression (McLaren 
and Ramji, 2009). However, the majority of studies show that IFN-γ increases the 
expression of SR-A and CXCL16 and the uptake of modified LDL (Reiss et al., 2004; 
Wuttge et al., 2004). CXCL16 is a marker of inflammation and atherosclerosis, which 
has a similar function to SR and also has inflammatory properties of chemokine 
(Lehrke et al., 2007). CXCL16 is a proatherogenic marker that is highly expressed in 
macrophages and aortic SMCs (Lehrke et al., 2007). Increased CXCL16 expression 
augments the uptake of oxLDL and facilitates foam cell formation (Wuttge et al., 
2004). CXCL16 has also been implicated in the pathogenesis of metabolic 
dyslipidaemia and coronary atherosclerosis (Lehrke et al., 2007; Wuttge et al., 2004). 
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In human macrophages in vitro and in vivo, activation of NF-κB was found to be 
sufficient to stimulate the induction of CXCL16 expression, which can be inhibited by 
administering aspirin (Lehrke et al., 2007). CXCL16 accumulates in the 
atherosclerotic lesion where it stimulates the production of T cells and IFN-γ (Abel et 
al., 2004). 
IFN-γ has also been demonstrated to reduce the expression of ApoE in both 
monocytes and macrophages, and to increase its intracellular degradation (Brand et 
al., 1993). In addition, IFN-  decreases cholesterol efflux and ABCA1 expression in 
murine and human macrophages and macrophage-derived foam cells (Reiss et al., 
2004; Panousis and Zuckerman, 2000). Furthermore, IFN-γ has been found to inhibit 
the expression of the 27-hydroxylase enzyme, which is important in the removal of 
cholesterol from foam cells (Reiss et al., 2001). 
1.14.9 Plaque destabilisation 
As atherosclerosis progresses, advanced plaques will be formed and these 
include lipid rich necrotic core, calcification and accumulation of cell debris (Lusis et 
al., 2004). IFN-γ encourages apoptosis of macrophage foam cells by increasing the 
expression of some pro-apoptotic molecules such as tumour necrosis factor-alpha 
receptor 1 (TNFR1) and caspase-8 (Inagaki et al., 2002). IFN-γ is also known to 
promote plaque destabilisation by weakening the fibrous cap by stimulating the 
production of MMPs by macrophages and SMCs (Schönbeck et al., 1997). MMPs 
have been found to be present in the lesion, predominantly in the shoulder regions 
where plaques are highly likely to rupture (Galis et al., 1994). These enzymes 
degrade the ECM and therefore cause plaque destabilisation. Tissue factor activity is 
also enhanced by IFN-γ treatment in synergy with C-reactive protein, so increasing 
the rate of thrombosis following rupture (Nakagomi et al.,2000) 
1.14.10 IFN-γ signalling 
IFN-γ mediates its signalling through binding to the receptors on the cell 
surface. The JAK-STAT pathway is the best mechanism understood in IFN-γ 
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signalling cascade (Wood, 2004). Binding of IFN-γ to its receptor complex, which is 
made of IFNγR1:IFNγR2, leads to the recruitment of two JAKs, JAK-1 and -2, each of 
which binds to IFNγR through N-terminal domains (Figure 1.9). Both JAKs become 
activated by tyrosine phosphorylation (van Boxel-Dezaire and Stark, 2007) and, in 
turn, they phosphorylate the IFN-γR tails. This results in the recruitment of STAT1 
monomers, which dock to the phosphorylation site via their Src-homology (SH2) 
domain (Levy and Darnell, 2002; Greenlund et al., 1995). The JAKs phosphorylate 
each STAT1 monomer on tyrosine 701. The STAT1 monomers then form dimers and 
then migrate to the nucleus where they bind to γ-activated sequence (GAS) elements 
in the promoters of genes regulated by this cytokine (van Boxel-Dezaire and Stark, 
2007; Darnell et al., 1994; Levy and Darnell, 2002). The STAT homodimers can also 
be phosphorylated at serine 727 and this increases their transcriptional acivity (Levy 
and Darnell, 2002). Many kinases have been found to affect STAT1 phosphorylation 
on serine 727, including phosphoinositide 3’-kinase and extracellular signal-regulated 
kinase (ERK) (Harvey et al., 2007; Li et al., 2010). STAT1 plays a major a role in the 
development of atherosclerosis (Li et al., 2010). Results from in vitro and in vivo 
studies have shown that STAT1 plays a role in foam cell formation and progression of 
atherosclerosis (Agrawal et al., 2007). STAT1 deficiency in a mouse model system 
showed a reduction in intraperitoneal inflammation and reduced atherosclerosis 
(Agrawal et al., 2007). The effect of STAT1 is likely to be mediated through CD36 as 
the activity of this scavenger receptor was absent in macrophages deficient in CD36 
(Agrawal et al., 2007).   
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Figure 1.8: JAK/STAT1 signalling in response to IFN-γ. 
The binding of IFN-γ to its cognate, cell surface receptor involves dimerisation of the two IFN-γ 
receptor (IFN-γR) subunits, made up of IFN-γR1: IFN-γR2 pairs, and results in the activation of 
two bound tyrosine kinases, JAK1 and JAK2, by tyrosine phosphorylation. Once the JAKs 
become activated, or tyrosine phosphorylated, they mediate tyrosine phosphorylation of the 
IFN-γ receptor tails through their catalytic, C-terminal kinase domain. Latent STAT1 
monomers, located in the cytoplasm are recruited to the receptor tails via their SH2 domains 
and are then phosphorylated on tyrosine 701. The tyrosine phosphorylated STAT1 monomers 
dimerise forming a STAT1:STAT1 homodimer which can translocate to the nucleus and bind to 
specific γ-activated sequence (GAS) elements in the promoters of IFN target genes. Tyrosine 
phosphorylated STAT1 homodimers can also be phosphorylated on serine 727 by kinases like 
PI3K and p38 MAPK that enhances their transcriptional capacity. Abbreviations: IFN-γ, 
interferon-γ; JAK, Janus kinase; p38 MAPK, p38 mitogen-activated protein kinase; PI3K, 
phosphoinositide 3-kinase; SH2, Src-homology 2; STAT1, Signal transducer and activator of 
transcription 1. Taken  from (McLaren and Ramji, 2009) 
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1.14.11 Mitogen-activated protein kinase (MAPK) pathways and IFN-γ 
signalling 
Mitogen-activated protein kinases are group of serine/threonine kinases that 
are responsible for translating extracellular signals to variety of cellular responses. 
MAPKs are extensively used in physiological and pathophysiological processes, 
including gene expression, mitosis and metabolism along with motility, survival, 
apoptosis and differentiation of cells (Cargnello and Roux, 2011). Each MAPK 
pathway is divided into three main linear components, a MAPK kinase kinase 
(MAPKKK, MEKK), a MAPK kinase (MAPKK, MKK or MEK) and a MAPK (Dhillon et 
al., 2007; Kim and Choi, 2010) (Figure 1.10). To date, three major, and well-studied, 
MAPK pathways have been identified in mammalian cells: ERK1/2; c-Jun N-terminal 
kinases (JNK)/stress-activated protein kinases (SAPK); and p38 kinases (Robinson 
and Cobb, 1997; Chang and Karin, 2001) (Figure 1.11). 
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Figure 1.9: A mitogen-activated protein kinase (MAPK) pathway. 
This figure shows a mitogen-activated protein kinase (MAPK) pathway. The MAPK is 
composed of three kinases [MAPK kinase kinase (MKKK), MAPK kinase (MKK), and 
MAPK] and they are all activated by phosphorylation, adapted from (Widmann et al., 1999). 
 A further explanation of the MAPK pathway is included in the next figure. 
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Figure 1.10: The best known MAP kinase pathways. 
The net result of these pathways is the activation of the three main MAP kinases: ERK, JNK, 
and p38 MAP kinase, all of which have different major downstream targets. ATF-2, activating 
transcription factor 2; ERK, extracellular signal regulated kinase; JNK, c-Jun NH2 terminal 
kinase; MAPK, MAP kinase; MAPKK, MAP kinase kinase; MAPKKK, MAP kinase kinase 
kinase; MEF; MEK, MAP/ERK kinase; MKK, MAP kinase kinase.;ATF-1 cyclic AMP- 
dependent transcription factor-1.  Adapted from (Hommes et al., 2003). 
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The following sections will explain in detail the properties and functions of the 
well-known MAPKs (ERK1/2, JNK1/2, and p38). 
1.14.12 ERK1/2 
The genes for ERK1/2 were cloned in 1990 and were found to be expressed at 
high levels in the brain, skeletal muscle, thymus, and heart (Boulton et al., 1990). 
They regulate many cellular processes including growth, proliferation, differentiation, 
survival and apoptosis (Cargnello and Roux, 2011). Growth factors, such as PDGF, 
epidermal growth factor (EGF) and nerve growth factor (NGF) can all activate ERK1/2 
(Boulton et al., 1990) along with cytokines and osmotic stress (Raman et al., 2007). 
Results from various gene knockout mice have demonstrated the physiological and 
pathological importance of the ERK1/2 pathway. ERK2 and MEK1-knockout mice 
have embryonic lethality as a consequence of defective mesoderm differentiation and 
placenta vascularisation respectively (Giroux et al., 1999; Hatano et al., 2003). These 
results show necessary roles of ERK2 and MEK1 in embryonic development. ERK1 
knockout mice are viable but show defective thymocyte maturation and reduced 
expression of α and β chains of the T cell receptor, and exhibit reduced activation by 
anti-CD3 antibody, illustrating that ERK1 is involved in T cell activation and 
inflammatory processes (Pagès, 1999). Studies from genetically modified animals 
have also revealed key roles of ERK activation in cardiac pathology, such as 
myocardial hypertrophy and ischemia/reperfusion injury, as well as in the mechanisms 
of cardio-protection such as ischemic precondition (Heinen et al., 2011). In addition, in 
vivo studies show that the amounts of ERK1/2 are elevated in atherosclerotic lesions 
compared with normal vessel tissue in cholesterol fed rabbits as demonstrated by 
immune-blotting (Hu et al., 2000). Previous studies from our laboratory have found 
that ERK-1/2 is integral to the IFN-γ-mediated phosphorylation of STAT1 on serine 
727, activation of many pro-atherogenic genes, and the uptake of modified LDL by 
human macrophages (Li et al., 2011). 
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1.14.13 JNK/SAPK 
There are three JNK isoforms, 1, 2 and 3. JNK1/2 are expressed ubiquitously 
whereas JNK3 expression is restricted to the brain, testis and cardiac myocytes (Bode 
and Dong, 2007). JNKs can be directly activated and phosphorylated by mitogen-
activated protein kinase kinase (MKK)4 and/or MKK7. c-Jun is a well-known substrate 
for JNKs. 
JNKs have important roles in the control of apoptosis (Ries et al., 2008) along 
with cell survival and proliferation (Yu et al., 2004). Studies in mice with deletion of 
JNK-1 and -2 in T helper cells found that JNK2 has an important role in Th 
differentiation to Th1 phenotype and is also involved in the production of Th1 
cytokines, such as IFN-γ (Dong et al., 1998; Sabapathy et al., 1999). In addition, 
ApoE-/- and JNK2-/- mice fed a high cholesterol diet had decreased amounts of 
atherosclerotic plaques probably from reduction in foam cell formation whereas 
knockout of JNK1 had no effect (Ricci et al., 2004). 
1.14.14 p38 MAPK 
There are four p38 isoforms in mammalian cells, p38α, p38β, p38γ and 
p38δ (Dong et al., 2002). p38β is expressed ubiquitously whereas p38γ is found in 
skeletal muscles and p38δ is expressed in multiple tissues including lung, kidney, 
testis, pancreas and small intestine (Kaminska, 2005). p38 MAPK can be activated by 
MKK3, MKK4 and MKK6 (Pearson et al., 2001; Raingeaud et al., 1996). Mammilian 
p38 is associated with inflammation, cell growth, differentiation and apoptosis 
(Hommes et al., 2003). For example, p38 MAPK regulates the expression of multiple 
genes implicated in inflammation such as TNF-α, IL-1β, IL-6 and IL-8 (Kaminska, 
2005).  
p38 MAPK regulates the level of cholesterol ester accumulation in 
macrophages, which is an important step in foam cell formation and development 
of atherosclerosis (Mei et al., 2012). Additionally, p38 MAPK plays a significant role 
in the development of atherosclerosis via many different ways including stimulation of 
 50 
 
secretion of MCP-1, which attracts monocytes to vascular enthothelial cells (Domoto 
et al., 2003; Matsuyama et al., 2004). p38 MAPK mediates the MCP-1-dependent 
transendothelial migration, integrin activation, and chemotaxis (Cambien, 2001).  
The role of p38 MAPK has also been investigated in mouse model systems. 
Macrophage deficiency of p38α MAPK was found to promote apoptosis and plaque 
necrosis in advanced atherosclerotic lesions of ApoE-/- mice (Seimon et al., 2009). On 
the other hand, Kardakaris (2011) showed that endothelial and macrophage-specific 
deficiency of p38α has no effect on the pathogenesis of atherosclerosis in ApoE-/- 
mice. Further studies will be required to clarify the role of p38 MAPK in 
atherosclerosis in vivo. 
1.15 Hypothesis 
1. Statins act in an anti-inflammatory manner and attenuate the expression of 
inflammatory markers expressed in response to pro-inflammatory 
cytokines in human macrophages. 
2. The anti-inflammatory action of statins is due to depletion of metabolites in the 
cholesterol biosynthetic pathway because of inhibition of HMG CoA 
reductase. 
3. Statins attenuate inflammatory gene expression induced by the pro-
inflammatory cytokine interferon-γ by affecting the activity of signal 
transducers and activators of transcription-1. 
4. Statins also effect pro-inflammatory gene expression by modulating the action 
of MAP kinase pathways. 
5. Statins affect lipid metabolism in human macrophages. 
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1.16 Aims of the study 
Atherosclerosis is recognised as a chronic inflammatory disorder, representing 
the major cause of mortality in the western society. Cytokines play an important role in 
the regulation of inflammatory responses during atherosclerosis progression, 
principally through the modulation of gene expression associated with this disease. 
The study of signalling mechanisms involved in the cytokine-mediated regulation of 
gene expression implicated in the progression of this disease is vital for the 
identification of new targets for therapeutic intervention (Harvey et al., 2007). 
Additionally, it is important to understand how lipid-lowering drugs such as statins 
mediate their anti-inflammatory actions. Therefore, the main purpose of this project 
was to investigate if statins inhibit gene expression regulated by cytokines using real-
time quantitative PCR and other techniques, and to delineate the mechanisms of 
actions. 
Previous studies on the anti-inflammatory actions of statins have been limited to 
certain classical cytokines (Bessler et al., 2005; Iwata et al., 2012). The main aim was 
therefore to investigate whether this occurs with newer cytokines such as IL-17 and 
TL1A along with the potentially master regulator of atherosclerosis, IFN-γ. The effect 
of statins was analysed using a combination of THP-1 macrophages, RAW 264.7 
macrophages and primary HMDMs (Chapter 4). 
As mentioned earlier, IFN-γ signals predominantly through the JAK–STAT 
pathway and other pathways including MAPK. It was therefore decided to study the 
effect of simvastatin on these pathways at the level of their activation and/or gene 
expression (Chapter 4). Particularly, the effect of simvastatin on STAT1 and the three 
MAPK cascades (ERK1/2, JNK/c-Jun and p38) was analysed. 
As statins are known for their pleiotropic actions, it was of interest to examine 
their effect on lipid content and composition of macrophages using a combination of 
thin layer chromatography, gas chromatography and radiolabelling experiments, such 
studies formed the focus of chapter 5. 
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2 Chapter 2: Materials and Methods
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2.1 Materials 
 
The table below shows the materials that were used to carry out experiments 
presented in this thesis and the suppliers from where they were sourced.
Table ‎2.1: The materials used for studies in this thesis and the 
suppliers from where they were sourced.  
Supplier Material 
Welsh Blood Service, UK. Buffy coats. 
Gibco-BRL, UK 
RPMI 1640 culture medium; Penicillin; 
Streptomycin; Foetal calf serum; 2-
mercaptoethanol. 
Sigma-Aldrich, UK 
Phorbol 12-myristate 13-acetate (PMA), 
Tween20; Syber Green; X-ray film; Dimethyl 
sulfoxide (DMSO); RIPA buffer; Protease 
inhibitor cocktail; Ethanol; Methanol; RNA Zap; 
Accuspin tubes; Geranylgeranyl 
pyrophosphate, ammonium salt (GGP); 
Farnesyl pyrophosphate, ammonium salt 
(FPP); Mevalonate; THP-1 cell line 
(88081201); RAW264.7 cell line (91062702); 
Bromophenol blue; Phosphate buffered saline 
(PBS) tablets. 
Qiagen, UK RNeasy plus minikit. 
NBS, UK Spin column RNA miniprep kit. 
Peprotech, UK IL-17A ; IFN-γ and TL1A.  
Calbiochem, UK 
Simvastatin, sodium salt; Insolation 
simvastatin sodium salt; Atorvastatin. 
Promega, UK 
Deoxyribonucleotide triphosphate (dNTPs); 
MMLV reverse transcriptase; RNasin 
ribonuclease inhibitor; Random hexamer 
primers. 
Greiner Bio One, UK 
Tissue culture flasks; 6-well plates; 12-well 
plates; Cell scrapers; 10ml stripettes; 25ml 
stripettes; 50ml Falcon tubes. 
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Fisher Scientific, UK 
Industrial methylated spirit (IMS); filter papers; 
Ethylenediaminetetraacetic acid (EDTA); 
Glycerol. 
Millipore, UK Sterile 0.22µm filters, PVDF membrane. 
Sigma Genosys, UK PCR primers. 
Applied Biosystems, UK I block, CDP star reagent. 
Invitrogen, UK 
NuPage™ Novex gel tank system; Blotting 
module; Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-
PAGE) gels; MOPS running buffer; Transfer 
buffer; RPMI 1640 with GlutaMAX™ liquid; 
Penicillin; Streptomycin; Foetal calf serum; 2-
mercaptoethanol; See Blue protein markers; 
Magic marker XP western protein standard. 
Santa Cruz Biotechnology, USA 
Goat anti-rabbit IgG alkaline phosphtase (AP) 
antibody (Ab) (sc-2007); Goat anti-mouse (AP) 
Ab (sc-2008); STAT1 p84/p91 Ab (sc592);  
ICAM-1Ab (H-108); p-c-Jun Ab (km-1) (sc-
822); c-Jun Ab (H-79) (sc-1694). 
Axis Shield, Norway Lymphoprep. 
Pierce, UK Bicinchoninic acid assay (BCA) protein assay. 
BioRad, UK Microplate Reader. 
MJ Research, UK Opticon 2 PCR machine. 
National Diagnostics, UK 10X TBE. 
Cell Signalling Technology, UK 
Phospho-p44/42 MAPK (ERK1/2) 
(Thr202/Tyr204) Ab (9101); p44/42 MAPK 
(ERK1/2) Ab (9102); phospho-p38 MAPK 
(Thr180/Tyr182) Ab (9211); p38 MAPK Ab 
(9212); Phospho-STAT1 (Ser727) Ab (9177s); 
Phospho-STAT1 (Tyr701) Ab (9167). 
Thermo Fisher Scientific, UK Restore Plus western blot stripping buffer. 
Amersham Life Sciences Ltd., UK 
[1-
14
C]-acetic acid (sp. activity = 1.85-2.29 GBq 
. mmol
-1
) 
Merck KGaA,, Germany TLC Silica gel G plates   
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2.2 Preparation of solutions, glass-and plastic-ware 
 
       Solutions, glass- and plastic-ware used for RNA/DNA and tissue culture related 
techniques were autoclaved at 121°C (975kPa) for 30 minutes. 
2.3 Cell Culture Techniques 
 
2.3.1 Cell lines 
2.3.1.1 THP-1 
 
THP-1 is a human monocytic leukaemia cell line. After differentiation with 
phorbol esters, THP-1 cells exhibit many of the properties and characteristics of 
human monocyte-derived macrophages (Kohro et al., 2004). Thus differentiated THP-
1 cells are considered as a practical model to examine properties of macrophages 
including cell signalling and gene expression in disease, including atherosclerosis, 
with demonstrated conservation of responses to primary cultures and in vivo 
(McLaren et al ., 2010a; McLaren et al., 2010b; Nakaya et al., 2010).  
2.3.1.2 RAW264.7 
 
RAW264.7 is a mouse leukaemic macrophage cell line that is widely used as a 
macrophage cell model exhibiting a high efficiency for DNA transfection (Dickins et al., 
2005). The RAW264.7 cell line was derived about 30 years ago from a tumour 
developing in a BAB/14 mouse, a BALB/c IgH congenic strain, inoculated with the 
Abelson murine leukaemia virus (Hartley et al., 2008). RAW264.7 cells are adherent 
to tissue culture flasks and dishes. 
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2.3.2 Maintenance of cell lines in culture 
 
2.3.2.1  THP-1 and RAW 264.7 
 
THP-1 and RAW 264.7 cells were grown in RPMI-1640 with GlutaMAX™. The 
medium was supplemented with 10% (v/v) heat-inactivated (56°C, 30 minutes) foetal 
calf serum (HI-FCS), penicillin (100U/ml) and streptomycin (100μg/ml) (pen/strep). 
Both the HI-FCS and pen/strep were filter-sterilised by passing them through a 0.2μm 
sterile filter before use. Both THP-1 and RAW264.7 cells were grown in medium 
tissue culture flasks in a humidified incubator at 37°C, 5% (v/v) CO2.  
2.3.3 Sub-culturing of cells 
 
2.3.3.1            THP-1 
 
THP-1 cells were subcultured when they reached approximately 60% 
confluence (0.6 x 106 cells/ml). The cells were transferred into a polypropylene tube 
(Falcon tubes) and centrifuged at 100g for 5 minutes. The medium was aspirated and 
the cells were re-suspended in fresh medium containing 10% (v/v) HI-FCS. Cells were 
placed in new tissue culture flasks and grown up at 37°C in a humidified, 5% (v/v) 
CO2 incubator. For experiments, cells between passage two and eight were used. 
2.3.3.2           RAW264.7 
 
RAW264.7 cells were sub-cultured when they reached approximately 80% 
confluence. The cells were removed from the surface of the dish by scrapping. The 
resulting cell suspension was transferred into a new dish at a ratio of 1:25 with fresh 
pre-warmed medium supplemented with 10% (v/v) HI-FCS and pen/strep. Cells were 
grown up at 37°C in a humidified, 5% (v/v) CO2 incubator. 
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2.3.4 Preserving and storing cells 
 
THP-1 and RAW264.7 cells were kept at -80°C or in liquid nitrogen for long-
term storage with only early passage cells (up to passage 6) being used. Prior to 
freezing, cells were centrifuged at 100g for 5 minutes and re-suspended in HI-FCS 
containing 10% (v/v) glycerol. Approximately 5 x 106 cells/ml were aliquoted into 1ml 
cryoampoules and stored at -80°C overnight before being transferred to liquid 
nitrogen. 
2.3.5 Thawing frozen cells 
 
Cells from liquid nitrogen were thawed by placing them in a water bath at 
37°C. Cells were transferred to a polypropylene tube containing 10ml HI-FCS and 
centrifuged at 100g for 5 minutes. After re-suspension with fresh medium containing 
10% (v/v) HI-FCS, the cells were plated out into tissue culture flasks and cultured as 
normal. 
2.3.6 Counting cells 
 
To count the THP-1 and RAW264.7 cells, a haemocytometer was used. After 
centrifugation at 100g for 5 minutes, cells were re-suspended in 3-5ml of culture 
medium containing 10% (v/v) HI-FCS. The haemocytometer was covered with a 
precise ground cover slip. Then, 7µl of cell suspension was used and the numbers of 
cells in a 5 x 5 grid were counted. The number of cells/ml was calculated by 
multiplying the number of cells in the counting area by 103. 
2.3.7 Treatment of cells with PMA, Simvastatin, Atorvastatin and 
cytokines 
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2.3.7.1           THP-1 
 
For experiments involving reverse transcription quantitative polymerase chain 
reaction (RT-qPCR), after counting the THP-1 monocytes, 500,000 cells were placed 
in each well of a 12-well plate and supplemented with 1ml of culture medium 
containing 10% (v/v) HI-FCS. The cells were then differentiated into macrophages 
with 0.16 µM PMA for 24 hours. The cells then were treated with vehicle, Simvastatin 
or Atorvastatin for 1 hour. The concentration of simvastatin used in this study was 10 
µM (Copaja et al., 2012) or 40 µM, as indicated in the relevant sections, whereas that 
for atorvastatin was 10 µM (Lin et al., 2009). The cells were then incubated in the 
absence or the presence of cytokines for a further 24 hours before harvesting for 
isolation of RNA. Table 2.2 shows the cytokines used in this study along with their 
concentrations. The concentration of the cytokines was based on maximal response 
obtained in previous studies in the laboratory and others in the same field (McLaren et 
al., 2010a; McLaren and Ramji, 2009; Kang et al., 2005). 
2.3.8 Treatment of THP-1 cells with FPP, GGP, mevalonate, Simvastatin 
and IFN-γ 
 
THP-1 cells (500,000) were placed in a 12-well plate and they were 
differentiated with PMA for 24 hours as detailed above. Simvastatin (10 µM), FPP (5 
µM), GGP (5 µM), mevalonate (500 µM) or vehicle were added for 1 hour and then 
the cells were incubated in the absence or the presence of IFN-γ (1000 U/ml) for 24 
hours before RNA extraction and RT-qPCR (see Chapter 4 for details on the 
experiments). 
2.3.9 Treatment of RAW264.7 cells with Simvastatin and IFN-γ 
 
Cells (5x105) were placed in each well of a 12-well plate and 1 ml of culture 
medium with 10% (v/v) HI-FCS and pen/strep was added. The cells were then 
incubated at 37°C in a humidified, 5% (v/v) CO2 incubator for 24 hour. Then, 
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simvastatin (40 µM) or vehicle were added for 1 hour and then incubated with vehicle 
or mouse IFN-γ (1000 U/ml) for 24 hours before RNA extraction and RT-qPCR. 
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Table ‎2.2: Cytokines used and their concentrations. 
Cytokines Concentrations used 
TL1A 100 ng/ml 
IL-17A 100 ng/ml 
IFN-γ 1000 U/ml 
mIFN-γ 1000 U/ml 
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2.3.10 Primary human monocyte-derived macrophage (HMDM) cultures 
 
For this, a buffy coat was obtained from the Welsh Blood Service and the 
monocytes were purified and plated out in 12-well plates. At the beginning, 
Lymphoprep solution was left to warm to room temperature and then 15 ml was added 
to Accuspin centrifuge tubes. The tube was centrifuged at 1000g for 1 minute to place 
the Lymphoprep below the filter. Then, 30 ml of the buffy coat was poured into the 
filter of the Accupsin tube and the tube was re-centrifuged at 1000g for 30 minutes at 
room temperature. The mononuclear cells were then collected and transferred to new 
50ml Falcon tube to which an equal volume of ice-cold PBS-0.4% (w/v) tri-sodium 
citrate was added and immediately centrifuged at 1000g for 5 minute at 4ºC. The 
pelleted cells were then re-suspended in 10 ml of 0.2% (v/v) saline solution (sodium 
chloride solution) and kept on ice for 30 seconds. Following this, 10 ml of 1.6% (v/v) 
saline solution (sodium chloride solution) was added followed by immediate 
centrifugation at 1000g for 5 minutes at 4ºC to remove the red blood cells. This step 
was repeated twice to remove any further red blood cells present in the sample. The 
resultant interface was then collected and washed 6-8 times with 10 ml of ice-cold 
PBS-0.4% (w/v) tri-sodium citrate to remove contaminating platelets. The cells were 
then plated out in RPMI media supplemented with 10% (v/v) HI-FCS and pen/strep. 
The cells were left to differentiate for 10 days before use in experiments. During this 
period, the media was continuously changed every two days. 
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2.4 RNA related techniques 
 
2.4.1 Isolation of RNA 
 
Total RNA was isolated from cells using a Spin Column RNA Miniprep Kit 
(NBS Biologicals). Before using the kit, the medium was aspirated from the cells. The 
cells were re-suspended in Lysis DR buffer, provided in the kit, containing 10 µl/ml β-
mercaptoethanol. The rest of the protocol was carried out according to the 
manufacturer’s instructions. A NanoDrop ND1000 spectrophotometer was used to 
determine the RNA concentration and quality of RNA (OD 260:280 ratio). 
2.4.2 Reverse Transcription 
 
RNA (0.5 μg) was mixed with random hexamer primers (200 pmol) and sterile 
water to a total volume of 13.5 μl. This was incubated at 72°C for 5 minutes and 
immediately cooled on ice. The following reagents were added to the reaction: 1μl of 
deoxyribonucleotide triphosphate (dNTP) mixture containing 10 mM each of 
deoxyadenosine triphosphate (dATP), deoxycytidine triphosphate (dCTP), 
deoxyguanosine triphosphate (dGTP) and deoxythymidine triphosphate (dTTP); 4 μl 
of 5X Molony Murine leukaemia virus (MMLV) reverse transcriptase buffer provided in 
the kit; 0.5 μl (50 U/μl) of recombinant RNase inhibitor; and 1 μl (200 U/μl) of MMLV 
reverse transcriptase. 
The total reaction mixture was incubated at 37°C for 1 hour and the reaction 
terminated by incubation at 92°C for 2 minutes. Synthesised cDNA was diluted by 
adding 30 μl of RNase-free water and the resulting solution was then stored at -20°C 
for future use. 
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2.4.3 RT-qPCR 
 
A RT-qPCR reaction was set up using the SYBER® GREEN JumpStart™ Taq 
Readymix™ for quantitative PCR (Sigma-Aldrich). The reactions were then “run” 
using an Opticon 2 PCR machine (MJ Research). The reagents were mixed and 
added into a 96 well plate and the program was set according to the optimised PCR 
conditions (Tables 2.3 and 2.4). The composition of each reaction is detailed in Table 
2.5. 
The RT-qPCR data were analysed using the comparative Ct (ΔΔCt) method 
(Livak and Schmittgen, 2001). The output of RT-qPCR reaction shows the number of 
PCR cycles against the increasing fluorescence. The ΔΔCt method relies on 
measuring the number of reaction cycles it takes for the amplification plot to cross the 
threshold level (Ct value) within the exponential phase of amplification (Livak and 
Schmittgen, 2001). The Ct values were then collected from the computer and 
analysed on Microsoft Excel using the ∆∆CT method (Ginzinger, 2002). The Ct value 
of the gene of interest was compared relative to the Ct value of a control 
housekeeping gene to normalise the data (Livak and Schmittgen, 2001). The ∆∆Ct 
method relies on two assumptions, firstly that the expression of the housekeeping 
gene does not vary under experimental conditions and secondly, that the PCR 
efficiencies for each primer set used in the analysis are similar (Ginzinger, 2002). The 
sequences of the primers and the size of the amplification products are shown in 
Table 2.3  
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Table ‎2.3: PCR primers for analysis of gene expression 
Gene 
Forward Primer 
(5’-3’) 
Reverse Primer 
(5’-3’) 
Size of 
product 
(bp) 
References 
SR-A 
CCAGGGACATGGA
ATGCAA 
CCAGTGGGACCTCG
ATCTCC 
365 
(Draude and 
Lorenz, 2000) 
CD36 
GAGAACTGTTATGG
GGCTAT 
TTCAACTGGAGAGG
CAAAGG 
388 
(Draude and Lorenz 
2000) 
GAPDH 
GAAGGTGAAGGTC
GGAGTC 
GAAGATGGTGATGG
GATTTC 
226 
(Yamanishi et 
al.,2002) 
ABCA1 
GCTGCTGAAGCCA
GGGCATGGG 
GTGGGGCAGTGGCC
ATACTCC 
90 (Kaplan et al.,2002) 
ABCG1 
TGCAATCTTGTGCC
ATATTTGA 
CCAGCCGACTGTTCT
GATCA 
90 (Kaplan et al.,2002) 
MCP-1 
CATTGTGGCCAAG
GAGATCTG 
CTTCGGAGTTTGGGT
TTGCTT 
91 (Locati et al.,2002) 
ICAM-1 
ACGCTGAGCTCCTC
TGCTACTC 
GGGCAGGATGACTT
TTGAGG 
162 (Nilesh et al.,2010) 
Apo-E 
TTCCTGGCAGGATG
CCAGGC 
GGTCAGTTGTTCCTC
CAGTTC 
270 (Wang et al.,1989) 
ERK-1 
GCAGGACCTGATG
GAGACTGAC 
CCAGAATGCAGCCC
ACAGAC 
344 QPPD 
ERK-2 
GCGCTACACCAAC
CTCTCGT 
CACGGTGCAGAACG
TTAGCTG 
377 QPPD 
p38 MAPK 
GTGGTACAGGGCT
CCTGAGA 
TATGCATCCCACTGA
CCAAA 
79  
c-Jun 
TCCAAGTGCCGAAA
AAGGAAG 
CGAGTTCTGAGCTTT
CAAGGT 
78 Primer Bank 
JNK-1 
TCTGGTATGATC 
CTTCTGAAGCA 
TCCTCCAAGTCCATA
ACTTCCTT 
127 Primer Bank 
JNK-2 
GAAACTAAGCCGTC
CTTTTCAGA 
TCCAGCTCCATGTGA
ATAACCT 
207 Primer Bank 
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mβ-actin 
GTGCCACCAGACA
GCACTGTGTTG 
TGGAGAAGAGCCTAT
GAGCTGCCTG 
202 
(McLaren  et al., 
2010A) 
 
mMCP-1 
CTGGATCGGAACC
AAATGAG 
CGGGTCAACTTCACA
TTCAA 
95 (Locati et al.,2002) 
mICAM-1 
CAGTCCGCTGTGCT
TTGAGA 
CGGAAACGAATACAC
GGTGAT 
75 (Locati et al.,2002) 
PrimerBank and QPCR primer database (QPPD) are both online databases containing primer 
sequences from previous studies. 
 
Table ‎2.4: Reaction set up used for all RT-PCR reactions 
PCR Step  
GAPDH, SR-A, 
c-JUN, JNK1, 
JNK2 and 
mICAM-1 
ABCA1, 
ABCG1, 
ERK1 
and ERK2 
CD36 and 
mβactin 
MCP-1, 
ICAM-1 
and p38 
Apo-E mMCP-1 
Initial Melting 
95°C for 5 
minutes 
95°C for 5 
minutes 
95°C for 5 
minutes 
95°C for 5 
minutes 
95°C for 
5 
minutes 
95°C for 
5 minutes 
Annealing 
60°C for 60 
seconds 
65°C for 
60 
seconds 
58°C for 
60 
seconds 
63°C for 
60 
seconds 
62°C for 
60 
seconds 
59°C for 
60 
seconds 
Extension 
72°C for 60 
seconds 
72°C for 
60 
seconds 
72°C for 
60 
seconds 
72°C for 
60 
seconds 
72°C for 
60 
seconds 
72°C for 
60 
seconds 
Melting 
95°C for 30 
seconds 
95°C for 
30 
seconds 
95°C for 
30 
seconds 
95°C for 
30 
seconds 
95°C for 
30 
seconds 
95°C for 
30 
seconds 
Final 
Extension 
72°C for 10 
minutes 
72°C for 
10 
minutes 
72°C for 
10 
minutes 
72°C for 
10 
minutes 
72°C for 
10 
minutes 
72°C for 
10 
minutes 
Number of 
Cycles 
35 35 35 35 35 35 
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Table ‎2.5: The composition of a 25µl Q-PCR reaction 
Reagent Amount (μl) 
SYBR Green Ready mix (Sigma Aldrich) 12.5 
Forward Primer (4 uM) 0.5 
Reverse Primer (4 uM) 0.5 
cDNA (10 ng) 1 
Water 10.5 
Total 25 
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2.5 Agarose Gel Electrophoresis 
 
Size fractionation of PCR products was carried out by agarose gel 
electrophoresis. For this, 1.5% (w/v) gels were made up with agarose melted into 1x 
Tris/borate/EDTA (TBE) buffer (Table 2.6). A volume of 0.5 μg/ml ethidium bromide 
was added to the dissolved agarose solution. Stock solutions for gel electrophoresis 
are shown below in Table 2.6. 
 
Table ‎2.6: Composition of reagents used in gel electrophoresis 
Reagent Composition 
10 x TBE 0.89M Tris borate, 890mM boric acid and 20mM EDTA, pH 8.3 
5 x DNA loading dye 1x TBE, 50% (v/v) glycerol and 2.25% (w/v) bromophenol blue 
 
DNA or RNA samples (20 μl) were mixed with 5 μl of DNA/RNA loading dye and 
electrophoresis was carried out in 1x TBE buffer at 100V for around 30-60 minutes 
using a horizontal gel unit (Fisher brand). The sizes of the PCR products were 
compared to standard DNA molecular weight markers. DNA/RNA was visualised 
under UV light using a Syngene Gel Documentation system. 
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2.6 Protein Analysis 
 
2.6.1 Preparation of protein extracts using RIPA buffer 
 
Following experimentation, the medium was aspirated from the well and the 
cells were washed with 1 ml of ice cold PBS. The PBS was then aspirated from the 
well and the cells were lysed using 50-100 μl of RIPA Buffer (Table 2.7) 
supplemented with a protease inhibitor cocktail (Sigma) at 1:100 dilution by scrapping. 
The lysate was transferred to a 1.5 ml micro-centrifuge tube and centrifuged at top 
speed for 5 minutes. Lysates were stored at -80°C or used immediately to determine 
protein concentration, followed by SDS-PAGE and western blotting. For analysis by 
SDS-PAGE, the gel sample buffer or running buffer (MOPS SDS running buffer) 
(Table 2.7) was added in a 1:1 ratio before loading. 
2.6.2 Determination of protein concentration 
 
Protein concentration was determined using the Micro BCA Protein Assay 
Reagent Kit (Pierce). Samples were processed in 96-well plates and a standard curve 
was prepared for each assay using bovine serum albumin (BSA) (2 mg/ml) solution to 
give final concentrations of 5 µg/ml, 10 µg/ml, 15 µg/ml, 20 µg/ml and 25 µg/ml. 
Samples were diluted in water in a ratio of 1:300 and placed into a 96-well plate in 
duplicate (150 μl). Then, 150 μl of reagents A, B and C, provided in the kit, were 
mixed according to the manufacturer’s instructions and added to each well. The plate 
was covered and left at 37°C for 2.5 hours. A Model 680 Microplate Reader (Biorad) 
was used to measure the absorbance of each sample at a wavelength of 570 nm. The 
concentration of proteins in the samples was determined from the standard curve. 
2.6.3 SDS polyacrylamide gel electrophoresis 
 
Protein separation was performed using a NuPage 4-12% Bis-Tris gel 
(Invitrogen) on a Mini-PROTEAN II slab electrophoresis cell (Bio-Rad Laboratories) 
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(see Table 2.7 for composition of buffers). Briefly, the gel was placed in the 
electrophoresis tank and the inner and outer compartments were filled with MOPS-
SDS buffer (Table 2.7). Equal amounts of protein sample were added to each well 
and then size-fractionated alongside protein markers (See Blue Plus 2 prestained 
standard 1x markers or Magic markers) (both from Invitrogen). Electrophoresis was 
carried out at 200V, 400 mA for 60 minutes. 
2.6.4 Western blotting 
 
Following electrophoresis, PVDF membrane (0.45 μm pore size, Millipore) was 
cut to the size of the gel and activated in methanol (100%) before being placed in 
transfer buffer (Table 2.7). The membrane was placed on top of the gel and both were 
sandwiched between Whatman 3MM filter paper and sponge pads that had also been 
soaked in transfer buffer (1x, Invitrogen) (Table 2.7). The whole assembly was then 
placed in a Mini Trans-Blot Cell (Bio-Rad Laboratories). Electro-blotting was carried 
out at 30V, 300mA for 60 minutes at 4°C. Transfer efficiency was checked at this 
stage by staining the PVDF membrane with Ponceau S solution. 
2.6.5 Immuno-detection of proteins 
 
Following blotting, the membrane was removed from the sandwich and 
washed once with PBS-Tween (Table 2.7) for 5 minutes. The membrane was then 
placed in I-BT solution (Table 2.7) shaking for 1 hour; this step was carried out to 
block any non-specific interactions of the antibodies with the membrane. After removal 
of the I-BT solution, the primary antibody was added (optimised dilution in I-BT, Table 
2.8) and left overnight shaking at 4°C. The membrane was then washed three times 
for 5 minutes with PBS-Tween. After the wash steps were completed, the secondary 
antibody ( alkaline phosphatase conjugated antibody)(1:5000) was added for 1 hour 
at room temperature (diluted in I-BT, Table 2.8). After 1 hour incubation, the 
membrane was again washed three times for 5 minutes with PBS-Tween. A detection 
reagent (CDP star) was added according to the manufacturer’s instructions (Applied 
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Biosystems) to the membrane before developing the membrane using Kodak film. 
Different exposures were then developed using a Kodak film placed inside a light 
resistant X-ray cassette. The film was developed using Agfa film processor and 
developer. 
2.6.6 Semi-quantitative densitometry analysis of western blots 
 
The densities of bands from immunoblots were analysed using GeneTools 
software (Syngene). All experimental values were normalised to their relevant 
housekeeping protein and the control values within each experiment were arbitrarily 
assigned as 1 (see relevant figure legends). All other values were then compared to 
the control. 
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Table ‎2.7: Composition of stock solutions used for protein analysis by SDS-
PAGE and western blotting. 
Solution Composition 
RIPA Buffer 
50 mM Tris-HCl, pH 8.0, 150 mM sodium 
chloride, 1.0% (v/v) IGPEAL CA-630 (NP-
40), 0.5% (w/v) sodium deoxycholate and 
0.1% (w/v) SDS 
NuPAGE MOPS SDS Running Buffer (X20) 
50 mM 3-(N-morpholino) propane sulfonic 
acid (MOPS), 50 mM Tris Base, 0.1% (w/v) 
SDS, 1 mM EDTA, pH 7.7. 
NuPAGE Transfer Buffer 
50 mM Bis-Tris propane, 50 mM Bicine, 20% 
(v/v) methanol. 
I-BT solution 
500ml PBS-Tween, 1gram Tropix I-Block 
(Applied Biosystems UK), 500ml of 5% (v/v) 
sodium azide. 
PBS-Tween 
10l ddH20, 100 PBS tablets (sigma), 20ml 
Tween20. 
Ponceau S 
0.1% (w/v) Ponceau S, 5 %( v/v) acetic acid, 
ddH2O. 
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Table ‎2.8: Antibodies and dilutions used for western blotting 
 
Protein 
Primary 
Antibody 
Species 
Primary 
Antibody 
Dilution 
Secondary 
Antibody 
Secondary 
Antibody 
Dilution 
Protein Size 
β-actin Mouse 1:10,000 
Goat Anti Mouse 
(AP) 
1:5000 42 kDa 
ICAM-1 Rabbit 1:200 
Goat Anti Rabbit 
(AP) 
1:5000 110 kDa 
Phospho 
p44/p42 
Rabbit 1:1000 
Goat Anti Rabbit 
(AP) 
1:5000 42 and 44 kDa 
Total p44/p42 Rabbit 1:1000 
Goat Anti Rabbit 
(AP) 
1:5000 
42 and 44 
kDa 
Phospho p38 Rabbit 1:1000 
Goat Anti Rabbit 
(AP) 
1:5000 43 kDa 
Total p38 Rabbit 1:1000 
Goat Anti Rabbit 
(AP) 
1:5000 43 kDa 
Phospho c-Jun Mouse 1:1000 
Goat Anti Mouse 
(AP) 
1:5000 39 kDa 
Total c-Jun Rabbit 1:1000 
Goat Anti Rabbit 
(AP) 
1:5000 39 kDa 
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2.7 Lipid Experiments 
2.7.1 Cell culture 
THP-1 cells were cultured as described above except that 4-6 millions cells 
were used in each experiments in 6 well plates. Following differentiation, Simvastatin 
(40 µM) or vehicle were added for 1 hour followed by vehicle or IFN-γ (1000 U/ml) for 
24 hours. PBS (1x) (pH 7.4) was added to the cells, which were then scraped from the 
surface using a plastic cell scraper. Cells were then transferred into an Eppendorf 
tube and centrifuged for 5 minutes at maximum speed in a microcentrifuge to obtain a 
pellet that was then stored on ice.  
2.7.2 Lipid Extraction 
2.7.2.1      Lipid extraction from cell suspension 
 
Lipids were extracted from macrophages using the method by Garbus et al. 
(1963). Briefly, 1ml of distilled water was added to the cell pellet and the contents 
transferred into a glass tube. Then, 2.5 ml of chloroform: methanol solution (1:2 by 
volume) was added. The samples were then vortexed and incubated at room 
temperature for 15 minutes. After addition of 1ml each of chloroform (100%) and 
Garbus solution (2 M KCl in 0.5 M potassium phosphate buffer (K2HPO4 and 
KH2PO4, both 0.5 M; pH 7.6), the samples were vortexed and centrifuged at 1500 
rpm for 3-5 minutes (Baird and Tatlock Auto Bench Centrifuge Mark IV, England). This 
step allows two-layer separation with cell debris at the interphase of chloroform and 
aqueous layers. The chloroform layer (containing lipids) was carefully transferred to a 
clean conical tube using a glass pipette. The solvent was then evaporated under a 
stream of nitrogen. The extracted lipids were re-constituted into a known volume of 
chloroform and stored at -20ºC.  
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2.7.2.2     Separation of total lipids using thin-layer chromatography 
 
Non-polar lipids were separated using one-dimensional thin-layer 
chromatography (TLC) on 10 x 10 cm Silica gel G plates using a solvent system of 
hexane: diethyl ether: acetic acid (80:20:1 by vol.). Following drying, plates were 
sprayed with 8-anilino-4-naphthosulphonic acid (0.05% in methanol (w/v), solution and 
viewed under UV-light to detect lipids. Bands corresponding to total polar lipids (PL), 
triacylglycerol (TAG) and sterol esters (SE) were identified and scraped of the plates 
along with silica gel for further fatty acid analysis as described below.  
2.7.3 Fatty acid analysis 
2.7.3.1      Transmethylation 
 
Individual lipid classes separated by TLC and aliquots of total lipid extracts 
were used for fatty acid (FAs) analysis. FAs were converted into fatty acid methyl 
esters (FAMEs) via transmethylation with 2.5% (v/v) H2SO4 in dry methanol: toluene 
(2:1, by vol.) at 70ºC for 2 hours. A known amount (30-50 µg) of heptadecanoic acid 
(C17:0) was added as an internal standard for FAs quantification. After incubation for 
2 hours, 2 ml of 5% (w/v) NaCl (aqueous solution) was added and FAMEs were 
extracted with 3 ml (two times) of hexane (100%) (HPLC grade). Combined hexane 
fractions were evaporated under a stream of nitrogen, reconstituted into a small 
volume (40-60 µl) of 100% hexane and stored under -20ºC for future analysis.  
2.7.3.2      Gas Chromatography  
 
FAMEs were separated and analysed by using a Clarus 500 gas 
chromatograph (Perkin-Elmer, Norwalk, Connecticut) with a flame ionising detector 
(FID) and equipped with a 30 m x 0.25 mm i.e. capillary column (Elite 225, Perkin 
Elmer, Waltham, MA, USA). The oven temperature was set to be 170ºC for 3 minutes, 
then heated up to 220ºC at 4ºC/minute and finally held at 220ºC for 30 minutes. 
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FAMEs were identified by comparing retention times of peaks with those of G411 
standard mixture (Nu-Chek Prep,Inc., Elysian, MN, USA). 
2.8 Radiolabeling experiments 
To investigate the effect of Simvastatin on the radiolabelling of cholesterol 
(CHO) and two other major lipid classes, triacylglycerols (TAG) and total polar lipids 
(TPL), 4x106/ml cells were incubated with 0.5 μCi of sodium [1-14C] acetate for 3 hour. 
After incubation, the cells were pelleted by centrifugation for 5 minutes at 1500 rpm. 
Cell lipids were extracted as described previously (Section 2.7.2.1). Lipid extracts 
were separated into three major fractions: TPL, CHO and TAG using one-dimensional 
TLC with hexane/diethyl ether/acetic acid (80:20:1, by volume) as solvent.  After 
drying, the plates were sprayed with a 0.05% (v/v) solution of 8-anilino-4-
naphthosulphonic acid in methanol and viewed under UV light to reveal lipids. 
Identification of lipids was made by reference to authentic standards. To measure the 
incorporation of radioactivity into individual lipid classes, the lipids following scraping 
from the plates, were transferred into scintillation vials to which 10 ml of OptiFluor 
(PerkinElmer Inc., Waltham, MA, USA) scintillant was added. The samples were 
counted in a Perkin-Elmer Tri-Carb 2800 TR liquid scintillation counter. Quench 
correction was made automatically by the external standard channels-ratio method. 
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2.9 Statistical analyses of data 
Statistical analysis was carried out using SPSS software. Normality of the data 
was examined using the Shapiro-Wilk test prior to performing statistical analyses. 
Statistical analysis was performed using Student's t-test for single comparisons (two-
tailed, paired) or one-way ANOVA for multiple comparisons with Tukeys post-hoc test. 
(* p< 0.05; ** p < 0.01; *** p < 0.001, and NS indicating not significant).  
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3 Chapter 3: The Effect of Statins on 
Cytokine Regulated Gene Expression in 
Macrophages
 78 
 
3.1 Introduction 
Atherosclerosis is the major cause of cardiovascular disease that affects 
mainly the large and medium arteries (Lusis, 2000). It is characterised by lipid 
accumulation and inflammation within the walls of the arteries. During the progression 
of the disease, an atherosclerotic plaque is formed as a result of a lesion developing 
in the vascular wall (Lusis, 2000). Rupture of an atherosclerotic plaque leading to 
thrombosis is one of the most common causes of mortality in Western societies. 
Complications arising from thrombosis include heart attacks, stroke and gangrenes. 
Plaque stability is an important factor in controlling the incidence of plaque rupture 
(Halvorsen et al., 2008). 
It has been shown that atherosclerosis is a state of chronic inflammation within 
the vascular wall. A large number of cytokines are released at different stages of the 
disease and these have been studied and reviewed in relation to them being pro- or 
anti-atherogenic (Tedgui and Mallat, 2006). High levels of pro-atherogenic cytokines 
are observed in atherosclerosic lesions (Harvey and Ramji, 2005). Such cytokines 
include TNF-, IFN-, IL-1, IL-17 and IL-12. On the other hand, anti-inflammatory 
cytokines include IL-10, IL-4, IL-33 and TGF-. Macrophages and infiltrating T- 
lymphocytes are the major source of cytokines in atherosclerotic lesions (Tedgui and 
Mallat, 2006). 
The transformation of macrophages into lipid-loaded foam cells through the 
uptake of cholesterol is a critical early step in atherosclerosis (Lusis, 2000). Activation 
of ECs is the main initiating factor in the disease, with the accumulation of LDL in the 
subendothelial matrix the major cause of such activation. The frequency such 
activation is correlated with the plasma concentration of LDL (Lusis, 2000). Once 
activated, the ECs express various chemoattractant molecules. The monocytes in the 
blood stream are then attracted towards the injury/activation site in response to these 
molecules and begin to produce fatty streaks in these locations (Li and Glass, 2002). 
Monocytes are initially attracted by adhesion molecules on the surface of the ECs 
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such as P- and E-selectin molecules expressed on the luminal surface of the activated 
endothelium, which interact with L-selectin molecules on the surfaces of monocytes 
(Bobryshev, 2006). The interaction between the selectins and adhesion molecules 
cause the monocytes to roll across the endothelial surface, which enables molecules 
such as vascular cell adhesion molecule-1 (VCAM-1) and Inter-cellular adhesion 
molecule-1 (ICAM-1) to initiate binding with integrins. Integrin binding causes a higher 
level of adhesion to the endothelium so that the migration through the endothelial 
layer to the intima can now begin. The migration process is aided by the expression of 
chemokines by ECs such as MCP-1, M-CSF, MIP-1,TNF-α and TGF- (Li and Glass, 
2002). 
Once the monocytes have passed through the endothelial layer and are 
present in the intima of the blood vessels, they differentiate into macrophages and 
begin to form foam cells by taking up oxidised LDL from the subendothelial 
environment. This process is called fatty streak formation and is the first step in the 
initiation of the disease. As the plaque progresses, cytokines control the migration and 
proliferation of SMC from the media to the intima of the vessel (Lusis, 2000). 
Cytokines are also involved in the maintenance of plaque stability by regulating 
protease expression, SMC migration/proliferation and apoptosis of SMC and other cell 
types. The cytokines play several roles in this disease, and this has led researchers to 
extensively investigate the role of different cytokines in this disease and whether they 
are pro-atherogenic or anti-atherogenic (Tedgui and Mallat, 2006). 
Many genes have been shown to co-ordinate macrophage cholesterol 
homeostasis to date. The function of numerous key genes implicated in the regulation 
of cholesterol efflux, typically ABCA1 and ABCG1, and AcLDL/OxLDL uptake, such as 
SR-A and CD36, have been the focus of research in the field of atherosclerosis 
(Lusis, 2000; Pluddemann et al., 2007; Mead et al., 2002). Because of the difficulties 
in accessing human atherosclerotic plaque samples and donor-specific heterogeneity 
associated with primary cultures, established cell lines, such as the human THP-1 cell 
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line, have been used extensively for studies on macrophage function and gene 
expression in response to atherosclerosis with conservation of most responses to 
those observed in primary cultures (Kohro et al., 2004; McLaren et al., 2010a; Nakaya 
et al., 2010; McLaren et al., 2010b). When stimulated with phorbol esters, such as 
PMA, THP-1 cells mimic monocyte-derived macrophages by becoming adherent to 
glass or plastic, exhibiting a macrophage-like morphology and expressing 
macrophage differentiation markers (Kohro et al., 2004). 
Statins are one of the major drugs currently used in the prevention and 
treatment of atherosclerosis and its complications. In clinical trials, they have been 
found to be beneficial in the primary and secondary prevention of CHD (Liao and 
Laufs, 2005).  Although the major action of statins is to lower circulating levels of LDL-
C by inhibiting HMG-CoA reductase, they have numerous so-called pleiotropic effects 
(Ridker et al., 2009). These include acting in an anti-inflammatory manner. 
Unfortunately, the anti-inflammatory actions of statins are not fully understood 
particularly in relation to newer cytokines such as TL1A and IL-17 ( Liao and Laufs, 
2005).
 
 
 
 81 
 
3.2 Aims and Experimental Design 
 
As detailed above, cytokines play an important role in the regulation of 
inflammatory responses during the progression of atherosclerosis, principally through 
the modulation of gene expression associated with this disease. The study of 
signalling mechanisms involved in cytokine-mediated regulation of gene expression 
implicated in the progression of this disease is vital for the identification of new targets 
for therapeutic intervention (Harvey et al., 2007). Additionally, it is important to 
understand how lipid-lowering drugs such as statins mediate their anti-inflammatory 
actions. Therefore, the main purpose of the work reported in this chapter was to 
investigate if statins inhibit gene expression by cytokines, such as IFN-γ, TL1A and IL-
17A via RT-qPCR and other techniques. 
Previous studies on the anti-inflammatory actions of statins have been 
restricted to certain classical cytokines. The main aim of studies presented in this 
chapter was therefore to investigate whether this occurs with novel cytokines such as 
IL-17 and TL1A. For this, THP-1 cells were used initially as an in vitro cell culture 
model (Figure 3.1) to study the regulation of expression of MCP-1, ApoE, SR-A, CD-
36, ABCA1 and ABCG1. The steps below represent the experimental strategies that 
were taken to address the aims in this chapter with a schematic representation shown 
in Figure 3.2. 
1-To validate the effectiveness of the action of Simvastatin using RT-qPCR on MCP-1 
gene expression from cells treated with IFN-γ as a positive control. 
2-Examine the effect of Simvastatin on ICAM-1 gene expression induced by IFN-γ as 
an additional marker to MCP-1. 
3-Investigate the effect of Simvastatin on TL1A, IL-17A and IFN-γ mediated changes 
in expression of SR-A, CD-36, ABCA1 and ABCG1 in differentiated THP-1 
macrophages by RT-qPCR. 
4-Examine the effect of Simvastatin on ApoE gene expression when the cells are 
treated with TL1A by RT-qPCR. 
 82 
 
5- Investigate whether the results obtained are not peculiar to Simvastatin by using 
another statin, Atorvastatin, at the mRNA level. 
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One million cells of untreated THP-1 monocytes were cultured in 6-well plate (A). 
The THP1 macrophages were treated with RPMI media plus 0.16 μM PMA for 24 
hours (B). The black scale bar equal to 100 μm.  
A) 
B) 
Figure 3.1: Morphology of THP-1 Monocytes and Macrophages 
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Figure 3.2: Overall experimental strategy. 
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3.3 Genes Selected for Study 
 
3.3.1 MCP-1 
MCP-1 (also known as CCL2) is the most characterised CC chemokine that 
tends to attract mononuclear cells and is found at sites of chronic inflammation (Ikeda 
et al., 2002). It has been well established that MCP-1 plays a crucial role in the 
inflammatory aspect of atherogenesis (Sheikine and Hansson, 2004; Zernecke and 
Weber, 2005). MCP-1 is produced by all atheroma-associated cells (ECs, SMCs, T 
cells and macrophages) (Boisvert, 2004). Increased expression and activity of MCP-1 
and its receptor CCR2 have been identified in atherosclerotic plaques, and elevated 
plasma levels of MCP-1 have been found to be associated with traditional risk factors 
for atherosclerosis (Ohtsuki et al., 2001; Peters and Charo, 2001; Deo et al., 2004). 
Numerous studies have focused on the role of chemokines and adhesion 
molecules on the progression of this disease because they are present in the initial 
stages of plaque formation (McLaren et al., 2011). The role of MCP-1 in the disease 
has been identified from studies using mouse model systems; for example, MCP-1 
deficiency in murine models decreased the progression of atherosclerotic plaque 
development (Charo and Taubman, 2004). On the other hand, lesion formation and 
deposition of macrophages was increased when MCP-1 was overexpressed in the 
bone-marrow-derived cells of Apo-E−/− mice (Aiello et al., 1999). 
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3.3.2 ICAM-1 
 
Adhesion molecules are another group of proteins that largely regulate the 
recruitment of monocytes and other immune cells into the arterial intima via 
transendothelial migration (Engelhardt and Wolburg, 2004). ICAM-1 is an important 
member of this family of proteins and plays crucial roles during the development of 
atherosclerosis (Blankenberg et al., 2003). The expression of ICAM-1 is detectable in 
macrophages, ECs and SMCs in human atherosclerotic plaques (Poston et al., 1992). 
The expression of ICAM-1 is low in these cells but markedly induced by inflammatory 
stimuli, such as IL-1, TNF-α and IFN-γ (Dustin and Springer, 1988; Yang et al., 2005). 
Deficiency of ICAM-1 in Apo-E-/-  mice fed normal chow diet was found to protect 
against atherosclerosis by reducing lesion area (Collins et al., 2000). 
3.3.3 SR-A 
 
SR-A was first reported in 1990 and was originally named MSR (Moore and 
Freeman, 2006). This gene gives rise to three differentially spliced mRNAs that code 
for type I transmembrane receptors predominantly expressed on macrophages. When 
it became apparent that these receptors were part of a larger receptor family (Moore 
and Freeman, 2006), they were designated as class A SRs and renamed SR-AI, SR-
AII and SR-AIII. SR-AI and SR-AII are expressed on the cell surface of tissue 
macrophages, including macrophage foam cells, and have also been found on aortic 
ECs and vascular SMCs within atherosclerotic plaques (Moore and Freeman, 2006). It 
was suggested that SR-AI and SR-AII contribute to the majority ( 80%) of 
macrophage uptake of AcLDL but have lower affinity for oxLDL (Suzuki et al., 1997; 
Kunjathoor et al., 2002). 
There is growing support for the proposition that SR-A acts differently in early 
and advanced atherosclerotic lesions. In advanced atherosclerotic lesions, in which 
macrophage cell death results in necrotic core formation and plaque destabilisation, 
SR-A may have important roles in both the induction of apoptosis and the removal of 
these dying cells (Zhu et al., 2011). During hypercholesterolemia, macrophage 
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pathways for metabolising modified lipoproteins are believed to become overwhelmed, 
leading to a toxic accumulation of free cholesterol in the cell that results in 
endoplasmic reticulum stress. In this setting, engagement of SR-A pathways by 
modified lipoproteins triggers apoptotic cell death, indicating that SR-A signalling 
contributes to macrophage death and necrotic core formation (Moore and Freeman, 
2006). In contrast, SR-A are predominantly involved in the uncontrolled uptake of 
oxLDL (and hence their clearance in early lesions).  
Early studies of SR-AI and SR-AII null (Msr–/–) mice performed in  Apo-E–/–  
mice on a hybrid background (ICR/129) fed a chow diet showed a 58% decrease in 
aortic sinus atherosclerosis lesion area compared with Apo-E–/– littermates (Suzuki et 
al., 1997). SR-A knockout also showed a significant decrease in atherosclerotic 
lesions in the Apo-E−/− and LDLR−/− mouse models(Suzuki et al., 1997; Babaev et al., 
2000). 
3.3.4 CD36 
CD36 is a member of class B scavenger receptors. It is an 88-kDa membrane 
glycoprotein that was first identified on monocytes by the use of monoclonal 
antibodies and then subsequently isolated from blood platelets. This membrane 
glycoprotein is expressed by many cell-types including ECs, SMC and 
monocytes/macrophages (Collot-Teixeira et al., 2007). 
Functional and structural characterisation showed CD36 to be a member of 
the scavenger receptor class B family with a capacity to bind oxLDL as well as various 
other ligands (Collot-Teixeira et al., 2007). In addition to thrombospondin (TSP-1) and 
oxLDL, CD36 recognises a broad variety of ligands including anionic phospholipids, 
apoptotic cells, collagen, Plasmodium falciparum–infected erythrocytes and long-
chain fatty acids (Nicholson, 2004). 
Studies over the last three decades have led to a deep appreciation of the 
multi-functionality of CD36.  For example, it has recently been shown to be a sensor 
for fatty acids in taste buds, eliciting a secretory response in the gut (Febbraio and 
Silverstein, 2007). CD36 is a mediator of both atherogenesis and thrombosis. 
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Febbraio et al. (2000) found that when they crossed CD36-null mice with Apo-E-null 
mice and fed them with a pro-atherogenic western diet, the mice demonstrated a 
dramatic decrease in the severity of atherosclerosis suggesting that CD36 has a 
proatherogenic role. 
3.3.5 ABCA1 
ABCA1 is a 2261 amino acid integral membrane protein that comprises two 
halves of similar structure. Each half has a transmembrane domain containing six 
helices and a nucleotide binding domain (NBD) containing 2 conserved peptide motifs 
known as Walker A and Walker B, which are present in many proteins that use ATP, 
and a Walker C signature unique to ABC transporters. ABCA1 is predicted to have an 
N terminus oriented into the cytosol and two large extracellular loops that are highly 
glycosylated and linked by one or more cysteine bonds (Oram and Heinecke, 2005). 
ABCA1 mediates the transport of cholesterol, phospholipids and other 
lipophilic molecules across cellular membranes, where they are taken away from the 
cells by lipid-poor HDL apolipoproteins. It is likely that ABCA1 forms a channel in the 
membrane that promotes "flipping" of lipids from the inner to the outer membrane 
leaflet by an ATPase-dependent process. ABCA1 seems to also target specific 
membrane domains for lipid secretion. These are likely to be regions that are sensitive 
to accumulation of cholesterol (Oram and Vaughan, 2006). 
Mutations in ABCA1 cause Tangier disease (TD). It is a rare autosomal 
recessive disorder of lipid metabolism characterised by almost complete absence of 
plasma HDL and the accumulation of cholesteryl esters in the cells of the 
reticuloendothelial system leading to splenomegaly and enlargement of tonsils and 
lymph nodes (Kaminski et al., 2006). Drugs that induce ABCA1 expression in mice 
increase the clearance of cholesterol from tissues and inhibit intestinal absorption of 
dietary cholesterol. ABCA1 has a major impact on cellular and whole body cholesterol 
metabolism and is likely to play an important role in protecting against cardiovascular 
disease. ABCA1 is highly expressed in macrophages where it plays an obvious role in 
cholesterol secretion.  
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3.3.6 ABCG1 
The ABCG or White subfamily with its five fully characterised human members 
consists of half-size ABC proteins that dimerise to form active membrane transporters. 
Among the half-size molecules ABCG proteins have a peculiar domain organisation 
characterised by a nucleotide-binding domain (ATP-binding cassette) at the N 
terminus followed by six transmembrane-spanning domains (Schmitz et al., 2001). 
There are five ABCG subfamily members in humans: ABCG1; ABCG2; 
ABCG4; ABCG5; and ABCG8. The founding member of this group, ABCG1, is highly 
expressed in the lung, brain, spleen and in macrophages (Matsuo, 2010). Over 
expression of ABCG1 in baby hamster kidney cells was found to increase cell 
membrane cholesterol pools available for efflux and increase the rate constant for 
efflux (Sankaranarayanan et al., 2009). The efflux appears to be diffusional and 
unidirectional and is more efficient for smaller HDL particles. Different models have 
been proposed to explain how ABCG1 promotes cholesterol efflux to HDL. One 
suggests that ABCG1 helps sterol molecules to overcome the energy barrier for entry 
into the hydrophilic water layer, perhaps by using ATP to promote protrusion of the 
cholesterol molecule into water, followed by a transient collision with an acceptor 
(Charvet et al., 2010). ABCG1 promotes cholesterol efflux to HDL and other 
lipoprotein particles but not to lipid-poor apoA-1 (Charvet et al., 2007). 
Wang et al found that RCT was significantly decreased in ABCG1-/- mice 
(Wang et al., 2007). Yvan-Charvet and his collegues showed that knockout of both of 
ABCA1 and ABCG1 reduced cholesterol efflux to HDL and ApoA-1 when ABCA1-/-
ABCG1-/- bone marrow (BM) was transplanted into LDLR-/+ mice and then fed a high 
cholesterol diet (Charvet et al., 2007). 
3.3.7 ApoE 
ApoE was first described by Shore and Shore (Shore and Shore, 1973). It has 
since been found to be a major component of various types of plasma lipoproteins 
and has been implicated in the maintenance of overall plasma cholesterol 
homeostasis by facilitating the hepatic uptake of lipoproteins by binding to their 
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receptors (Greenow et al., 2005). It is synthesised by the liver, brain, spleen, lung, 
ovary, adrenal gland, kidney and muscles (Elshourbagy et al., 1985). In general, most 
of the ApoE found in the plasma is synthesised by the liver with about 20-40% derived 
from sources other than the liver, such as macrophages (Newman et al., 1985). 
Deficiency of ApoE leads to the development of atherosclerosis and 
hypercholesterolemia explaining why ApoE deficient mice are often used as a model 
for the disease. There is accumulating evidence that suggests that ApoE plays a 
potent anti-atherogenic role (Greenow et al., 2005). The major anti-atherogenic 
property of ApoE is the stimulation of cholesterol efflux from foam cells. It has been 
demonstrated that ApoE can act as an acceptor of both cholesterol and phospholipids 
released from macrophages via ABCA1 and is able to interact with ABCA1, at least in 
vitro (Greenow et al., 2005). 
Several studies have shown that macrophage-derived ApoE exerts anti-
atherogenic properties largely independent of its effects on plasma lipid levels (Fazio 
et al., 1997; Van Eck et al., 2000). For example work by Zhang et al. (1994) 
demonstrated that atherosclerosis was more severe in cholesterol-fed ApoE–
heterozygous (+/-) mice than in cholesterol-fed Apo-E (+/+) mice, despite the relative 
similar plasma cholesterol levels in the two groups. It has also been shown that the 
lack of macrophage ApoE in C57BL/6 mice leads to a 10-fold increase in diet-induced 
atherosclerosis in the absence of any changes in serum cholesterol levels or 
lipoprotein profiles (Fazio et al., 1997; Boisvert and Curtiss, 1999). Moreover, 
transgenic mice expressing human ApoE in the vessel wall show reduced 
atherosclerotic lesions in the absence of any changes in plasma cholesterol and 
lipoprotein profile (Shimano et al., 1995). 
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3.4 Results 
 
3.4.1 Optimisation of PCR Conditions 
 
Before carrying out the PCR optimisation studies, the integrity of macrophage 
RNA samples was examined by electrophoresis on 1.5% (w/v) agarose gels. As 
shown in Figure 3.3, the comparative amount of the 28S rRNA was almost double that 
of the 18S rRNA, which is what would be expected for good quality, undegraded RNA. 
Such quality RNA was obtained in all experiments and hence the data in these cases 
are not shown 
 
Figure 3.3: Determination of the integrity of RNA isolated from THP-
1 macrophages 
Four different RNA samples from THP-1 macrophages were prepared and subjected 
to electrophoresis on 1.5% agarose gels to check integrity of RNA. 28S, 28S rRNA; 
18S, 18S rRNA. 
 
 
28S 
 
 
 
18S 
     1            2           3            4 
      Samples 
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Primer sequences for ABCA1, ABCG1, SRA and CD36 were taken from 
previously published papers and ordered from Genosys (Sigma-Aldrich). The amount 
of reagents required for each reaction and the optimal PCR annealing temperatures 
were well established in our laboratory. It was found that the optimum annealing 
temperature was: 60C for GAPDH and SR-A; 65C for ABCA1 and ABCG1; and 58 
C for CD36. Previous studies had shown that 35 cycles also produced optimal 
amount of PCR products. In all cases, no products of expected size were obtained 
when the reverse transcriptase step was omitted, thereby showing that the 
amplication products were from cDNA, and hence RNA, but not because of 
contamination of the samples with genomic DNA. 
The optimised conditions for the different human primer sets were then used to 
carry out RT-qPCR. The ΔΔCT method was used for the analysis.(Ginzinger, 2002). 
The data for GAPDH, MCP-1 and ICAM-1 are shown in Figure 3.4. Panels A-C show 
change in fluorescence with cycle numbers with the dashed line showing the 
threshold with cycle number reaching this point taken into account in the data 
analysis. Panels D-F show melting curve that was generated by increasing the 
temperature in small increments and monitoring the fluorescent signal at each step. A 
plot of the rate of change in fluorescence vs. temperature had a distinct major peak 
that corresponded to the melting temperature of each specific product  
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Figure 3.4: RT-qPCR analysis using primers against MCP-1, ICAM-1 and GAPDH 
Panels A-C illustrates changes in fluorescence with cycle number for the cycles for the 
different human primer sets GAPDH (housekeeping) (A), MCP-1 (B) and ICAM-1 (C) using 
cDNA against RNA from THP-1 macrophages Panels D-F show melting curve for the same set 
of primers: GAPDH (D) MCP-1 (E) and ICAM-1 (F). 
A) 
C) 
B) 
F) E) 
D) 
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3.4.2 Treatment of THP-1 Cells with Simvastatin 
In order to validate the effectiveness of Simvastatin, RT-qPCR was performed 
on the MCP-1 gene using RNA from cells treated with IFN-γ as a positive control. 
Previous studies have shown that Simvastatin inhibits the IFN-γ-induced MCP-1 
mRNA expression in THP-1 macrophages (Li et al., 2011). After 24 hours stimulation 
with PMA, activated Simvastatin (10 µM) or DMSO (as vehicle control) was added to 
the cells for one hour before stimulation with the cytokine. The concentration of 
simvastatin was based on previous work (Li et al., 2001; Yamashita et al., 2008). As 
expected, IFN-γ induced the expression of MCP-1 and this was attenuated in the 
presence of Simvastatin (Figure 3.5). On the other hand, Simvastatin had no effect on 
the constitutive expression of MCP-1 in these cells (Figure 3.5). 
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Figure 3.5: The Effect of simvastatin on the IFN-γ-Induced MCP-1 Expression in 
THP-1 Macrophages.  
PMA-differentiated THP-1 macrophages were pre-treated for 1 hour with Simvastatin 
(10 M) or DMSO as a vehicle control. The cells were then incubated for 24 hours with 
or without IFN-γ (1000 U/ml). Statistical analysis was performed using one-way ANOVA 
with Tukeys post-hoc analysis,*P<0.05, ***P<0.001, NS not significant. The data shown 
are from five independent experiments. 
 
The RT-qPCR experiments were repeated with the ICAM-1 gene to provide an 
additional robust marker of inflammation for subsequent studies. The data showed 
that IFN-γ produced a statistically significant increase in ICAM-1 expression. 
Simvastatin by itself had no effect on constitutive ICAM-1 expression but produced a 
statistically significant reduction in the IFN-γ-induced ICAM-1 expression (Figure 3.6). 
***	 *	
NS	
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Figure 3.6: The Effect of simvastatin on the IFN-γ-induced ICAM-1 expression in 
THP-1 macrophages. 
PMA-differentiated THP-1 macrophages were pre-treated for 1 hour with Simvastatin 
(10 μM) or DMSO as a vehicle control. The cells were then incubated for 24 hours with 
or without IFN-γ (1000 U/ml). The expression in DMSO control samples has been 
arbitrarily assigned as 1. The results are displayed as fold change in relation to the 
control from four independent experiments. Statistical analysis was performed using 
one-way ANOVA with Tukeys post-hoc analysis, ** P<0.01, ***P<0.001; NS not 
significant. 
 
***	 **	
NS	
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3.4.3 Effect of Simvastatin on cytokine regulated expression of SR-A, 
CD36, ABCA1 and ABCG1 
Having confirmed the positive action of Simvastatin, their effects on cytokine-
mediated changes in the expression of two lipoprotein/cholesterol uptake genes (SR-
A and CD36) and two cholesterol efflux genes (ABCA1 and ABCG1) were 
determined. The analysis was extended to two more recently identified cytokines, TL-
1A and IL-17A. Thus, after 24 hours stimulation with PMA, activated Simvastatin or 
DMSO (as vehicle control) was added to the cells for one hour before stimulation with 
the cytokines.  
3.4.3.1 SR-A 
 
IFN-γ and TL-1A produced a statistically significant increase in SR-A 
expression (Figure 3.7). Although an increase in SR-A was also observed with IL-17A, 
this was not statistically significant (Figure 3.7). In all cases, Simvastatin had no effect 
on the constitutive expression of SR-A (Figure 3.7). In addition, simvastatin had no 
statistically significant effect on SR-A expression in the presence of IFN-γ and IL-17A 
though a trend of reduced expression was observed with IL-17A (Figure 3.7). In 
contrast, Simvastatin significantly attenuated the TL1A-induced expression of SR-A 
(Figure 3.7).  
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Figure 3.7: The effect of Simvastatin on cytokine-regulated expression 
of SR-A mRNA by RT-qPCR.  
PMA-differentiated THP-1 macrophages were pre-treated for 1 hour with 
Simvastatin (10 μM) or DMSO as a vehicle control. The cells were then 
incubated for 24 hour in the absence or the presence of IFN-γ (1000 U/ml) 
(A), IL-17A (100 ng/ml) (B) or TL1A (100 ng/ml) (C). The results are 
displayed as fold change in relation to the control from four independent 
experiments. Statistical analysis was performed using one-way ANOVA 
with Tukeys post-hoc analysis * p<0.05, **p<0.01, NS not significant. 
* ** 
NS 
NS NS 
NS 
** NS 
NS 
B) 
A) 
C) 
 99 
 
3.4.3.2     CD36 
All three cytokines induced the expression of CD36 though this was only 
statistically significant in the case of IFN-γ and TL1A (Figure 3.8). In all cases, 
Simvastatin had no effect on the constitutive expression of CD36 (Figure 3.8). 
Inclusion of Simvastatin produced no statistically significant reduction of the 
expression of all three genes seen in the presence of IFN-γ though a trend of slight 
reduction was observed with IFN-γ and IL-17A (Figure 3.8). 
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Figure 3.8: The effect of Simvastatin on cytokine-regulated 
expression of CD36 mRNA by RT-qPCR.  
PMA-differentiated THP-1 macrophages were pre-treated for 1 hour with 
Simvastatin (10 μM) or DMSO as a vehicle control. The cells were then 
incubated for 24 hours in the absence or the presence of IFN-γ (1000 
U/ml) (A), IL-17A (100 ng/ml) (B) or TL1A (100 ng/ml) (C). The results 
are displayed as fold change in relation to the control from four 
independent experiments. Statistical analysis was performed using one-
way ANOVA with Tukeys post-hoc analysis * P<0.05 and NS not 
significant. 
* NS 
NS 
NS NS 
NS 
* NS 
NS 
B) 
A) 
C) 
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3.4.3.3      ABCA1 
Simvastatin produced a statistically significant reduction in the constitutive 
expression of ABCA1 mRNA (induced by PMA as part of the differentiation program) 
(Figure 3.9). TL-1A also produced a statistically significant reduction in ABCA1 mRNA 
expression whereas IFN-γ and IL-17A had no effect (Figure 3.9). Consistent with the 
effect of simvastatin on constitutive expression, the levels of ABCA1 mRNA in the 
presence of simvastatin and either cytokine were significantly lower than that in the 
presence of the corresponding cytokine alone (Figure 3.9). 
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Figure 3.9: The Effect of Simvastatin on cytokine-regulated 
expression of ABCA-1 mRNA by RT-qPCR.  
PMA-differentiated THP-1 macrophages were pre-treated for 1 hour with 
Simvastatin (10 μM) or DMSO as a vehicle control. The cells were then 
incubated for 24 hours in the absence or the presence of IFN-γ (1000 
U/ml) (A), IL-17A (100 ng/ml) (B) or TL1A (100 ng/ml) (C). The results are 
displayed as fold change in relation to the control from four independent 
experiments. Statistical analysis was performed using one-way ANOVA 
with Tukeys post-hoc analysis, *P<0.05, **P<0.01, ***P<0.001 and NS not 
significant. 
 
NS 
*** 
*** 
NS ** 
*** 
* *** 
*** 
B) 
A) 
C) 
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3.4.3.4      ABCG1 
Similar to ABCA1, Simvastatin produced a reduction in the constitutive 
expression of ABCG1 mRNA (induced by PMA as part of the differentiation program) 
(Figure 3.10). Although this was statistically significant in experimental series involving 
IL-17A and TL1A, there was, nevertheless, a trend in reduced expression in 
experiments involving IFN-γ though this failed to reach significance (Figure 3.10). TL-
1A also produced a statistically significant reduction in ABCA1 mRNA expression 
(Figure 3.10). On the other hand, IFN-γ produced a statistically significant increase in 
ABCG1 expression whereas IL-17A had no effect (Figure 3.10). Consistent with the 
effect of Simvastatin on constitutive expression, the levels of ABCG1 mRNA in the 
presence of Simvastatin and either cytokine were significantly lower than those in the 
presence of the corresponding cytokine alone (Figure 3.10).   
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Figure 3.10: The effect of simvastatin on cytokine-regulated 
expression of ABCG-1 mRNA by RT-qPCR.  
PMA-differentiated THP-1 macrophages were pre-treated for 1 hour with 
Simvastatin (10 μM) or DMSO as a vehicle control. The cells were then 
incubated for 24 hours in the absence or the presence of IFN-γ (1000 U/ml) 
(A), IL-17A (100 ng/ml) (B) or TL1A 
 (100 ng/ml) (C). The results are displayed as fold change in relation to the 
control from four independent experiments. Statistical analysis was 
performed using one-way ANOVA with Tukeys post-hoc analysis, * P<0.05, 
**P<0.01, ***P<0.001 and NS not significant. 
 
*** *** 
NS 
NS * 
* 
** *** 
*** 
B) 
A) 
C) 
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3.4.4 Effect of TL1A on ApoE Expression in THP-1 Cells 
The experiments on ApoE expression were restricted to TL1A. This cytokine 
produced a statistically significant reduction of ApoE mRNA expression (Figure 3.11). 
In addition, Simvastatin produced a statistically significant decrease in constitutive 
ApoE mRNA expression (Figure 3.11). However, there was no additional significant 
effect of Simvastatin on ApoE mRNA levels observed in the presence of TL1A alone 
(Figure 3.11).  
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Figure 3.11: The effect of Simvastatin on TL1A-regulated expression of ApoE 
mRNA by RT-qPCR.  
PMA-differentiated THP-1 macrophages were pre-treated for 1 hour with 
Simvastatin (10 μM) or DMSO as a vehicle control. The cells were then incubated 
for 24 hours in the absence or the presence of TL1A (100 ng/ml). The results are 
displayed as fold change in relation to the control from three independent 
experiments. Statistical analysis was performed using one-way ANOVA with 
Tukeys post-hoc analysis, ** p<0.01, ***p<0.001 and NS not significant. 
 
**	 NS	
***	
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3.4.5 Atorvastatin attenuates the IFN-γ induced expression of MCP-1 
and ICAM-1 
3.4.5.1  MCP-1 
To examine whether the results obtained so far were not peculiar to 
Simvastatin, Atorvastatin was used in further experiments. The studies were restricted 
to IFN-γ. After 24-hour stimulation with PMA, activated atorvastatin (10 µM) or DMSO 
(as vehicle control) was added to the cells for one hour before stimulation with IFN-γ. 
The concentration of Atorvastatin was based on previous research (Li et al., 2001).  
The data shows that IFN-γ induced the expression of the MCP-1 gene in a 
statistically significant manner when compared to the DMSO control with about 130-
fold induction (Figure 3.12). Atorvastatin by itself had no effect on constitutive MCP-1 
expression but produced a statistically significant reduction of about 50% in MCP-1 
mRNA expression levels seen in the presence of IFN-γ. 
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Figure 3.12: The effect of Atorvastatin on the IFN-γ-induced 
MCP1 expression in THP-1 macrophages.  
PMA-differentiated THP1 macrophages were pre-treated for 1 hour 
with Atorvastatin (10 μM) or DMSO as a vehicle control. The cells 
were then incubated for 24 hours with or without IFN-γ (1000 U/ml). 
The results are from five independent experiments. Statistical 
analysis was performed using one-way ANOVA with Tukeys post-
hoc analysis, *** p<0.001, NS not significant. 
 
***	 ***	
NS	
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3.4.5.2   ICAM-1 
 
There was a significant induction of ICAM-1 expression by IFN-, and this was 
reduced in a statistically significant manner in the presence of Atorvastatin (Figure 
3.13). In addition, Atorvastatin had no effect on constitutive ICAM-1 expression. 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: The effect of Atorvastatin on the IFN-γ-induced 
ICAM-1 expression in THP-1 macrophages.  
PMA-differentiated THP1 macrophages were pre-treated for 1 
hour with Atorvastatin (10 µM) or DMSO as a vehicle control. The 
cells were then incubated for 24 hours with or without IFN-γ (1000 
U/ml). The results are from five independent experiments. 
Statistical analysis was performed using one-way ANOVA with 
Tukeys post-hoc analysis, ** p<0.01, *** p<0.001, NS not 
significant 
 
***	 **	
NS	
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3.5 Discussion 
In the context of disease or pathophysiology of atherosclerosis, cytokines are 
often grouped according to their pro- or anti–inflammatory actions. High levels of pro-
inflammatory cytokines are observed in atherosclerotic lesions (Harvey and Ramji, 
2005). Pro-inflammatory cytokines include TNF-, IFN-, IL-1, IL-12, TL1A and IL-17. 
On the other hand, anti-inflammatory cytokines include IL-10, IL-4, TGF- and IL-33. 
Macrophages and T-lymphocytes are the main source of cytokines in the 
atherosclerotic lesion (Dinarello, 2000; Tedgui and Mallat, 2006; McLaren et al., 
2010a). 
The studies presented in this chapter investigated the action of Simvastatin on 
cytokine-mediated changes in the expression of key genes implicated in the control of 
macrophage cholesterol homeostasis and the inflammatory response. These studies 
were divided in to five parts. The first part was to validate the effectiveness and action 
of Simvastatin on a well-characterised response in macrophages, the induction of 
MCP-1 gene expression by IFN-γ. The second part was focussed on investigating the 
action of Simvastatin on IFN-γ-induced expression of the ICAM-1 gene to provide 
another marker in addition to MCP-1. The third part focussed on investigating the 
action of Simvastatin on the expression of key genes implicated in the regulation of 
macrophage cholesterol uptake and efflux in the absence or the presence of the 
cytokines IFN-γ, TL-1A or IL-17A. The efflux of cholesterol from macrophages 
primarily involves reverse cholesterol transport by members of the ABC transporter 
family, such as ABCA1 and ABCG1, and also requires lipid-free components of high-
density lipoprotein, such as ApoE and ApoA-I as cholesterol acceptors. It was 
therefore decided to investigate whether TL1A and IL-17 modulates the expression of 
these genes by RT-qPCR and if this was regulated by Simvastatin, and that was the 
fourth part of the study. The fifth part was to examine the effect of Atorvastatin on the 
IFN-γ induced expression of MCP-1 and ICAM-1. 
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THP-1 cells were used as an in vitro cell culture model to study the expression 
of SR-A, CD36, ABCA1, ABCG1 and ApoE genes.  
3.5.1  The effect of Simvastatin on the IFN-γ induced mRNA expression 
of MCP-1 and ICAM-1 
Consistent with previous studies in a range of cell types (Zhou et al, 2001; 
Martin-Ventura, 2009; Chang et al, 2002), IFN-γ induced the expression of MCP-1 
and ICAM-1 genes (Figures 3.5 and 3.6). Simvastatin has been shown to inhibit the 
IFN-γ-induced gene expression of MCP-1 and ICAM-1 in primary human ECs and 
transformed endothelial ECV304 cell lines (Kwak et al., 2001; Chung et al, 2002). 
Consistent with these previous findings, work presented in this chapter clearly shows 
that pre-treatment of THP-1 macrophages with Simvastatin inhibits the IFN-γ-induced 
expression of MCP-1 and ICAM-1, thereby suggesting an anti-inflammatory and 
immunomodulatory effect of this statin in human macrophages (Figures 3.5 and 3.6).  
3.5.2  The effect of Simvastatin on cytokine regulated gene expression 
of SR-A, CD36, ABCA1 and ABCG1: 
IFN-γ plays a complex role in atherosclerosis with both pro- and anti-atherogenic 
actions being reported though most of the in vivo studies point to a pro-atherogenic 
role (McLaren and Ramji., 2009; Harvey and Ramji, 2005). It was originally shown that 
IFN-γ inhibits SR-A and CD36 expression in HMDMs and reduces the level of AcLDL 
uptake (Geng and Hansson, 1992). This indicated a role of this cytokine in reducing 
foam cell formation in lesions. However, numerous subsequent studies have shown 
that IFN-γ promotes foam cell formation by stimulating the uptake of modified 
lipoproteins (McLaren and Ramji, 2009; Li et al., 2010). Consistent with this finding, 
the studies presented in this chapter show that IFN-γ induces the expression of SR-A 
and CD36 in THP-1 macrophages (Figures 3.7 and 3.8), IFN-γ has been shown to 
decrease cholesterol efflux from mouse peritoneal macrophages by inhibiting ABCA1 
expression (Panousis and Zuckerman, 2000; Wang et al., 2002). However, this 
cytokine was found to produce no significant change in ABCA1 expression in THP-1 
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macrophages and increased the expression of ABCG1 expression (Figures 3.9 and 
3.10).  
As previously described, statins are potent inhibitors of cholesterol biosynthesis. 
In clinical trials, they have been found to be beneficial in the primary and secondary 
prevention of CHD (Liao and Laufs, 2005). Statins are potent inhibitors of HMG-COA 
reductase, a key enzyme in cholesterol biosynthesis (Ridker et al., 2009). In addition, 
statins have additional anti-atherogenic actions, the so called pleiotropic actions. For 
example, statins have been shown to prevent the activation of monocytes and to 
inhibit the production of pro-inflammatory cytokines (Kwang, 2000). Furthermore, 
animal studies and clinical trials have demonstrated that statins can raise HDL levels 
(Natarajan et al., 2010). Statins have also been found to directly attenuate 
macrophage foam cell formation by regulating macrophage scavenger receptor 
expression, oxLDL uptake and cholesterol efflux. For example, Atrovastatin has been 
found to reduce macrophage SR-A and CD36 expression (Hofnagel et al., 2007; 
Fuhrman et al., 2002; Han et al., 2004). 
The IFN-γ-induced expression of SR-A was not affected by Simvastatin (Figure 
3.7) while the induction of CD36 was attenuated though this was not statically 
significant so more experimental repeats will be required (Figure 3.8). The induction of 
ABCG1 by IFN-γ was decreased by Simvastatin and this was statically significant 
(Figure 3.10). Although, IFN-γ had no effect on ABCA1 expression, the constitutive 
levels were attenuated in the presence of simvastatin (Figure 3.9). These findings are 
consistent with the reduction of expression of ABCA1 and ABCG1 in Caco-2 cells by 
simvastatin (Genvigir et al., 2011). 
TL1A is a pro-inflammatory cytokine that has been shown to drive the 
progression of numerous inflammatory disorders, including arthritis (Meylan et al., 
2008; Croft, 2009). The cytokine has been shown to drive macrophage foam cell 
formation by both promoting cholesterol uptake and reducing cholesterol efflux 
(McLaren et al., 2010a). Consistent with this finding, TL1A was found to induce the 
expression of SR-A and CD36 and to decrease the expression of ABCA1 and ABCG1 
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in THP-1 macrophages (Figures 3.7, 3.8, 3.9 and 3.10). The TL1A induced expression 
of SR-A was attenuated by Simvastatin but no change was seen with CD36 (Figures 
3.7 and 3.8). These actions are consistent with the anti-atherogenic, foam cell 
inhibitory action of Simvastatin. On the other hand, the TL1A reduction of ABCA1 and 
ABCG1 was further reduced with simvastatin (Figures 3.9 and 3.10). 
It has previously been shown in our laboratory that IL-17 promotes 
macrophage foam cell formation by increasing cholesterol uptake and decreasing 
cholesterol efflux (unpublished results by Daryn Michael and James McLaren). 
Consistent with this finding, IL-17 was found to induce the expression of SR-A and 
CD36 and reduce that of ABCA1 and ABCG1 in THP-1 macrophages (Figures 3.7, 
3.8, 3.9 and 3.10). The IL-17A-mediated induction of SR-A and CD36 was reversed 
by Simvastatin but it was not significant so more experiments will be required (Figures 
3.7 and 3.8). On the other hand, the IL-17A mediated reduction of ABCA1 and 
ABCG1 was reduced further with Simvastatin (Figures 3.9 and 3.10). 
3.5.3  Effect of TL1A on ApoE mRNA expression 
It was also decided to investigate the role of TL1A on the expression of ApoE 
and the effect of Simvastatin on this. This study demonstrated that TL1A decreases 
the expression of ApoE, which confirms the results of previous study by McLaren et 
al. (2010a) where it was shown that TL1A significantly decreases the expression of 
ApoE in THP-1 macrophages and HMDMs. However, when THP-1 cells were treated 
with Simvastatin there was no change observed in the expression of APO-E. Because 
the changes were not significant, it can be concluded that Simvastatin has no effect 
on the TL1A-mediated decrease in ApoE expression (Figure 3.11). 
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3.5.4 Effect of Atorvastatin on IFN-γ induced mRNA expression 
In order to examine whether the results obtained are peculiar to Simvastatin, 
representative experiments were carried out using Atorvastatin. The data showed that 
Atorvastatin attenuates the IFN-γ induced expression of MCP-1 and ICAM-1 (Figures 
3.12 and 3.13). Although, there is no study that has examined the effect of 
Atorvastatin on the inhibition of the IFN-γ induced expression of MCP-1 and ICAM-1, 
this statin was found to reduce the expression of MCP-1 in swine (Martinez-Gonzalez 
et al., 2001). This indicates that MCP-1 down regulation by statins could reduce the 
inflammation within the vascular wall and play a role in the inhibition of lesion 
progression.  
The results of this chapter are summarised in Table 3.1. 
The next chapter concentrates on IFN-γ signalling, and effects of Simvastatin 
on these pathways. IFN-γ was chosen for the studies because it is potentially a 
master regulator of atherosclerosis and produces a robust increase in inflammatory 
marker gene expression in human macrophages. 
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Table 3.1: Summary of the results 
 
Treatment Gene expression 
 
1- IFN-γ      MCP-1, ICAM-1 
              Simvastain + IFN-γ 
 
    MCP-1, ICAM-1 
2- IFN-γ      SR-A 
             Simvastatin + IFN-γ No change. 
             IL-17A No change. 
             Simvastatin + IL-17A No change. 
            TL1A       SR-A. 
            Simvastatin + TL1A 
 
     SR-A. 
3- IFN-γ     CD36 
              Simvastatin + IFN-γ No change. 
             IL-17A No change. 
             Simvastatin + IL-17A No change. 
             TL1A      CD36 
              Simvastatin + TL1A 
 
No change. 
4- IFN-γ No change with ABCA1 
              Simvastatin + IFN-γ    ABCA1. 
              IL-17A No change. 
              Simvastatin + IL-17A    ABCA1. 
              TL1A     ABCA1. 
              Simvastatin + TL1A 
 
    ABCA1. 
5- IFN-γ      ABCG1. 
              Simvastatin + IFN-γ      ABCG1. 
              IL-17A  No change. 
             Simvastatin + IL-17A      ABCG1. 
             TL1A      ABCG1. 
             Simvastatin + TL1A 
 
     ABCG1. 
6-   TL1A      APOE. 
                 Simvastatin + TL1A 
 
 No change. 
7-   IFN-γ    MCP-1, ICAM-1. 
                 Atorvastatin + IFN-γ 
 
   MCP-1, ICAM-1. 
  : Increase Expression and    : Decrease Expression.
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Chapter 4: Effects of Simvastatin on IFN-γ 
Signalling 
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4.1 Introduction  
As mentioned earlier in Chapter One, atherosclerosis is an inflammatory 
disease that affects large and medium arteries, which is regulated by cytokines (Lusis 
2000). IFN-γ is a pro-inflammatory cytokine that controls several steps in 
atherosclerosis (McLaren and Ramji 2009). IFN-γ signals mainly through the JAK-
STAT pathway though other pathways, such as ERK, have also been found to play an 
important role (Harvey et al. 2007; Li et al. 2010). These two signalling pathways are 
discussed below in detail. 
4.1.1 JAK-STAT Pathway 
IFN-γ signalling is initiated following binding of the cytokine to its receptors, 
which consists of two subunits: IFN-γR1 and IFN-γR2. The signalling pathway is 
shown in Figure 4.1 and explained in detail in the legend.  
 
 
Figure ‎1.14: JAK-STAT Pathway. 
Once IFN-γ binds to its receptors, it induces their oligomerisation resulting in the activation 
of JAK-1 and -2 by trans-phosphorylation (A). In the cytoplasmic domain of the receptors, a 
critical tyrosine residue is then phosphorylated by activated JAKs (B). This region becomes 
as a docking site for the protein STAT1, which is then phosphorylated on tyrosine 701 (C). 
In addition to phosphorylation of STAT1 on tyrosine 701, phosphorylation on serine 727 is 
required for maximal activity. After that, the phosphorylated STAT1 dimerises (D) and then 
translocates to the nucleus. In the nucleus, STAT1 interacts with γ-activated sequence 
elements (GAS) in the regulatory regions of target genes (E). 
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4.1.2 MAPK Signalling 
MAPK is a family of serine/threonine kinases that controls cell proliferation, 
differentiation, motility, survival and apoptosis (Chang and Karin, 2001; Roux and 
Blenis 2004). Each MAPK pathway contains three major components, a MAPK kinase 
kinase (MAPKKK, MEKK), a MAPK kinase (MAPKK, MKK or MEK) and a MAPK 
(Dhillon et al., 2007; Kim and Choi, 2010). Five distinct classes of MAPKs have been 
categorised in mammals: ERK1/2; JNK1/2/3; p38 isoforms α, β, γ, and δ; ERKs-3 and 
-4; and ERK5 (Chang and Karin, 2001).The most widely studied groups of MAPKs to 
date are ERK1/2, JNKs, and p38 kinases (Dhillon et al. 2007). Extracellular stimuli 
such as growth factors and cytokines or stress can initiate signal transduction from the 
membrane via the phosphorylation and activation of specific MAPKs. These then 
cause the phosphorylation and activation of transcriptions factors that regulate the 
expression of target genes (Chang and Karin, 2001). The ERK1/2, JNK and p38 
MAPK pathways have been described in detail in Chapter 1. 
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4.2 Aims and Experimental Design 
The major aim of this chapter was to investigate the mechanisms underlying the 
Simvastatin-mediated inhibition of IFN-γ signalling, a pleiotropic anti-atherogenic 
action of statins. As the studies presented in Chapter 3, THP-1 macrophages were 
mainly used as an in vitro cell culture model to study the expression of MCP-1, ICAM-
1, ERK-1 and -2, JNK-1 and -2, p38 and c-Jun along with the activation of these 
signalling pathways. However, in order to confirm that the responses were not 
peculiar to this cell line, representative experiments were also performed in primary 
cultures of HMDMs. Furthermore, some experiments were performed in the mouse 
RAW264.7 cell line in order to determine whether the responses were conserved 
between mouse and human macrophages. 
The steps below describe the experimental strategies that were taken to 
address these overall aims: 
1-To examine if the inhibitory action of Simvastatin was reversed by FPP and GGP, 
intermediates in the HMG-CoA reductase pathway; 
2- To investigate if Simvastatin affects  the phosphorylation-mediated activation of 
STAT1 in THP-1 macrophages and primary cultures of HMDMs; 
3- To analyse if the action of Simvastatin is conserved in mouse RAW264.7 
macrophages; 
4- To examine if Simvastatin affects other key components of IFN-γ signalling such as 
MAPK pathways; 
5- To confirm representative results obtained in THP-1 macrophages to primary 
HMDMs; 
The experimental design conducted in this project is illustrated in Table 4.1. 
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Table ‎1.2: Experimental design. 
The table below shows a summary of the experimental design carried out in this chapter using 
different cell systems and treatments.  
 
 
Experiments 
1 2 3 4 
Cell System 
THP-1 
Macrophages 
THP-1 
macrophages 
and primary 
HMDMs 
RAW264.7 
Macrophages 
THP-1 Macrophages 
Treatment 
Simvastatin (10 
µM) + FPP or + 
GGP or + Mev 
for 1 hour 
 
 
 
24-hour IFN-γ 
treatment 
Simvastatin (40 
µM) for 1 hour 
 
 
 
 
 
24-hour IFN-γ 
treatment 
Simvastatin (40 
µM) for 1 hour 
 
 
 
 
 
24-hour IFN-γ 
treatment 
Simvastatin (40 µM) 
for 1 hour 
 
 
 
 
24-hour IFN-γ 
treatment (3 hour 
IFN-γ treatment only 
for western blotting 
analysis of P-p38) 
Techniques 
RT-qPCR for 
MCP-1 
1- Western blot 
for P-STAT1 
 
2- RT-qPCR for 
MCP-1 and /or 
ICAM-1 
RT-qPCR for 
MCP-1 and 
ICAM-1 
1- RT-qPCR for c-
Jun, ERK, JNK and 
p38  
2- Western blotting  
for P-c-Jun, P-ERK 
and P-p38 
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4.3 Results 
4.3.1 The inhibitory action of Simvastatin is mediated via the HMG-CoA 
reductase pathway 
To investigate the mechanisms by which Simvastatin inhibits IFN-γ induced 
MCP-1 expression in vitro, the potential involvement of the HMG-CoA reductase 
pathway was investigated. In particular, the ability of mevalonate and the isoprenoid 
intermediates, FPP and GGP, to reverse the IFN-γ-induced MCP-1 mRNA expression 
was analysed. GGP and FPP are required for the post-translational modification of 
GTP-binding proteins of the Rho and Ras family (Lee et al., 2008). These agents were 
added to THP-1 macrophages 1 hour prior to IFN-γ treatment for 24 hours. IFN-γ 
induced the expression of MCP-1 mRNA and this was significantly inhibited by 
simvastatin (Figure 4.2). In contrast, no such significant decrease was seen when 
mevalonate, FPP or GPP was included in addition to Simvastatin (Figure 4.2). These 
data suggest that the agents, particularly FPP and GPP, reverse, at least in part the 
Simvastatin-mediated inhibition of IFN-γ-induced MCP-1 expression. 
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Figure ‎1.15: The inhibitory effect of simvastatin is dependent on the HMG-CoA 
reductase pathway. 
THP-1 macrophages were treated with simvastatin (10µM) in the absence or the presence of 
mevalonate (500 µM), FPP (5 µM) and GGP (5 µM) for 1 hour followed by incubation with IFN-
γ for 24 hour (cells treated with IFN-γ or DMSO vehicle for the same period served as 
controls). Total RNA was isolated and gene expression was analysed by RT-qPCR using 
primers specific for MCP-1 and GAPDH. Ct values were normalised to GAPDH mRNA. The 
data shown are from four independent experiments. Statistical analysis was performed using 
one-way ANOVA with Tukeys post-hoc analysis, *p<0.05, ***p<0.001, NS not significant. 
 
***	 *	 NS	 NS	 NS	
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4.3.2 Simvastatin inhibits the IFN-γ induced STAT1 phosphorylation in 
THP-1 macrophages and primary HMDMs 
Previous studies used Simvastatin at concentration of 10 μM (Copaja et al. 
2012). However, problems were encountered in subsequent studies using this 
concentration and the inhibition of IFN-γ-induced gene expression was often variable 
and not always marked (data not shown). The precise reason(s) for such problems 
are unclear. It was therefore decided to carry out a dose response experiment using 
different concentrations of Simvastatin (10, 20, 30 and 40 µM) to identify a 
concentration that produced maximal reduction of both MCP-1 and ICAM-1 mRNA 
expression. The results from two experiments showed that 40 µM of Simvastatin 
produced maximal reduction of both MCP-1 and ICAM-1 expression (Figure 4.3 A and 
B). The results also showed little inhibition of ICAM-1 expression with lower 
concentrations of Simvastatin. In the light of this finding and substantial time lost 
previously because of variable inhibition with the low concentration used, subsequent 
studies were performed using 40 µM simvastatin.   
STAT1 is a potential master regulator of IFN-γ signalling and the cytokine 
activates the transcription factor by phosphorylation on Tyr 701 and Ser 727. It was 
possible that Simvastatin exerted its effect on IFN-γ signalling through the modulation 
of STAT1 phosphorylation, and this was therefore investigated. For this, PMA-
differentiated THP-1 macrophages were pre-treated with Simvastatin (40 µM) as 
mentioned above for 1 hour prior to IFN-γ treatment for 24 hours. Total cellular 
proteins were then extracted and the concentration determined using a MicroBCA 
Protein Assay Reagent Kit (Pierce). Equal amount of the protein was then subjected 
to western blot analysis as described in Chapter 2. Densitometric analysis of the data 
was then carried out with intensity of signals for phospho-STAT1 Ser 727 or –Tyr 701 
normalised to total STAT1 (p84/91). 
As shown in Figure 4.5, IFN-γ significantly induced the phosphorylation of 
STAT1 on Ser 727 and Tyr 701.The two closely migrating bands seen in some cases 
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is because the antibody recognises both the p91 and p84 isoforms produced due to 
alternative splicing.  Inclusion of Simvastatin produced a statistically significant 
attenuation of the IFN-γ-induced STAT1 phosphorylation at either Ser 727 or Tyr 701. 
In contrast, the expression of total STAT1 protein was not affected when compared to 
the β-actin control (Figure 4.4 D). In addition, Simvastatin had no effect on the basal 
STAT1 phosphorylation observed in control cells. These results suggest that STAT1 
activation is an important target for the inhibitory action of Simvastatin on IFN-γ 
signalling in THP-1 macrophages. 
In order to rule out the possibility that the Simvastatin-mediated inhibition of 
STAT1 phosphorylation was not peculiar to THP-1 macrophages, the experiments 
were repeated in primary cultures of HMDM. As shown in Figure 4.5, IFN-γ induced 
STAT1 phosphorylation on both Ser 727 and Tyr 701 in HMDM and this was 
significantly attenuated by the inclusion of Simvastatin. The expression of the total 
STAT1 protein was not affected when compared to the β-actin control (Figure 4.5 D). 
In addition, Simvastatin had no effect on the basal STAT1 phosphorylation observed 
in control cells.  
 125 
 
 
Figure ‎1.16: Simvastatin dose response experiment. 
THP-1 macrophages were pre-treated with different concentrations of Simvastatin (10, 20, 30 
and 40 µM) prior to IFN-γ treatment for 24 hours. Total RNA was isolated and analysed by RT-
qPCR with specific primers for MCP-1 (A), ICAM-1(B) and GAPDH. The expression of MCP-1 
or ICAM-1 mRNA was normalised to that of GAPDH. The data shown are mean from two 
independent experiments. 
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Figure ‎1.17: Effect of Simvastatin on STAT1 phosphorylation in THP-1 macrophages 
Differentiated THP-1 macrophages were pre-treated with Simvastatin (40 µM) for 1 hour prior 
to IFN-γ treatment for 24 hours. Equal amount of protein extracts were then subjected to 
western blot analysis using antibodies specific for PSTAT1-Ser727, PSTAT1-Tyr701, STAT1 
p84/91 and β-actin (A). Panels B and C show the average fold induction in the phosphorylation 
level of STAT1 at these sites (Ser 727 and Tyr 701) respectively normalised to the expression 
of the total STAT1 protein level as determined by densitometric analysis. Panel D shows the 
average fold induction in total STAT1 normalised to β-actin. The data are from four 
independent experiments. The fold induction in control sample was arbitrarily assigned as 1. 
Statistical analysis was performed using one-way ANOVA with Tukeys post-hoc analysis,* 
p<0.05, ** p<.0.01, *** p<0.001, NS not significant. 
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Figure ‎1.18: Effect of Simvastatin on STAT1 phosphorylation in HMDM. 
Primary HMDMs were pre-treated with Simvastatin (40 µM) for 1 hour prior to IFN-γ 
treatment for 24 hours. Equal amount of protein extracts were then subjected to western blot 
analysis using antibodies specific for PSTAT1-Ser 727, PSTAT1-Tyr 701, STAT1 p84/91 and 
β-actin (A). Panels B and C show the average fold induction in the phosphorylation level of 
STAT1 at these sites (Ser 727 and Tyr7 01) respectively, normalised to the expression of the 
total STAT1 protein level as determined by densitometric analysis. Panel D shows the 
average fold induction in total STAT1 normalised to β-actin. The data are from four 
independent experiments. The fold induction in the control sample was arbitrarily assigned as 
1. Statistical analysis was performed using one-way ANOVA with Tukeys, post-hoc analysis,* 
p<0.05, ** p<.0.01, *** p<0.001, NS not significant. 
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4.4 Simvastatin attenuates the IFN-γ induced expression of MCP-1 and ICAM-1 
in RAW 264.7 macrophages 
In order to investigate whether the action of Simvastatin observed in human 
macrophages is conserved in mice, representative experiments were performed in 
mouse RAW264.7 macrophages. Simvastatin or DMSO (vehicle control) was added 
to the cells for 1 hour before stimulation with IFN-γ. RT-qPCR was carried out on RNA 
prepared from the cells using primers against MCP-1, ICAM-1 or β-actin control.  IFN-
γ induced the expression of MCP-1 mRNA by 3.4 fold and this was significantly 
inhibited by Simvastatin (Figure 4.6A). Similarly, IFN-γ induced the expression of 
ICAM-1 (2.3 fold) and this was significantly reduced in the presence of Simvastatin 
(Figure 4.6B). These data suggest that the anti-inflammatory actions of Simvastatin 
are conserved between human and mouse macrophages.  
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Figure ‎1.19: The effect of Simvastatin on the IFN-γ-induced MCP1 
and ICAM-1 expression in RAW264.7 macrophages.  
The cells were pre-treated for 1 hour with Simvastatin (40μM) or DMSO 
as a vehicle control. The cells were then incubated for 24 hours with or 
without IFN-γ (1000 U/ml). Total RNA was isolated and subjected to RT-
qPCR with specific primers for mouse MCP-1, mouse ICAM-1 and mouse 
β-actin. The expression of MCP-1 (A) and ICAM-1 (B) was normalised to 
the β-actin control. The results are displayed as fold change in relation to 
vehicle-treated cells from three independent experiments. Statistical 
analysis was performed using one-way ANOVA with Tukeys post-hoc 
analysis. *** p<.001. 
***	 ***	
A	
***	 ***	
		
B	
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4.4.1 Effect of Simvastatin on the IFN-γ induced expression of ICAM-1 
protein 
The analysis of gene expression was so far restricted to mRNA levels. In order 
to confirm that the changes also occurred at the level of protein, representative 
experiments were performed on ICAM-1 in both THP-1 macrophages and primary 
HMDMs using western blot analysis. As shown in Figures 4.7 and 4.8, IFN-γ induced 
the expression of ICAM-1 protein in both THP-1 macrophages and HMDM and 
Simvastatin attenuated this. In addition, Simvastatin had no significant effect on the 
constitutive expression of the ICAM-1 protein. 
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Figure ‎1.20: Simvastatin inhibits the IFN-γ induced expression of the 
ICAM-1 protein in THP-1 macrophages. 
PMA differentiated THP-1 macrophages were pre-treated with Simvastatin (40 
µM) for 1 hour prior to IFN-γ treatment for 24 hours. Equal amount of protein 
extracts were subjected to western blot analysis using antibodies specific for 
ICAM-1 and β-actin (A). The histogram shows the changes in ICAM-1 
expression, as determined by densitometric analysis, from four independent 
experiments (the value for the control sample was arbitrarily assigned as 1) 
(B). Statistical analysis was performed using one-way ANOVA with Tukeys 
post-hoc analysis, * p<0.05, ** p<.0.01, NS not significant. 
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Figure ‎1.21: Simvastatin inhibits the IFN-γ induced expression of ICAM-1 
protein in HMDM. 
Primary HMDMs were pre-treated with Simvastatin (40 µM) for 1 hour prior to IFN-y 
treatment for 24 hours. Equal amount of protein extracts were subjected to western 
blot analysis using antibodies specific for ICAM-1 and β-actin (A). The histogram 
shows the changes in ICAM-1 expression (B), as determined by densitometric 
analysis, from four independent experiments (the value in the control sample was 
arbitrarily assigned as 1). Statistical analysis was performed using one-way ANOVA 
with Tukeys post-hoc analysis,* p<0.05, ** p<.0.01, NS not significant. 
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4.4.2 Optimisation of Simvastatin incubation time using a new source of 
this statin dissolved in water 
The Simvastatin that was used in previous studies was an activated form that 
had to be dissolved in an organic solvent like DMSO. In the latter part of the studies, 
another, more cheaper form of activated Simvastatin that was dissolved in water 
became commercially available. It was decided to use this source for further studies.  
However, variable results were obtained with pre-incubation time of 1 hour (data not 
shown). Because some previous studies have used pre-incubation periods of up to 24 
hours, it was possible that a longer pre-incubation period was required. It was 
therefore decided to do this optimisation experiment with the new Simvastatin in which 
THP-1 macrophages were treated with this statin (40 µM) for 1 hour, 3 hours and 6 
hours prior to IFN-γ stimulation for 24 hour. Total RNA was then isolated and RT-
qPCR was carried out for MCP-1 and ICAM-1. A significant inhibition of the IFN-γ 
induced MCP-1 and ICAM-1 expression was only obtained following pre-incubation 
with Simvastatin for 6 hours (Figure 4.9). It was therefore decided to use this 6 hours 
pre-incubation period with Simvastatin for subsequent studies. 
 
 
 134 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎1.22: The effect of pre-treatment of cells with Simvastatin 
for different time periods on IFN-γ actions.  
THP-1 macrophages were pre-treated with Simvastatin for different 
time periods (1, 3 and 6 hours) prior to IFN-γ treatment for 24 hours. 
Total RNA was isolated and subjected to RT-qPCR with specific 
primers for MCP-1 (A), ICAM-1 (B) and GAPDH. The levels of MCP-1 
or ICAM1 was normalised to GAPDH mRNA with values from control 
cells arbitrarily assigned as 1. The data are from three independent 
experiments. Statistical analysis was performed using one-way 
ANOVA with Tukeys post-hoc analysis, * p<0.05, *** p<0.001, NS not 
significant. 
***	 NS	 ***	 NS	 ***	 ***	A	
*	 NS	 *	 NS	
***	 ***	
B	
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4.4.2.1.1 Effect of Simvastatin on the IFN-γ induced expression of MCP-1 and 
ICAM-1 in primary HMDMs 
 
In order to confirm that the effect of Simvastatin following 6 hours incubation 
period was not peculiar to THP-1 macrophages, the experiments were repeated using 
primary cultures of HMDMs. The cells were treated with 40 µM Simvastatin for 6 hour 
prior to IFN-γ treatment for 24 hours, and RNA was analysed by RT-qPCR analysis 
for MCP-1 and ICAM-1 genes. As shown in Figure 4.10, IFN-γ induced the expression 
of MCP-1 and ICAM-1 and Simvastatin significantly reduced this by more than 50%. 
In addition, Simvastatin produced a significant decrease in constitutive MCP-1, but not 
ICAM-1, expression. 
4.4.3 Effects of Simvastatin on MAPKs pathways 
Figures 4.4 and 4.5 shows that Simvastatin inhibits the IFN-γ induced STAT1 
phosphorylation on Ser 727 and Tyr 701. The phosphorylation of STAT1 on Ser 727 is 
known to be modulated by MAP kinases (Goh et al., 1999; Zhang et al., 2004; Li et 
al., 2010). The effect of Simvastatin on the expression and/or activation of different 
MAPKs were therefore investigated.  
4.4.3.1            Effect of Simvastatin on JNK-1 and -2 
PMA differentiated THP-1 macrophages were treated for 6 hour with 40 μM 
simvastatin followed by treatment with IFN-γ for 24 hours. Total RNA was isolated and 
RT-qPCR was carried out for JNK-1 and -2 genes. Before carrying out the 
experiments on JNK-1 and -2, the expected changes in MCP-1 and ICAM-1 
expression was confirmed by additional experiments in light of the new source of 
Simvastatin and 6 hours pre-incubation period. Figure 4.11 shows that IFN-γ induces 
MCP-1 and ICAM-1 expression, and this was significantly attenuated by Simvastatin. 
These data also acted as a positive control for subsequent studies on the MAPK 
family as the same RNA was used. As shown in Figure 4.12, IFN-γ produced a 
significant increase in the expression of both JNK-1 and -2 mRNA.  However, this 
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induction in gene expression was not affected by Simvastatin. In addition, the 
constitutive expression of JNK-2, but not JNK-1, was induced by Simvastatin (Figure 
4.12). Unfortunately, it was not possible to investigate the activation of JNK-1/2 
phosphorylation because of problems with commercially available antibodies (data not 
shown). It was therefore decided to analyse the expression and activation of c-Jun, a 
key downstream target of JNK-1/2 actions. 
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Figure ‎1.23: Effect of Simvastatin on the IFN-γ induced MCP-1 and 
ICAM-1 mRNA expression in primary HMDMs. 
Primary macrophages were pre-treated with Simvastatin for 6 hours prior to 
IFN-γ treatment for 24 hours. Total RNA was analysed by RT-qPCR with 
specific primers for MCP-1(A), ICAM-1(B) or GAPDH. The expression of 
MCP-1 or ICAM-1 was normalised to GAPDH mRNA levels. The data are 
from three independent experiments. Statistical analysis was performed 
using one-way ANOVA with Tukeys post-hoc analysis, ** p<.0.01, *** 
p<0.001, NS not significant. 
***	 ***	
**	
A	
***	 ***	
NS	
B	
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Figure ‎1.24: Simvastatin inhibits the IFN-γ induced MCP-1 and ICAM-1 
mRNA expression. 
THP-1 macrophages were pre-treated with Simvastatin for 6 hours prior 
to IFN-γ treatment for 24 hours. Total RNA was isolated and subjected to 
RT-qPCR with specific primers for MCP-1 (A), ICAM-1 (B) and GAPDH.  
The expression of MCP-1 or ICAM-1 was normalised to GAPDH with the 
relative mRNA expression from control cells being arbitrarily assigned as 
1. The data shown are from four independent experiments. Statistical 
analysis was performed using one-way ANOVA with Tukeys post-hoc 
analysis, *** p<0.001, NS not significant. 
 
 
 
***	 ***	
NS	A	
***	 ***	
NS	B	
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Figure ‎1.25: Effect of Simvastatin on JNK-1 and -2 
THP-1 macrophages were pre-treated with Simvastatin for 6 hours prior to IFN-γ 
treatment for 24 hours. Total RNA was analysed by RT-qPCR with specific primers to 
JNK-1 (A), JNK-2 (B) and GAPDH. The expression of JNK-1 and -2 was normalised 
to GAPDH mRNA levels. The data are from four independent experiments. Statistical 
analysis was performed using one-way ANOVA with Tukeys post-hoc analysis, * 
p<0.05, ** p<.0.01, NS not significant.   
 
 
 
 
**	 NS	
NS	
*	 NS	
**	
A	
B	
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4.4.4 Effect of Simvastatin on c-Jun 
Initial experiments investigated the effect of IFN-γ on c-Jun mRNA expression 
and, if a change was identified, whether this was affected by Simvastatin. For this 
PMA differentiated THP-1 macrophages were pre-treated with 40 µM Simvastatin for 
6 hours prior to IFN-γ treatment for 24 hour. Total RNA was isolated and used for RT-
qPCR analysis.  
IFN-γ produced a significant induction of expression of c-Jun mRNA 
expression (Figure 4.13). However, Simvastatin had no significant effect on this 
induction (Figure 4.13). Simvastatin also had no significant effect on constitutive c-Jun 
mRNA expression though a trend of increased levels was observed.  
 
 
 
 
 
 
 
 
 
 
 
Figure ‎1.26: Effect of Simvastatin on c-Jun 
THP-1 macrophages were pre-treated with Simvastatin for 6 
hours prior to IFN-γ treatment for 24 hours. Total RNA was 
isolated and subjected to RT-qPCR with specific primers for c-Jun 
or GAPDH. The expression of c-Jun was normalised to GAPDH 
with values from control cells being arbitrarily assigned as 1. The 
data shown are from four independent experiments. Statistical 
analysis was performed using one-way ANOVA with Tukeys post-
hoc analysis, * p<0.05, NS not significant. 
*	 NS	
NS	
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c-Jun is activated by phosphorylation  and represents a key downstream target 
of JNK actions. It was therefore decided to first investigate whether the levels of 
phosphorylated, activated c-Jun changes following treatment of the cells with IFN-γ, 
and if this were the case, if Simvastatin affects this. As shown in Figure 4.14, IFN-γ 
had no significant effect on the levels of phospho-c-Jun. Similarly, IFN-γ had no 
significant effect on total c-Jun levels. 
 
Figure ‎1.27: Effect of Simvastatin on c-Jun 
PMA differentiated THP-1 macrophages were treated with IFN-γ for 24 hours. Equal amount of 
protein was then subjected to western blot analysis using antibodies specific for phospho c-
Jun, total c-Jun and β-actin (A). Panel B shows the levels of phospho-c-Jun normalised to total 
c-Jun and panel C shows the average fold induction of total c-Jun normalised to β-actin, from 
three independent experiments. The values from control cells have been arbitrarily assigned 
as 1. Statistical analysis was performed using one-way ANOVA with Tukeys post-hoc analysis, 
NS not significant. 
 
Phospho-c-jun 
Total c-jun 
	
β-actin 
	
	Control														IFN-γ	
NS	
A	
B	
NS 
C	
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4.4.5 Effect of Simvastatin on ERK-1 and -2 
RT-qPCR was carried out to investigate whether IFN-γ affected the expression 
of ERK-1 and -2 mRNA in THP-1 macrophages.  IFN-γ induced the expression of both 
ERK-1 and -2 mRNA though this failed to reach significance for ERK-2 (Figure 4.15). 
Inclusion of simvastatin had no further effect on the IFN-γ-mediated increase in ERK-1 
mRNA expression but significantly increased the levels of ERK-2 RNA. Interestingly, 
the constitutive levels of ERK-1 and -2 (produced during differentiation in response to 
PMA) were significantly increased by Simvastatin (Figure 4.15).  
ERK-1/2 is activated by phosphorylation. It was decided to first investigate 
whether the levels of phosphorylated, activated ERK1/2 change in response to IFN-γ 
treatment and, if any changes are identified, whether Simvastatin affects this. Figure 
4.16 shows that IFN-γ produces a significant increase in the levels of phospho-
ERK1/2 without affecting the total levels of the protein. The effect of Simvastatin on 
both the constitutive and IFN-γ-induced levels of ERK-1/2 was next investigated. As 
shown in Figure 4.17, both the constitutive (associated with differentiation by PMA) 
and IFN-γ inducible levels of phospho-ERK-1/2 were significantly attenuated by 
Simvastatin. However, Simvastatin had no effect on the levels of total ERK-1/2 
protein.  
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Figure ‎1.28: Effect of Simvastatin on ERK-1 and -2 mRNA 
expressions. 
THP-1 macrophages were pre-treated with Simvastatin for 6 hours prior to 
IFN-γ treatment for 24 hours. Total RNA was analysed by RT-qPCR with 
primers specific for ERK-1 (A), ERK-2 (B) or GAPDH. The expression of 
ERK-1 and -2 was normalised to GAPDH mRNA expression. The data 
shown are from six independent experiments. Statistical analysis was 
performed using one-way ANOVA with Tukeys post-hoc analysis, * p<0.05, 
*** p<0.001, NS not significant. 
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Figure ‎1.29: Effect of IFN-γ on the phospho- ERK levels. 
PMA differentiated THP-1 macrophages were treated with IFN-γ for 24 hours. Protien extracts 
were then subjected to western blot analysis using antibodies specific for phospho-ERK1/2 
(P44/42), total ERK1/2 and and β-actin (A). The levels of ERK-1/2, as determined by 
densitometric analysis of the data, were normailsed to that of total ERK-1/2 (B). Panel C 
shows the average fold induction in total ERK1/2 normalised to β-actin. The values are from 
three independent experiments and those from the control sample have been arbitrarily 
assigned as 1. Statistical analysis was performed using one-way ANOVA with Tukeys post-
hoc analysis, * p<0.05.NS= not significant. 
 
      Control                                IFN-y 
Phospho-ERK 
Total ERK 
β-actin 
A	
NS 
C	
*	
B	
NS * 
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Figure ‎1.30: Effect of Simvastatin on IFN-γ-induced phospho-ERK-1/2 
expression 
THP-1 macrophages were pre-treated with Simvastatin for 6 hours prior to IFN-γ treatment for 
24 hours. Protein extracts were prepared and subjected to western blot analysis using 
antibodies specific for phospho-ERK-1/2 (P44/42), total ERK-1/2 and β-actin (A). The levels of 
phospho-ERK-1/2, as determined by densitometric analysis, were normalised to that of total 
ERK-1/2 (B), Panel C shows the average fold induction of total ERK1/2 normalised to β-actin. 
The data are from four independent experiments and the values from control sample have 
been arbitrarily assigned as 1. Statistical analysis was performed using one-way ANOVA with 
Tukeys post-hoc analysis, * p<0.05, *** p<0.001.  
 
 
Control        IFN-y         Simvastatin     Simvastatin+ 
                                                                  INF-y 
Phospho-ERK 
Total ERK 
β-actin 
A	
NS NS 
NS C	
*	 ***	
***	
B	
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4.4.6 Effect of Simvastatin on p38 
PMA differentiated THP-1 macrophages were pre-treated for 6 hours with 40 
µM Simvastatin and then treated with IFN-γ for 24 hours. The expression of p38α 
(major isoforms expressed in macrophages and implicated in inflammation) mRNA 
was then determined by RT-qPCR analysis. IFN-γ significantly induced p38 mRNA 
expression and this was not affected by simvastatin (Figure 4.18). Interestingly, 
Simvastatin significantly increased basal p38 mRNA expression. 
Initial western blot analysis using the 24-hour incubation with IFN-γ showed no 
signals with the phospho-p38 antibody. Because the phosphorylation of many 
components of signal transduction pathways is often seen at earlier time points and 
the activation can be transient, it was decided to do a preliminary time course 
experiment where IFN-γ was added for different time periods (15 minutes, 30 minutes, 
1 hour, 3 hours, and 12 hours). Treatment of the cells with IFN-γ for 3 hours produced 
the most induction of phospho-p38 levels (Figure 4.19).  It was thus decided to treat 
the cells with IFN-γ for 3 hours for subsequent experiments. 
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Figure ‎1.31: Effect of Simvastatin on p38α mRNA expression. 
THP-1 macrophages were pre-treated with Simvastatin for 6 
hours prior to IFN-γ treatment for 24 hours. Total RNA was 
analysed by RT-qPCR with specific primers to p38α and GAPDH. 
The expression of p38α was normalised to GAPDH mRNA levels. 
The data shown are from four independent experiments. 
Statistical analysis was performed using one-way ANOVA with 
Tukeys post-hoc analysis, * p<0.05, NS not significant. 
 
 
*	 NS	
*	
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Figure ‎1.32: Time dependent actions of IFN-γ on levels of phospho-p38. 
THP-1 macrophages were treated with IFN-γ for different times (15 minutes, 30 
minutes, 1 hour, 3 hours and 12 hours). Protein extracts were subjected to western 
blot analysis using antibodies specific for phospho–p38, total p38 and β-actin (A). 
The histogram shows phospho-p38 levels normalised to total p38 from one 
experiment (B). 
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The effect of Simvastatin on the IFN-γ induced phospho-p38 levels was next 
determined. Differentiated THP-1 macrophages were treated with 40 µM Simvastatin 
for 6 hours and then IFN-γ was added to the cells for 3hour. Western blot analysis on 
cell lysates was then performed using phospho-p38 antibody. As it shown in the 
Figure 4.20, IFN-γ increased the expression of phospho-p38 and addition of 
simvastatin produced a slight, but significant, reduction. In contrast, there was no 
effect on the total p38 levels or constitutive phospho-p38 levels.  
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Figure ‎1.33: Effect of Simvastatin on phospho-p38 
THP-1 macrophages were pre-treated with Simvastatin for 6 hours prior to IFN-γ treatment for 
3 hours. Protein extracts were subjected to western blot analysis using antibodies specific for 
phospho-p38, total p38 and β-actin (A). Panel B shows the level of phospho-p38 normalised to 
total-p38 whereas panel C shows the average fold induction in total p38 normalised to β-actin. 
The data are from four independent experiments with the values in control sample being 
arbitrarily assigned as 1. Statistical analysis was performed using one-way ANOVA with 
Tukeys post-hoc analysis, * p<0.05, ** p<.0.01, NS not significant. 
 
Control     IFN-γ          Simvastatin  Simvastatin+IFN-γ       
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4.5 Discussion 
4.5.1 The effect of metabolites of cholesterol biosynthesis pathway on 
the IFN-γ induced MCP-1 mRNA expression 
Statins are potent inhibitors of the endogenous mevalonate pathway and also 
play a role in the biosynthesis of cholesterol and isoprenoids (Goldstein and Brown 
1990). Consequently, statins inhibit the biosynthesis of cholesterol and isoprenoid 
intermediates including GGP and FPP. The isoprenoids act as lipid attachment site for 
various intracellular proteins to the plasma membrane, including small guanosine 
triphosphate-binding proteins, such as Ras and Ras-like proteins (eg, Rho, Rac and 
Rab), resulting in their activation (Takai et al. 2001). Isoprenylation of these proteins, 
in turn, regulates the downstream signalling pathways involved in cytoskeletal 
organisation, motility, membrane trafficking, transcriptional activation, and cell 
proliferation and differentiation. Therefore, statins may interfere with these processes 
by depleting intracellular GGP and FPP, resulting in the inhibition of protein 
isoprenylation (Chow, 2009). 
In the current study, Simvastatin was found to inhibit the IFN-γ induced 
expression of MCP-1 mRNA expression and that the inhibition was reversed by the 
addition of isoprenoid intermediates FPP and GGP toTHP-1 macrophages. Similary, 
Cakmak et al. (2012) found that addition of FPP and GGP to endometritic  mice cells 
reversed the effect of Simvastatin in MCP-1 expression  (Cakmak et al. 2012). 
Another study by Lee and his colleagues in RAW 264.7 cells showed that mevalonate 
and GGP reversed the Simvastatin-mediated inhibition of IFN-γ induced CIITA mRNA 
expression (Lee et al., 2008). 
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4.5.2 Simvastatin inhibits the IFN-γ induced STAT1 phosphorylation in 
THP-1 macrophages and primary HMDMs 
As mentioned in Chapter 1, IFN-γ controls many steps in the pathogenesis of 
atherosclerosis, including the recruitment of inflammatory cells to the activated 
endothelium, foam cell formation, apoptosis and plaque stability (McLaren and Ramji, 
2009; Li et al. 2010). The JAK-STAT pathway plays a key role in IFN-γ signalling 
(McLaren and Ramji, 2009). Simvastatin inhibited the IFN-γ-mediated STAT1 
phosphorylation on Ser 727 and Tyr 701 (Figures 4.4 and 4.5). These findings are 
consistent with Lee and colleagues (2007) that showed that Simvastatin inhibits 
STAT1α at the transcriptional and protein levels in RAW264.7 macrophages (Lee et 
al. 2007). Moreover, a study by Townsend and colleagues found that in primary 
microglial cells, Atorvastatin (10 µM) inhibited Ser 727 phosphorylation of the STAT1 
protein by IFN-γ (30 minutes)  (Townsend et al., 2004). However, other studies have 
not found an effect of Simvastatin on STAT1 phosphorylation (Lee et al. 2007). For 
example, simvastatin does not affect the IFN-γ-induced STAT1 phosphorylation in 
human microvascular endothelial cells (Sadeghi et al. 2001). In addition, the results in 
this study are different from those by Li et al. (2011) in THP-1 macrophages where it 
was demonstrated that Simvastatin had no effect on STAT1 phosphorylation. 
Although the exact reasons are unclear, this may reflect the use of a lower 
concentration of simvastatin  (10 µM) or a reduced treatment period with IFN-γ (30 
minutes) (Li et al. 2011). Thus, the effect of Simvastatin on STAT1 phosphorylation in 
macrophages might be dependent on the concentration of the statin or the incubation 
time with the cytokine. Further dose response and time course experiments will be 
required to address this issue further. 
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4.5.3 Simvastatin attenuates the IFN-γ induced expression of MCP-1 
and ICAM-1 in primary HMDMs and RAW 264.7 cells 
To further confirm that the results obtained in THP-1 macrophages are not 
peculiar to the cell line, representative experiments were performed in primary 
cultures of HMDMs. A number of studies have previously shown conservation of 
responses between THP-1 macrophages and primary HMDMs (McLaren et al., 
2010a; McLaren et al., 2010b). Consistent with these studies, Simvastatin inhibited 
the IFN-γ induced expression of MCP-1 and ICAM-1 mRNA levels along with STAT1 
Ser727 and Tyr 701 phosphorylation in both THP-1 macrophages and HMDMs 
(Figures 4.4, 4.5, 4.10 and 4.11). 
The simvastatin-mediated inhibition of the IFN-γ-induced expression of MCP-1 
and ICAM-1 was also conserved in the mouse RAW264.7 cell line (Figure 4.6).  Kota 
et al. (2006) have also found that IFN-γ  induces MCP-1 gene expression in RAW 
264.7 cells (Kota et al. 2006). A study by Romano et al. (2000) showed that 
Simvastatin and Lovastatin decreased MCP-1 production in peripheral blood 
mononuclear cells (PBMC) and ECs (Romano et al. 2000). 
4.5.4 Effect of Simvastatin on  the IFN-γ induced expression of ICAM-1 
Numerous studies have analysed the effects of statins on ICAM-1 expression 
in various cellular systems (Lee et al., 2009; Chung et al, 2013; Takahashi et al., 
2005).  Atorvastatin was found to inhibit  the constitutive expression of ICAM-1 in 
human umbilical vein ECs (Korybalska et al., 2012). Consistent with these studies, 
simvastatin was found to decrease ICAM-1 expression in THP-1 macrophages, 
HMDMs and RAW264.7 macrophages (Figures 4.6, 4.10 and 4.11). 
4.5.4.1 Effects of Simvastatin on MAPKs Pathways 
4.5.4.1.1 Effect of Simvastatin on JNK-1 and -2 
 
The effect of IFN-γ on the JNK pathway is well known as it was found that IFN-
γ and TNF-α work synergistically to activate JNK/SAPK in a pancreatic β cell line 
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(MIN6N8 cells) (Kim et al. 2005). Another study also showed that there was a very 
weak activation of JNK1 in bone marrow–derived macrophages after treatment with 
IFN-γ for more than 2 hours whereas JNK2 was present at undetectable levels 
(Valledor, Arpa, et al. 2008). JNK2-/- mice have decreased foam cell formation 
compared to  wild-type or JNK1-/-, thereby showing an important role for JNK2 in 
atherosclerosis (Ricci et al. 2004). Another study by Jin and his colleagues (2011) 
found that both the JNK inhibitor SP600125 and Simvastatin together protected 
porcine islets from apoptosis. Atorvastatin also inhibits JNK (ERK and p38) proteins 
(western blotting) in hyperlipidaemic mice (Shen et al. 2011). In recent study, It has 
been shown that Fluvastatin decreased phospho JNK levels in rat cardiomyocytes 
(Sakai et al. 2014). 
As mentioned above, there were problems with the phospho JNK antibody, 
and hence the studies on the activation of this pathway investigated the key 
downstream target, c-Jun.  For future work it may be useful to try phospho JNK from 
other sources or to produce the antibody in rabbits. However, the results from RT-
qPCR showed that IFN-γ increases the expression of JNK-1 and -2 mRNA and this is 
not affected by treatment with Simvastatin (Figure 4.12).  
4.5.4.2 Effect of Simvastatin on c-Jun 
IFN-γ increased the expression of c-Jun, a finding that is in agreement with 
Rubio (1997) that showed that this cytokine induces the expression of c-Jun and c-
Fos in astrocytes (Rubio 1997). Simvastatin had no effect on the IFN-γ induced 
expression of c-Jun mRNA levels (Figure 4.13). In contrast, Atorvastatin was found to 
significantly decrease c-Jun nuclear content in human and murine osteosarcoma cells 
(Fromigué et al. 2008). Another study also found that lovastatin and simvastatin 
reduces c-Jun expression in prostate cancer cells (Hoque et al. 2008). Moreover, a 
study by Sakai  (2014) showed that Fluvastatin decreases c-Jun mRNA expression 
and phospho-c-Jun levels in rat cardiomyocytes (Sakai et al. 2014). 
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Results from western blotting did not show an induction of phospho c-Jun in 
THP-1 macrophages (Figure 4.14). This finding differs from the IFN-γ-mediated 
activation of c-Jun observed in wild type (wt) murine embryonic fibroblasts (MEFs) 
(Gough et al., 2007). 
4.5.4.3 Effect of Simvastatin on ERK-1 and -2 (p44/42) 
IFN-γ stimulates the phosphorylation of ERK-1 and -2 in (wt) MEFs (Gough et 
al. 2007). The phosphorylation-mediated activation of ERK-1/2 was decreased by 
simvastatin (40 µM) (Figure 4.17). The finding are consistent with those of Zhang et 
al. (2010) who found that Mevastatin decreases phosphorylation of ERK-1/2 in a dose 
dependent manner in cancer cells (SACC cells) (Zhang et al. 2010). Furthermore, 
statins (Simvastatin, Mevastatin and Fluvastatin) were found to inhibit ERK-1/2 
phosphorylation in C6 glioma cells (Yanae et al. 2011). Another study found that 
atorvastatin inhibited ERK activation in neonatal rat cardiomyocytes (Liao et al. 2008). 
In RAW264.7 cells, Atorvastatin was also found to inhibit ERK-1/2 phosphorylation 
(Shao et al. 2012). A very recent study showed that Simvastatin decreases phospho-
ERK and -p38 levels in human platelets suspension (Du et al. 2014). In contrast, 
lovastatin did not decrease phospho ERK levels in microglial cells (Townsend et al. 
2004) 
4.5.4.4            Effect of Simvastatin on p38  
IFN-γ increased the expression of p38 mRNA levels and Simvastatin had no 
effect on this (Figure 4.18). An early study by Lehner and his collegues (2002) 
showed that the expression of IFN-γ was decreased in mice lacking MAPK-activated 
protein kinase 2 (MK2), which is a kinase activated by p38 (Lehner et al. 2002). Other 
studies also showed that there was a strong activation of p38 by IFN-γ treatment in 
primary BMDM (Valledor, Sánchez-Tilló, et al. 2008). 
Simvastatin had no effect on the IFN-γ induced p38 mRNA expression (Figure 
4.20) but significantly decreased the phosphorylation and the activation of the 
corresponding protein (Figure 4.20). This finding is in agreement with Lee and 
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collegues (2010) that showed that Simvastatin decreases p38 phosphorylation in 
suspension of human platelets (Lee et al. 2010). However, these studies contrast with 
that by Zhang et al. (2010) who found that treatment of human salivary adenoid cystic 
carcinoma (SACC) cells with Mevastatin increased p38 phosphorylation (Zhang et al. 
2010).  
The studies presented in this chapter determined the molecular mechanisms 
underlying Simvastatin in macrophages. Simvastatin and IFN-γ are also likely to 
modulate lipid profiles of macrophages in addition to intracellular cholesterol levels. 
Such studies formed the focus of the next chapter. 
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Chapter 5: Effects of Simvastatin on lipid 
profiles in THP-1 and RAW 264.7 cells 
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5.1 Introduction 
Lipids are complex biological molecules; they are insoluble in water but soluble 
in organic solvents. Lipids play many important roles in all living organisms and are 
divided into two main groups: the non-polar lipids (triacylglycerols, sterols, free fatty 
acids, and sterol esters) and polar lipids (e.g. phosphoglycerides, or phospholipids) 
(Guschina and Harwood, 2009). Polar lipids and sterols are important structural 
components of cell membranes. In all organisms each membrane has its own 
characteristic lipid profile, which is tightly maintained because of functional 
requirements (Gurr et al. 2002). In addition to this structural function, some polar lipids 
(or their precursors) act as intermediates in cell signalling pathways (e.g. sphingolipids 
and inositol lipids) (Rustan and Drevon, 2005). As to the nonpolar lipids, 
triacylglycerols are common storage molecules, providing metabolic energy for many 
biochemical reactions and cellular functions.  
Glycerolipids are synthesised from a glycerol (propane-1,2,3-triol) and fatty 
acids (FA). FAs are carboxylic acids (containing –COOH group) with aliphatic 
hydrocarbon chains of carbon atoms (Yeagle 2009). If the carbon-to-carbon bonds are 
all single, FA is classified as saturated. If any of the bonds are double or triple, the FA 
is classified as unsaturated. Over 1000 fatty acids are known with various chain 
lengths and positions, configurations and types of unsaturation. In most animal fats, 
saturated FAs with even number of carbon atoms (usually between 12-22) are 
dominant (Yeagle 2009). This feature of saturated FA allows them to pack tightly in a 
solid form, which enables them to accumulate inside the organs and arteries leading 
to pathophysiological conditions such as atherosclerosis (Gurr et al. 2002). On the 
other hand, unsaturated FAs have double bonds within the carbon chain that causes 
a “twist” in their physical structure to allow them to adopt an oil form at room 
temperature (Gurr et al. 2002). Unsaturated FAs can be arbitrarily divided into 
monounsaturated FAs (MUFAs) and polyunsaturated FAs (PUFAs) (Rustan and 
Drevon, 2005). MUFAs have a single double bond between two carbon atoms and the 
position of this double bond regulates its structure (configuration can either be cis or 
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trans) (Gurr et al. 2002). PUFA contains two or more double bonds of the cis-
configuration separated by a single methylene group. Long chain PUFA are 
composed of 18 or more carbon atoms with 2 or more double bonds (Rustan and 
Drevon, 2005). From very many long chain PUFAs (LCPUFAs), two groups are widely 
known i.e. omega-3 (ω-3 or n-3) and -6 (or n-6) FAs named according to the positions 
of the 1st double bond i.e. between 3rd and 4th carbon atoms and 6th and 7th carbon 
atoms, respectively (Rustan and Drevon, 2005). n-3 PUFA comprise of α-linolenic 
acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), whereas 
n-6 PUFA include linoleic acid (LA) and arachidonic acid (AA) (Zuliani et al., 2009).  
Due to the lack of enzymes, namely delta-12 and delta-15 desaturases (Δ12 
and Δ15) in mammals, they are not able to synthesise linolenic and α-linolenic acids, 
and therefore the human body needs to obtain adequate amount of these essential 
FAs  from the diet or plant foods (Gurr et al., 2002). The metabolic pathways of 
omega-3 and omega-6 fatty acids members are shown in Figure 5.1. The majority of 
omega-6 fatty acids (e.g. arachidonic acid) promote inflammation, whereas omega-3 
fatty acids (e.g. EPA and DHA) have anti-inflammatory properties (Kang and 
Weylandt, 2008).  
The mechanisms of n-3 and n-6 LCPUFA actions are related to the fact that 
these fatty acids are precursors for a wide range of biologically active metabolites. 
The LCPUFA metabolites, eicosanoids and docosanoids, are oxidation products 
produced by the activities of cyclooxygenases (COX), lipoxygenases (LOX), 
cytochrome P450 as well as by some non-enzymatic oxidation. Eicosanoids are 
synthesised from the C20 n-3 and n-6 LCPUFA. They include prostaglandins, 
leukotriens, thromboxanes, lipoxins and E-series resolvins. Docosanoids are 
produced from C22 LCPUFAs (Kruger et al. 2010).  Additionally, DHA can produce 
protectins, docosatrienes and maresins, a novel class of macrophage mediators 
(Poudyal et al. 2011). DHA and EPA are known for their anti-inflammatory properties 
(Wall et al., 2010), while arachidonic acid is a proinflammatory (Caspar-Bauguil et al., 
2012).  
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EPA and DHA are known for their anti-inflammatory actions, and have been 
found to reduce the risk of cardiovascular morbidity and mortality (Lusis 2000; 
Breslow 2006; Alberts et al. 2002; Bucher et al. 2002). This is not surprising given that 
atherosclerosis is an inflammatory disorder of the vasculature. Several studies have 
found that EPA and DHA have the ability to reduce plasma triglyceride levels and 
arterial stiffness  (Kris-Etherton et al. 2002; Cleland et al. 2006).  
Furthermore, n3 FAs have been found to lower plasma levels of the pro-
inflammatory cytokines TNF-α and β in healthy subjects (Caughey et al. 1996). 
Additionally, n3 fatty acids contribute to regulating heart beats in patients with cardiac 
disease where it increases the fluidity of the membrane in cardiac cells and decreases 
the accessibility of inflammatory cytokines to bind to their receptors, thereby 
decreasing fatal and non-fatal cardiac events (Wilkinson et al. 2005; Ergas et al. 2002; 
Schwalfenberg 2006; Gallai et al. 1995).  
The joint guidelines from the American Heart Association, American College of 
Cardiology, the European Society for Cardiology, and national Cardiac Societies 
recommend supplements of 1g/day of omega-3 fatty acids EPA and DHA for 
secondary prevention of cardiovascular disease, and for the treatment after 
myocardial infarction (Smith et al. 2006; De Backer et al. 2003; Van de Werf et al. 
2003; Schacky and Harris, 2007). The n3 FAs are also very important to improve 
functions of numerous other systems including the immune system and the skin. 
Thus, supplementation of n3 fatty acids has been shown to be effective in 
inflammatory diseases such rheumatoid arthritis (Goldberg and Katz, 2007). A number 
of studies have shown that n3 fatty acid reduce the pain intensity and morning 
stiffness in patients with rheumatoid arthritis, and reduce lipids profiles in patients with 
type 2 diabetes (Goldberg and Katz 2007; Jeppesen et al., 2013).  
Previously, statins have shown a strong suppression effect on inflammatory 
processes in cardiovascular disease, as they have pleotropic actions beyond lowering 
plasma cholesterol. Treatment with statins and omega-3 FAs after myocardial 
infarction (MI) synergistically decreased mortality and fatal cardiovascular events 
 161 
 
(Macchia et al. 2013). In a study by Fritsche et al. (1999) in mice with Listeria 
infection, treatment with omega-3 fatty acids from fish oil in its early stage was found 
to reduce IL-12 and IFN-γ production. Potential effect of statins include enhancing 
fatty acids synthesis, stimulatory peroxisomal activity and increasing arachidonic acid 
and thromboxane production (Williams et al. 1992; Hrboticky et al. 1994) . Statins also 
decrease Cox-2 and MMP-9 expression and activity in the vascular endothelium 
(Massaro et al. 2010). In THP-1 cells, Simvastatin in particular, increases the 
conversion of exogenous linoleic and EPA to their long-chain PUFA derivatives (Risé 
et al. 1997). 
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Figure ‎0.1: Omega-3 and omega-6 fatty acid metabolic pathways. 
The longer chain n-3 and n-6 PUFAs can originate from the dietary 18-carbon precursors 
ALA and LA, respectively. Through a series of elongation enzymes that sequentially add 2-
carbon units to the FA backbone and desaturation enzymes that insert double bonds into the 
molecules, longer-chain PUFAs are synthesised. The most important LCPUFAs with regards 
to health are AA, EPA and DHA. 
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5.2 Aims and experimental strategies 
Atherosclerosis is a progressive disease that is characterised by lipid 
accumulation and inflammation within the walls of the large and medium arteries 
(Lusis 2000). The main aim of the studies presented in this chapter was to study the 
lipid and FA profile of THP-1 and RAW 264.7 macrophages, and to investigate the 
effect of Simvastatin on these parameters in macrophages. To achieve this, two 
experimental approaches were used (Figure 5.2). In the first approach, radiolabelled 
acetate was used in order to study the synthesis of the major lipid classes, namely 
total polar lipids (TPL), cholesterol (CHO) and triglycerides (TAG) in THP-1 
macrophages. Thus, vehicle-treated cells or those stimulated with IFN-γ in the 
absence or the presence of Simvastatin, FPP or GGP were analysed (Chapter 4). In 
the second approach, the lipid and FA profiles of two different macrophage systems 
(THP-1 and RAW 264.7) were analysed using various chromatographic techniques. 
The cells were treated with vehicle or IFN-γ (with or without Simvastatin) in order to 
identify any possible effect of Simvastatin on lipid composition of the cells.  
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Figure ‎0.2: Experimental Strategies  
THP-1 and RAW 264.7 macrophages were used. The two experimental regimes used in this 
chapter are shown. These studies were carried out using activated Simvastatin in DMSO with 
pre-treatment time of 1 hour. 
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5.3 Results 
5.3.1 The effect of Simvastatin on the biosynthesis of the major lipid 
classes and cholesterol in THP-1 macrophages 
 THP-1 macrophages were treated with vehicle DMSO or Simvastatin (40 µM) with or 
without FPP (5 µM) or GGP (5 µM) for 1 hour followed by IFN-γ for 24 hours. The 
cells were then incubated with 0.5 μCi of sodium [1-14C] acetate for 3 hours. After 
incubation, cells were separated by centrifugation and collected. Lipids were extracted 
and separated into three major fractions: TPL, CHO and TAG using one-dimensional 
TLC, to measure the incorporation of radioactivity into individual lipid classes. The 
samples were counted in a Perkin-Elmer Tri-Carb 2800 TR liquid scintillation counter. 
This experiment was performed only once with three replicates so no statistics was 
performed. 
As shown in Figure 5.3, IFN-γ produced slight increase in the labelling of TPL 
and CHO compared to the control DMSO, whereas there was a slight reduction in the 
synthesis of TAG. Addition of Simvastatin resulted in a 50% reduction in CHO 
biosynthesis as expected. Such a reduction was maintained following addition of 
either FPP or GGP together with Simvastatin. On the other hand, the levels of TPL or 
TAG radiolabelling observed in IFN-γ treated cells changed only slightly in the 
presence of Simvastatin, FPP or GGP. 
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Figure ‎0.3: Effect of IFN-γ, Simvastatin, FPP or GGP on the relative incorporation of [1-
14
C] acetate into three major lipid classes: total polar lipids (TPL); free cholesterol 
(CHO) and triacylglycerols (TAG) in THP-1 macrophages. 
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5.4 Effect of IFN-γ and Simvastatin on FA distribution into polar lipids and 
TAG in THP-1 macrophages 
THP-1 macrophages were treated with Simvastatin (40 µM) for 1 hour and then 
IFN-γ was added to the cells for 24 hours (cells incubated with DMSO or IFN-γ alone 
was included for comparison). Lipids were extracted and then separated into polar 
lipids and TAG using thin-layer chromatography. FAs of both fractions were analysed 
by gas chromatography. Figure 5.4 shows changes in FAs profile in polar lipid fraction 
(see Table 5.1 for list of FAs). In this fraction, three fatty acids were dominant: palmitic 
(C16:0), oleic (C18:1n9) and stearic (C18:0). Their relative amounts were around 20% 
of the total FA. The amounts of linoleic (C18:2n6), vaccenic (C18:1n7) and 
arachidonic (C20:4n6) acids were found in the relative amounts that did not exceed 
10%. Long chain polyunsaturated fatty acids (LCPUFA), EPA (C20:5n-3), DHA 
(C22:6n3) and DPA (C22:5n-3) were present in this fraction varying from 2% to 5% of 
total FAs. No significant changes in fatty acid composition were produced with the 
various treatments from four independent experiments. 
Figure 5.5 shows the FA profile in TAG fraction from THP-1 macrophages. In 
this fraction, palmitic (C16:0) and oleic acids (C18:1n9) were the major FA reaching 
up to 20-25% of total FA. Stearic (C18:0), vaccenic (C18:1n7) and linoleic acids 
(C18:2n6) were present in TAG at the levels of around 10% of total FA. The relative 
amounts of arachidonic acid (C20:4n6) and DPA (C22:5n3) were lower in TAG in 
comparison to TPL whereas the levels of other LCPUFA were similar to that found in 
the fraction of TPL. Similar to polar lipids, no significant changes in fatty acid 
composition were produced by any of the treatments (see Table 5.1 for list of fatty 
acids). 
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Table ‎0.1: List of FAs, their common names and abbreviations. 
Fatty acid profile Common name Abbreviation 
C14:0 Myristic acid  
C16:0 Palmitic acid (Palmitate)  
c16:1n7 Palmitoleic acid  
c16:1n9 Palmitoleic acid  
C18:0 Stearic acid  
C18:1n7 cis-Vaccenic acid  
C18:1n9 Oleic acid  
C18:2n6 Linoleic acid LA 
C18:3n3 Alpha-linolenic acid ALA 
C18:3n6 Gamma-linolenic acid GLA 
C18:4n3 Stearidonic acid SDA 
C20:1n9 Eicosenoic acid  
C20:2n6 Eicosadienoic acid EDA 
C20:3n3 Eicosatrienoic acid ETE 
C20:3n6 Dihomo-gamma-linolenic DGLA 
C20:4n3 Eicosatetraenoic acid ETA 
C20:4n6 Arachidonic acid AA 
C20:5n3 Eicosapentaenoic acid EPA 
C22:0 Behenic  
C22:5n3 Docosapentaenoic acid DPA 
C22:6n3 Docosahexaenoic acid DHA 
C24:0 Lignoceric acid  
C24:1n6 Nervonic acid  
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Figure ‎0.4 Effect of IFN-γ and Simvastatin on FA distribution (% of total fatty 
acids) in polar lipids from THP-1 cells.  
FAs are indicated with the number before the colon showing the number of carbon atoms, the 
figure afterwards denoting the number of double bonds followed by the position of the first 
double bond. Data are means ± SD from four independent experiments. Statistical analysis 
was performed using one-way ANOVA with Tukeys post-hoc analysis 
 
Figure ‎0.5: Effect of IFN-γ and Simvastatin on FA distribution (% of total fatty acids) in 
TAG from THP-1 cells.  
FAs are indicated with the number before the colon showing the number of carbon atoms, the 
figure afterwards denoting the number of double bonds followed by the position of the first 
double bond. Data are mean ± SD of four independent experiments. Statistical analysis was 
performed using one-way ANOVA with Tukeys post-hoc analysis.  
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5.5 Effects of IFN-γ and Simvastatin on FA distribution in polar lipids and TAG 
from RAW 264.7 cells 
RAW264.7 macrophages were pre-treated with DMSO vehicle or Simvastatin (40 
µM) for 1 hour and then incubated for 24 hours with IFN-γ. Lipids were extracted and 
were separated into three fractions: PL; TAG; and CE. However, only the data for PL 
and TAG are presented as the CE were at undetectable levels. Figure 5.6 shows the 
changes in FAs from PL in RAW264.7 cells.  
The major FAs were palmitic (C16:0), stearic (C18:0), oleic (C18:1n9) and 
vaccenic (C18:1n7) acids varying from 15% to 29% of total FA. Palmitoleic (C16:1n9) 
and linoleic acids (C18:2n6) were also present in this fraction at the level of around 
5%. Among LCPUFA, arachidonic acid (C20:4n6), DHA (C22:6n3) and DPA 
(C22:5n3) were the major FAs and their levels were 4-6%. The relative amounts of 
other fatty acids did not exceed 2%. Similar to THP-1 macrophages, no significant 
changes were observed with any of the treatment. 
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Figure ‎0.6: Effect of IFN-γ and Simvastatin on FA distribution (% of total FAs) in polar 
lipids from RAW264.7 cells.  
FAs are indicated with the number before the colon showing the number of carbon atoms, the 
figure afterwards denoting the number of double bonds followed by the position of the first 
double bond. Data are mean ± SD of three independent experiments. Statistical analysis was 
performed using one-way ANOVA with Tukeys post-hoc analysis. 
 
 
 
Figure ‎0.7: Effect of IFN-γ and Simvastatin on FA distribution (% of total FAs) 
in triacylglycerols from RAW264.7 cells.  
FAs are indicated with the number before the colon showing the number of carbon 
atoms, the figure afterwards denoting the number of double bonds followed by the 
position of the first double bond. Data are mean ± SD of three independent 
experiments. Statistical analysis was performed using one-way ANOVA with Tukeys 
post-hoc analysis. 
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Figure 5.7 indicates changes in FAs profile in TAG. The major FAs were 
palmitic (C16:0), stearic (C18:0) and two isomers of C18:1 fatty acids: oleic (C18:1n9) 
and vaccenic (C18:1n7) acids. In TAG fraction, linolenic acid (C18:2n6) was found in 
the relative large amount (4% of total fatty acids) in comparison to the fraction of polar 
lipids. Only three LCPUFA were present in TAG from RAW 262.7 cells: arachidonic 
acid (C20:4n6), DHA (C22:6n3) and DGLA (C20:3n6). Their levels did not exceed 3-
5%. Similar to THP-1 macrophages, no significant changes were observed with any of 
the treatments. 
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5.6 Discussion 
5.6.1 The effect of Simvastatin on the synthesis of the major lipid 
classes and cholesterol in the THP-1 cell line 
Atherosclerosis is an inflammatory disease of the vasculature and 
characterised by lipid accumulation within the walls of arteries (Lusis et al., 2004). 
Statins, the most widely used drugs for the treatment of hypercholesterolemia, act 
through the inhibition of the HMG-CoA reductase, a key enzyme in cholesterol 
biosynthesis. Statins have been shown to decrease cholesterol level both in vitro and 
in vivo (Jenkins et al., 2005).  
In this chapter, the effect of Simvastatin on the synthesis of the major lipid 
classes in THP-1 cells was studied when the cells were treated with IFN-γ. In addition, 
two intermediates of the isoprenoid biosynthesis, FPP and GGP, were used in order 
to better understand the mechanisms involved in the reduction of intracellular 
cholesterol by Simvastatin treatment.  
IFN-γ produced a slight increase in total free cholesterol levels, which were 
reduced by almost 50% in the presence of Simvastatin (Figure 5.3). The labelling of 
the total PLs was not affected by IFN-γ whereas synthesis of TAG was slightly 
decreased under this treatment. Simvastatin alone, as well as in combination with 
each intermediate, slightly increased the incorporation of radiolabel into PLs but did 
not affect the synthesis of TAG. In some previous work where an effect of simvastatin 
on de novo lipid and cholesterol synthesis has been studied in THP-1 cells, it has 
been shown that treatment with Simvastatin (5 µM, 24 hours) caused a significant (up 
to 90%) inhibition of cholesterol synthesis (Risé et al., 1997). Synthesis of neither PLs 
nor TAG from radiolabelled acetate was affected in that study that may be due to the 
lower concentration of Simvastatin used as well as an additional effect of IFN-γ. 
However, when [3H] glycerol was used as a radiolabel, an increase in the labelling of 
TAG with a concomitant reduction of PL synthesis was noted (Risé et al., 1997). In 
 174 
 
hepato carcinoma cell line Hep G2, simvastatin also inhibited the synthesis of 
cholesterol and cholesterol esters from [14C] acetate, but did not affect phospholipid, 
free FAs and TAG synthesis (Nagata et al., 1990).   
In this study, the addition of downstream metabolites of HMG-CoA reductase, 
FPP or GGP, did not reverse the inhibitory effect of Simvastatin on cholesterol 
synthesis. These finding demonstrate that the reduction in intracellular cholesterol 
levels are due to inhibition of HMG-CoA reductase and not because of an effect on 
signalling pathways due to depletion of intracellular lipid metabolites. Moreover, 
isoprenoid intermediates have been shown to affect the activation of receptors, which 
are involved in the regulation of cellular cholesterol metabolism, e.g. PPARα, PPARγ 
and LXR (Argmann et al., 2003). It has been also shown that Simvastatin affects 
PUFA metabolism in THP-1 cells, and this effect is partly prevented by mevalonate 
and GGP, but not FPP (Risé et al., 1997). Thus, the pathways for cholesterol and 
PUFA synthesis have been suggested to be mutually modulated (Risé et al., 1997).  
5.6.2 Effects of IFN-γ and Simvastatin on fatty acid distribution in polar 
and TAG lipids from THP-1 and RAW 264.7 Cells 
In this work, the fatty acid composition of the two major lipid classes, PLs and 
TAG, have been studied in order to reveal some possible changes as a result of IFN-γ 
and/or Simvastatin treatment. Previously, it had been shown that IFN-γ influenced the 
composition or synthesis of phospholipids in different cell types (Mattila et al., 1993). 
An increased amount of linoleic and arachidonic acids in phosphatidylethanolamine 
(PE) in both murine peritoneal macrophages and macrophage-like cell line (P388D) 
have been demonstrated by IFN-γ (Jackson et al. 1992). The same group later 
showed a redistribution of linoleic acid among different lipid classes and found no 
increase in incorporation into saturated stearic acid in IFN-γ-activated cells (Darmani 
et al., 1994). Also, the liberation of arachidonic acid from phospholipids as well as a 
release of linoleic acid from PE in BCG-sensitive murine peritoneal macrophages 
have been shown as an effect of endotoxin (Stark et al. 1990). The authors suggested 
that IFN-γ may increase host susceptibility to endotoxin by increasing the level of 
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PUFA in the membrane lipids of macrophages which may be metabolised to produce 
biologically active metabolites: mediators and signals related to defence reactions 
(Darmani et al. 1994). 
In the present study, no statistically significant effect of IFN-γ on FA composition 
of either membrane PLs or stored TAG was found. This maybe potentially because of 
many possible factors/differences related to the treatment, culturing conditions and 
data analysis. For example the IFN-γ treatment time are different than others previous 
studies that used for 18 hours, 24 hours, and 48 hours. Another reason would be that 
we studied the actual relative concentrations of individual FAs but not a turnover of 
specifications, e.g. arachidonic acid. In addition, combining the data from four 
independent experiments resulted in relatively large standard deviations that did not 
show any statistically significant differences between controls and the treatment 
groups.  
Statins affect not only cholesterol biosynthesis but also PUFA production and it 
has been shown that  they cause an elevated accumulation of arachidonic acid (a 
conversion product of linoleic acid) in vitro and in vivo (Risé et al., 1997; Risé et al., 
2001).  For Simvastatin, this has been demonstrated using a range of concentrations 
from 0.1 to 0.5 µM. It is interesting that an increased linoleic acid conversion was 
accompanied by a stronger inhibition of cholesterol synthesis (Risé et al., 2003).  In 
more recent studies, this group showed that Simvastatin increased the expression of 
Δ5 desaturase, an enzyme directly involved in the production of arachidonic acid 
production from C20:3 FAs (Risé et al., 2007).These previous studies on the effects of 
Simvastatin and PUFA biosynthesis were carried out using radiolabelled FA 
precursors, e.g. radiolabelled linoleic acid. In that case, a turnover of a fatty acid in its 
metabolic product would take only few hours whereas in the case of our study, more 
time was required to show the differences at the level of actual FA concentrations. 
IFN-γ was found to increase PUFA profile in peritoneal macrophages (Jackson et al. 
1992). Similarly, IFN-γ increased the percentage of C18:2n6 in TAG of RAW264.7 
macrophages though this failed to reach significance (Figure 5.7). Overall, the precise 
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reasons for the differences seen with previous studies are unclear but could represent 
variations between cell line and primary cultures and also differences in treatments 
and time points. 
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Chapter 6: General Discussion 
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6.1 General Discussion: 
Atherosclerosis is a disorder of large and medium arteries and a major cause of 
CD. It’s a progressive inflammatory disorder that’s regulated by cytokines at all 
stages. Several cytokines are released at different stages of the disease and have 
been studied in relation to them being pro- or anti-atherogenic. Pro-atherogenic 
cytokines including TNF-, IFN-, IL-1, IL-17 and IL-12, are observed in 
atherosclerosic lesions whereas IL-10, IL-4, IL-33 and TGF- are anti-inflammatory 
cytokines generally present at lower levels (McLaren et al. 2011; Ait-Oufella et al. 
2011). 
Currently, statins are the most effective drugs used in the prevention and 
treatment of atherosclerosis and its adverse complications. Although statins are 
mainly used to lower circulating levels of LDL-cholesterol by inhibiting HMG-CoA 
reductase, they have multiple pleiotropic effects such as acting in an anti-inflammatory 
manner (Table 6.1). The anti-inflammatory actions of statins are not fully understood 
particularly in relation to newer cytokines such as TL1A and IL-17 along with classical 
cytokines such as IFN-γ.  Thus, the work presented in this thesis concentrated on 
such studies in relation to the actions of TL1A, IL-17A and IFN-γ in the first 
experimental chapter and after this it was decided to focus on the inhibitory action of 
Simvastatin on IFN-γ signalling. The studies were carried out on THP-1 macrophages, 
RAW 264.7 cells and primary HMDMs. 
The role of IFN-γ in the progression of atherosclerosis is still debatable due to 
its dual action. Although IFN-γ is known to be a pro-inﬂammatory cytokine, it also 
demonstrates some anti-inﬂammatory properties (Mühl and Pfeilschifter 2003). The 
anti-inflammatory role of IFN-γ includes inhibition of macrophage LPL expression and 
the oxidation of LDL (Jonasson et al., 1990; Hughes et al., 2002). IFN-γ has been 
shown to also to control many features of atherosclerosis such as foam cell formation, 
the adaptive Th1 speciﬁc immune response and plaque development (McLaren and 
Ramji 2009). In mouse model systems, IFN-γ has been demonstrated to decrease 
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cholesterol efﬂux from peritoneal macrophages by inhibiting ABCA1 expression 
(Panousis and Zuckerman, 2000). Overall, the proatherogenic activities of IFN-γ is 
associated with the stimulation of foam cell formation through the induction of 
cholesterol uptake and the reduction of cholesterol efﬂux, which consequently disrupts 
cholesterol homeostasis (McLaren and Ramji, 2009). In addition, IFN-γ facilitates 
monocyte inﬁltration into the atherosclerotic lesion by augmenting the expression of 
ICAM-1 and VCAM-1 in both ECs and SMCs (Li et al., 1993; Chung et al., 2002). A 
number of studies have also found that IFN-γ plays a significant role in reducing the 
stability of the fibrous cap around atherosclerotic plaques (Gupta et al., 1997; 
Hansson and Libby, 2006). Furthermore, IFN-γ enhances the activity of TF, which 
stimulates thrombosis in contact with blood (Nakagomi et al., 2000). 
Compelling evidence has shown that statin therapy influences IFN-γ production 
and signalling (Chung et al., 2002; Schönbeck and Libby, 2004; Hakamada-Taguchi 
et al., 2003). For example, Atorvastatin and Cerivastatin have shown the ability to 
inhibit the Th1 immune response by reducing the secretion of IFN-γ, along with other 
Th1 cytokines like IL-2, from activated T-lymphocytes and by promoting the release of 
Th2 cytokines like IL-4 (Schönbeck and Libby, 2004; Hakamada-Taguchi et al., 2003). 
Simvastatin and Fluvastatin have also been found to decrease IFN-γ release from 
phytohemagglutinin-stimulated lymphocytes in patients with primary type II 
dyslipidemia (Okopień et al., 2004). 
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Table 6.1: Effect of statins on inflammatory biomarkers. 
Type of Statin Effect of Statin Reference 
Pravastatin and 
Simvastatin 
Results in rapid and significant 
improvement in endothelial dysfunction 
in patients with high cholesterol. 
(Mason, 2003; Wolfrum et al., 
2003). 
Atorvastatin Decreases the levels of ICAM-1 in 
patients with heart failure from left 
ventricular remodeling. 
(Tousoulis et al., 2013). 
Simvastatin Decreases MCP-1, MIP-1α and β. (Veillard et al., 2006). 
Atorvastatin  Reduces post-ischemic brain damage 
and improves neurological outcome by 
inhibiting oxidative stress and 
inflammatory responses. 
(Saito et al., 2014). 
Simvastatin Has anti-inflammatory effects in patients 
with rheumatoid arthritis. 
(Cojocaru et al., 2013). 
Simvastatin Reduces IL-8, IL-6 and MCP-1 levels in 
patients with high cholesterol. 
(Rezaie-Majd, 2002). 
Simvastatin Inhibits the proliferation, and induces 
apoptosis, of human lung cancer cells. 
(Yu et al., 2013) 
Atorvastatin  Reduces levels of CRP in patients with 
type 2 diabetes. 
(Sathyapalan et al., 2010) 
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6.2 Anti–inflammatory effects of statins and clinical outcomes 
 A number of large randomised clinical studies have shown that the beneficial 
effects of statins are beyond lowering cholesterol level at reducing incidents of CVD 
(Sacks et al., 1996; Downs et al., 1998). For example, the Air Force/Texas Coronary 
Atherosclerosis Prevention Study (AFCAPS/TexCAPS) trial demonstrated that 
lovastatin reduced cardiovascular events in patients with low LDL cholesterol and high 
CRP levels, whereas it had no clinical benefit in patients with both low LDL cholesterol 
and low CRP levels (Downs et al., 1998). These findings suggested that patients with 
inflammatory disease (i.e. increased CRP levels) could constitute an additional group 
that could benefit from statin treatment, irrespective of their baseline LDL cholesterol 
levels. Moreover, the effect of statins treatment is not just limited to the reduction of 
CHD risk, but it also extends to reducing the risk of stroke (Byington et al.,2001; 
Amarenco et al.,2007). In the SPARCL (Stroke Prevention by Aggressive Reduction in 
Cholesterol Levels) trial, high dose of Atorvastatin treatment (80mg/day) in patients 
with previous history of cerebrovascular accident (CVA) but without known risk of 
CHD improved cardiovascular outcomes. After a follow up of nearly five years, 
Atorvastatin reduced ischemic stroke risk by 33% and risk of major CHD by 37% 
(Amarenco et al., 2007). 
The MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol 
Lowering) study provided further evidence on the anti-inflammatory effects of statins 
in high risk subjects (Schwartz et al., 2001). Treatment with high dose of Atorvastatin 
(80mg/day) for 16 weeks in patients with unstable angina or recent MI showed 
significantly reduction in cardiac events, particularly symptomatic ischemia (Schwartz 
et al., 2001). This population had low baseline LDL cholesterol levels (124mg/dL) that 
were significantly reduced at 16 weeks (from 124 to 72mg/dL). Atorvastatin also 
reduced the levels of inflammatory biomarkers including CRP and serum amyloid A 
which are independent risk predictors of stroke (Kinlay et al., 2003; Kinlay et al., 
2008).  
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The timing and dosage selection of statins is also crucial in controlling anti-
inflammatory effects post-acute MI event (Sposito et al., 2011). For example, 
additional administration of high-dose Atorvastatin before percutaneous coronary 
intervention (PCI) further reduced periprocedular myocardial injury and 30-day 
cardiovascular morbidity in patients who were already on chronic statin treatment (Di 
Sciascio et al.,2009). 
These important findings provide strong evidence that administration of statin 
therapy could be beneficial for patients with normal cholesterolemia for the prevention 
of CHD based on their anti-inflammatory, plaque stabilising and overall vasoprotective 
effects. Statins therapy could also be extended to individuals who are at great risk, or 
have had a previous history, of CVA.  
In the light of current extensive experimental evidence, statins also seem to be 
an attractive option for therapy of patients with autoimmune or inflammatory diseases, 
indeed clinical evidence has demonstrated that statins have a potent ability to be 
beneficial in a number of pathological disorders including osteoporosis, Alzheimer’s 
disease, Parkinson’s disease, multiple sclerosis and rheumatic diseases, all of which 
involve inflammatory responses (Paraskevas et al., 2007). Statins administration post 
lung transplantation has also been associated with improved survival and improved 
grafted lung function (Li et al., 2011). Additionally, combining Rosuvastatin with 
indomethacin treatment in patients with acute pericarditis resulted in greater reduction 
in CRP levels; pericardial effusion and ST segment normalisation, though it did not 
reduce the hospitalisation period (Di Pasquale et al., 2007).  
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6.3 Results and Perspective 
6.3.1 The effect of statins on the IFN-γ induced mRNA expression of 
MCP-1 and ICAM-1 
The result of this study found that IFN-γ induced the expression of the MCP-1 
and ICAM-1 genes in THP-1 macrophages, which was inhibited by the action of 
Simvastatin (Figures 3.5 and 3.6). These results in are in agreement with previous 
studies in a wide range of cell types (Zhou et al, 2001; Martin-Ventura, 2009; Chang 
et al, 2002). Similar findings have also been found in previous studies that 
demonstrated that statins attenuate the expression of ICAM-1 induced by IFN-γ in the 
ECV304 cell line (Chung et al, 2002).  
In order to examine whether the results obtained are peculiar to Simvastatin, 
representative experiments were carried out using Atorvastatin. The data showed that 
Atorvastatin attenuated the IFN-γ induced expression of MCP-1 and ICAM-1 (Figures 
3.12 and 3.13). As there are no studies that have examined the effect of Atorvastatin 
on the inhibition of IFN-γ induced expression of MCP-1 and ICAM-1, it is not possible 
to make any comparisons. In swine, Martinez-Gonzalez and colleagues (2001) found 
that Atorvastatin reduced the expression of MCP-1. This indicates that downregulation 
of MCP-1 expression by statins could reduce the inflammation within the vascular wall 
and inhibit the progression of atherosclerotic lesions. Overall, the results in this 
chapter suggest that statins have an anti-inflammatory and immunomodulatory effect 
in human macrophages. This may be useful for patients with inflammatory disease 
who could benefit from taking statins, which may attenuate or inhibit the sources of 
inflammation. 
 184 
 
6.3.2 Effect of TL1A on ApoE mRNA expression 
The results of this experiment demonstrated that TL1A decreased the expression of 
ApoE (Figure 3.11). However, when THP-1 macrophages were treated with 
Simvastatin there was no further change observed in the expression of ApoE. A 
similar finding has been reported by McLaren and colleagues (2010a) who showed 
that TL1A significantly decreased the expression of ApoE in THP-1 macrophages and 
HMDMs. However, the action of Simvastatin on TLA1-mediated regulation of ApoE 
expression has previously not been analysed so further studies will be required for 
confirmation, particularly in other macrophage systems such as primary cultures
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6.3.3 The effect of metabolites of cholesterol biosynthesis pathway on 
the IFN-γ induced MCP-1 mRNA expression 
In the current study, Simvastatin was found to inhibit the IFN-γ induced 
expression of MCP-1 mRNA expression and this inhibition was reversed, at least in 
part, by the addition of isoprenoid intermediates FPP and GGP in THP-1 
macrophages. Statins are potent inhibitors of the endogenous mevalonate pathway 
and also play a role in the inhibition of biosynthesis of cholesterol and isoprenoid 
intermediates including GGP and FPP (Goldstein and Brown 1990). Similar findings 
have been reported in a study by Cakmak et al. (2012) who found that addition of FPP 
and GGP in endometritic mice cells reversed the effect of Simvastatin on constitutive 
MCP-1 expression. Another study by Lee and colleagues (2008) in RAW 264.7 cells 
demonstrated that mevalonate and GGP reversed the Simvastatin-mediated inhibition 
of IFN-γ induced CIITA mRNA expression. These findings suggest that isoprenoid 
generation through the mevalonate pathway may be one of the potential mechanisms 
for regulation of MCP-1 expression by statins in THP-1 macrophages and 
atherosclerosis. 
 
6.3.4 Simvastatin inhibits the IFN-γ induced STAT1 phosphorylation in 
THP-1 macrophages and primary HMDMs 
In this study, Simvastatin inhibited the IFN-γ-induced STAT1 phosphorylation on Ser 
727 and Tyr 701 (Figures 4.4 and 4.5). IFN-γ controls many steps in the pathogenesis 
of atherosclerosis, including the recruitment of inflammatory cells to the activated 
endothelium, foam cell formation, apoptosis and plaque stability (McLaren and Ramji, 
2009; Li et al. 2010). The JAK-STAT pathway plays an important part in IFN-γ 
signalling (McLaren and Ramji 2009). Statins have recently been found to exert 
profound anti-inflammatory and protective effects in the development of 
atherosclerosis. Despite their well established significance in inflammatory responses 
and potential clinical benefits in atherosclerosis, the molecular mechanisms 
underlying such anti-inflammatory and athero-protective effects remain poorly 
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understood, particularly in relation to IFN-γ actions and the JAK-STAT pathway. The 
findings of the current study are consistent with a study by Lee and colleagues (2007) 
who showed that Simvastatin inhibits STAT1α at transcriptional and protein levels in 
RAW264.7 macrophages. Moreover, a study by Townsend and colleagues (2004) 
found that in primary microglial cells, Atorvastatin (10 µM) inhibited Ser 727 
phosphorylation of the STAT1 protein by IFN-γ (30 minutes). However, other studies 
have not found an effect of Simvastatin on STAT1 phosphorylation (Lee et al. 2007). 
For example, Simvastatin does not affect the IFN-γ-induced STAT1 phosphorylation in 
human microvascular endothelial cells (Sadeghi et al. 2001). In addition, the results in 
this study are different from those reported by Li et al. (2011) in THP-1 macrophages 
where it was demonstrated that Simvastatin had no effect on STAT1 phosphorylation. 
Although the exact reasons are unclear, this may reflect the use of a lower 
concentration of Simvastatin (10 µM) or a reduced treatment period with IFN-γ (30 
minutes) (Li et al. 2011). Thus, the effect of Simvastatin on STAT1 phosphorylation in 
macrophages might be dependent on the concentration of the statin or the incubation 
time with the cytokine. Further dose response and time course experiments will be 
required to address this issue further. Such studies will not only enhance current 
understanding of the molecular mechanisms underlying the anti-inflammatory and 
atheroprotective effects of statins, but may also benefit the development of effective 
and safe therapeutic intervention for atherosclerosis in the future 
6.3.5  Simvastatin attenuates the IFN-γ induced expression of MCP-1 
and ICAM-1 in primary HMDMs and RAW 264.7 cells 
To further confirm that the results obtained in THP-1 macrophages are not 
peculiar to the cell line, representative experiments were performed in primary 
cultures of HMDMs. Simvastatin inhibited the IFN-γ induced expression of MCP-1 and 
ICAM-1 mRNA levels in both Raw 264.7 and primary HMDMs (Figures 4.6, and 4.10). 
A number of studies have previously shown conservation of responses between THP-
1 macrophages and primary HMDMs (McLaren et al., 2010a; McLaren et al. 2010b). 
Kota et al. (2006) have also found that IFN-γ induced MCP-1 gene expression in RAW 
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264.7 cells. A study by Romano et al (2000) showed that Simvastatin and Lovastatin 
decreased MCP-1 production in peripheral blood mononuclear cells (PBMC) and ECs. 
Therefore, Statins are the principal therapy for hypercholesterolemia due to 
their ability to inhibit the synthesis of cholesterol with relatively mild side effects. 
However, mounting evidence suggests that some of the clinical benefits of statins may 
not be attributed to the lipid-lowering properties of these drugs. Our study suggests 
that statins also have anti-inflammatory properties in macrophages that aids in the 
treatment of atherosclerosis. 
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6.3.6 Effects of Simvastatin on MAPKs pathways 
6.3.6.1      Effect of Simvastatin on JNK-1 and -2 
The results from RT-qPCR showed that IFN-γ increased the expression of 
JNK-1 and -2 mRNA and this was not attenuated by treatment with Simvastatin 
(Figure 4.11). The effect of IFN-γ on the JNK pathway is well known as it has been 
found that IFN-γ and TNF-α work together to activate JNK/SAPK in a pancreatic β cell 
line (MIN6N8 cells) (Kim et al., 2005). Another study also showed weak activation of 
JNK1 in bone marrow–derived macrophages after treatment with IFN-γ for 2 hours 
whereas JNK2 was present at undetectable levels (Valledor et al.,2008). JNK2-/- mice 
in the ApoE-/- background have decreased foam cell formation compared to wild-type 
mice or JNK1-/- ApoE-/- mice, thereby showing an important role of JNK2 in 
atherosclerosis (Ricci et al. 2004). Another study by Jen and colleagues (2011) found 
that both the JNK inhibitor and Simvastatin together protected porcine islets from 
apoptosis. In hyperlipidaemic mice, Shen and colleagues (2011) showed that 
Atorvastatin also inhibits the JNK levels (along with ERK and p38) proteins (western 
blotting). Recently, Fluvastatin has been demonstrated to decrease phospho JNK 
levels in rat cardiomyocytes (Sakai et al. 2014). In the current study, we were not able 
to carry out such experiments because of problems with the antibody. Therefore, it 
maybe useful in the future to try another source for the antibody, and also different cell 
types because various cells respond differently.  
 
6.3.6.2      Effect of Simvastatin on c-Jun 
6.3.6.2.1 Effect of Simvastatin on c-Jun 
The results in Chapter 4 showed that IFN-γ increased the expression of c-Jun 
(Figure 4.13). A similar finding has been reported in a study by Rubio (1997) that 
showed that IFN-γ induces the expression of c-Jun in astrocytes. Our experiment 
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showed that Simvastatin had no effect on the IFN-γ induced expression of c-Jun 
mRNA levels (Figure 4.13). In contrast, Fromigué et al. (2008) used another type of 
statin (i.e. Atorvastatin) and found that it significantly decreased c-Jun nuclear content 
in human and murine osteosarcoma cells (Fromigué et al. 2008). Another study also 
reported that Lovastatin and Simvastatin reduced c-Jun expression in prostate cancer 
cells (Hoque et al., 2008). Recently, a study by Sakai et al. (2014) showed that 
Fluvastatin decreased c-Jun mRNA expression and phospho-c-Jun in rat 
cardiomyocytes. The results of western blotting showed that IFN-γ had no effect on 
the induction of phospho c-Jun levels in THP-1 macrophages (Figure 4.14). In 
contrast, Gough and colleagues (2007) found that IFN-γ activated c-Jun in wt MEFs. 
6.3.6.2.2 Effect of simvastatin on ERK-1 and -2 (p44/42) 
The results of this experiment found that the phosphorylation-mediated 
activation of ERK-1/2 was decreased by Simvastatin (40 µM) (Figure 4.17). IFN-γ 
stimulates the phosphorylation of ERK-1 and -2 in wt MEFs (Gough et al. 2007). A 
similar finding was reported in a study by Zhang et al. (2010) who found that 
Mevastatin decreased the phosphorylation of ERK-1/2 in a dose dependent manner in 
cancer cells (SACC cells). Different types of statins such as Simvastatin, Mevastatin 
and Fluvastatin have been found to inhibit ERK-1/2 phosphorylation in C6 glioma cells 
(Yanae et al. 2011). Another study found that Atorvastatin inhibited ERK activation in 
neonatal rat cardiomyocytes (Liao et al. 2008). In RAW264.7 cells, Shao and 
colleagues (2012) reported that Atorvastatin inhibits ERK-1/2 phosphorylation. A very 
recent study showed that Simvastatin reduced phospho-ERK and -p38 levels in 
human platelet suspensiosn (Du et al. 2014). In contrast, another study used a 
different type of statin (i.e. Lovastatin) and found that Lovastatin did not decrease 
phospho ERK levels in microglial cells (Townsend et al., 2004). Overall, the results of 
our study suggest that statins may be potentially useful as anti-atherogenic agents in 
the treatment or slowing the progression of atherosclerosis via modulation of ERK 
activity. 
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6.3.6.2.3 Effect of Simvastatin on p38 
IFN-γ increased the expression of p38 mRNA levels and Simvastatin had no 
effect on this (Figure 4.18). An early study by Lehner and collegues (2002) showed 
that the expression of IFN-γ was decreased in mice lacking MAPK-activated protein 
kinase 2 (MK2), which is a kinase activated by p38. Other studies also showed that 
IFN-γ treatment strongly activates p38 in primary BMDM (Valledor et al., 2008), 
Simvastatin showed no effect on the IFN-γ induced p38 mRNA expression (Figure 
4.20). However, it significantly decreased the phosphorylation and the activation of the 
corresponding protein (Figure 4.20). This finding is consistent with Lee and colleagues 
(2010) who showed that Simvastatin decreased p38 phosphorylation in suspension of 
human platelets. However, Zhang et al. (2010) reported a conflicting result and found 
that treatment of SACC cells with Mevastatin increased p38 phosphorylation. This 
could be as a result of using a different type of statin, which may have a different 
action, or represent cell-specific effects. 
Overall, studies in Chapter 4 provide a new insight into the anti-atherogenic 
mechanisms of Simvastatin action and this may help for clinical refinements in the 
future. 
6.3.7 The effect of Simvastatin on the synthesis of the major lipid 
classes and cholesterol in the THP-1 cell line 
The effect of Simvastatin on the synthesis of the major lipid classes in THP-1 
cells was examined when the cells were treated with IFN-γ. In addition, two 
intermediates of the isoprenoid biosynthesis, FPP and GGP were used in order to 
better understand the mechanisms involved in the reduction of intracellular cholesterol 
by Simvastatin treatment. IFN-γ produced a slight increase in total free cholesterol 
levels, which were reduced by almost 50% in the presence of Simvastatin (Figure 
5.3). The labelling of the total polar lipids was not affected by IFN-γ whereas synthesis 
of TAG was slightly decreased under this treatment (Figure 5.3). Simvastatin alone, 
as well as in combination with each intermediate, slightly increased the incorporation 
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of radiolabel acetate into polar lipids but did not affect the synthesis of TAG. In some 
previous work where an effect of Simvastatin on de novo lipid and cholesterol 
synthesis has been studied in THP-1 cells, it was shown that treatment with this statin 
(5 µM, 24 hours) caused a significant (up to 90%) inhibition of cholesterol synthesis 
(Risé et al., 1997). Synthesis of neither PLs nor TAG from radiolabelled acetate was 
affected in that study and this may potentially be explained by the lower concentration 
of Simvastatin used as well as an additional effect of IFN-γ. However, when [3H] 
glycerol was used as a radiolabel, an increase in the labelling of TAG with a 
concomitant reduction of polar lipid synthesis was noted (Risé et al., 1997). In 
hepatocytic cell line Hep G2, Simvastatin also impaired the synthesis of cholesterol 
and CE from [14C] acetate, but had no influence on phospholipid, free FAs and TAG 
synthesis (Nagata et al., 1990).   
In this study, the addition of downstream metabolites of HMG-CoA reductase, 
FPP or GGP, did not reverse the inhibitory effect of Simvastatin on cholesterol 
synthesis (Figure 5.3). These findings demonstrated that the reduction in intracellular 
cholesterol levels are due to inhibition of HMG-CoA reductase and not as a 
consequence of an effect on signalling pathways due to depletion of intracellular lipid 
metabolites. Moreover, isoprenoid intermediates have been shown to influence 
activation of receptors, which are involved in the regulation of cellular cholesterol 
metabolism, e.g. PPARα, PPARγ and LXR (Argmann et al., 2003). It has been also 
shown that Simvastatin influenced PUFA metabolism in THP-1 cells, and this effect 
was partly prevented by mevalonate and GGP, but not FPP (Risé et al. 1997). 
Therefore, the pathways for cholesterol and PUFA synthesis have been suggested to 
be mutually modulated (Risé et al., 1997). 
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6.3.8 Effects of IFN-γ and Simvastatin on FA distribution in polar and 
TAG lipids from THP-1 and RAW 264.7 cells 
In the present study, IFN-γ showed no statistically significant effect on FA 
composition of either membrane PL or stored TAG and addition of Simvastatin had no 
further changes. This could be as a result of several possible factors/differences 
related to the treatment, culturing conditions and data analysis compared to previous 
study/studies (Neville et al., 2005). For instance, the time period of IFN-γ treatment 
was different than previous studies that included 18 hours, 24 hours and 48 hours 
(Spinelle-Jaegle et al., 2001; De Saint Jean et al., 1999). Another reason is that we 
studied the actual relative concentrations of individual FAs but not a turnover of some 
particular one, e.g. arachidonic acid. In addition, there were relatively large standard 
deviations in our studies that could have contributed to the non-significant results.  
In this study, the FA composition of the two major lipid classes, polar lipids and 
TAG, was investigated in order to identify possible changes as a result of IFN-γ and/or 
Simvastatin treatment. Previously, it has been shown that IFN-γ modulated the 
composition or synthesis of phospholipids in different cell types (Mattila et al., 1992). 
An increased amount of linoleic and arachidonic acids in  PE was observed in both 
murine peritoneal macrophages and macrophage-like cell line P388D by IFN-γ 
(Jackson et al. 1992). The same group later showed a redistribution of linoleic acid 
among different lipid classes and found no increase in  the incorporation of the 
saturated stearic acid in IFN-γ-activated cells (Darmani et al. 1994). Also, the 
liberation of arachidonic acid from phospholipids alongside a release of linoleic acid 
from PE in BCG-sensitive murine peritoneal macrophages was shown in response to 
endotoxin treatment (Stark et al. 1990). The authors suggested that IFN-γ may 
increase host susceptibility to endotoxin by augmenting the level of PUFA in the 
membrane lipids of macrophages which may be metabolised to produce biologically 
active metabolites: mediators and signals related to defence reactions (Darmani et al. 
1994). 
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Statins influence not only cholesterol biosynthesis but also PUFA production and it 
has been shown that they cause increased accumulation of arachidonic acid (a 
conversion product of linoleic acid) in THP-1 cells (Risé et al. 1997).  For Simvastatin, 
this has been demonstrated at a range of concentrations from 0.1 to 0.5 µM. It is 
interesting that increased linoleic acid conversion was accompanied by a stronger 
inhibition of cholesterol synthesis (Risé et al. 2003). In more recent studies, this group 
showed that Simvastatin increased the expression of Δ5 desaturase, the enzyme 
directly involved in the production of arachidonic acid from C20:3 (Risé et al. 2007). 
These previous experiments on the effects of Simvastatin and PUFA biosynthesis 
were carried out using radiolabelled FA precursors, e.g. radiolabelled linoleic acid. In 
that case, a turnover of a fatty acid in its metabolic product would take only few hours, 
whereas in the case of the present study, more time would be required to show the 
differences at the level of actual FA concentrations. 
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6.4 Future work 
The overall aim will be to delineate the molecular mechanisms underlying the action of 
statins. Some of the future aims and approaches are as follows: 
1. To further investigate the roles of the HMG-CoA reductase pathway and, in 
particular, small G-proteins in the Simvastatin-mediated attenuation of IFN-
γ induced expression of key genes implicated in atherosclerosis. The 
pleiotropic effects of statins are often mediated through the inhibition of a 
parallel pathway of isoprenoid synthesis (Lee et al., 2008; Zhou et al., 
2009). Isoprenoids constitute lipid attachments that allow membrane 
anchoring and activation of GTP-binding proteins of the Rho and Ras 
family, which then activate various downstream signalling pathways. 
Future studies will therefore first investigate whether this is also the case in 
relation to the actions of Simvastatin on the IFN-γ-regulated expression of 
key genes implicated in atherosclerosis. This will involve a combination of 
biochemical studies, use of pharmacological agents and RNA interference 
assays (RNAi) against the large number of potential monomeric G-
proteins. For example, the activation of such G-proteins and their inhibition 
by Simvastatin can be analysed by biochemical assays. In addition, 
studies can investigate whether inhibition or knockdown of such 
monomeric G-proteins affects IFN-γ regulated gene expression. In 
addition, the effect of over-expression/activation of such pathways in 
overcoming the Simvastain-mediated inhibition can be analysed.. 
2. To investigate whether PPARs are involved in the response. Statins have 
been found to activate MAPK cascades, which then leads to the activation 
of PPARs via the production of the endogenous ligand 15-deoxy-Δ12,14-
prostaglandin J2 (15d-PGJ2) through induced expression of Cox2 in Raw 
264.7 macrophages (Yano et al., 2007; Paumelle et al., 2007; Ramji, 
2009). 15d-PGJ2 activates PPARγ and also PPARα. Initial experiments will 
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determine whether knockdown of PPAR-α or –γ or both affects the 
Simvastatin-mediated attenuation of IFN-γ-induced expression of key 
genes (RT-qPCR) (the use of PPAR antagonists such as TOO70907 
represents an alternative that may be used for further confirmation –e.g. 
see Yano et al., 2007). Should a role for PPARs in the regulation of any 
genes be identified then the effect of Simvastatin on the following in 
vehicle- and IFN-γ treated cells will be determined: 
- Expression of PPAR-α and –γ (RT-qPCR and western blot analysis); 
simple addition of Simvastatin and IFN-γ and carry out RT-qPCR analysis 
for these mentioned genes as this study. 
- PPAR activity (transcription factor assay kit (Cayman Chemical) (Bujold et 
al., 2009). 
- Intracellular expression of 15d-PGJ2 (ELISA) (Yano et al., 2007; Bujold et 
al., 2009). 
- Increased expression of COX2 (RT-qPCR) and dependency of the 
responses on it (RT-qPCR analysis of gene expression detailed above 
following knockdown of COX2 and, if necessary for further confirmation, 
following treatment of the cells with a specific inhibitor (e.g. NS-398) (Yano 
et al., 2007; Bujold et al., 2009). 
3. To investigate globally the effect of Simvastatin on IFN-γ in macrophages. 
The studies in this thesis have been restricted to selective genes, such as 
MCP-1 and ICAM-1. It would be desirable to extend the findings at the cellular 
level. For example, the effect on the whole transcriptome could be determined 
by microarray analysis or RNA-seq analysis (Tisoncik et al., 2012; Dong et al., 
2013).  Also, the studies could be extended to protein levels (proteomics) and 
phospho-protein levels (Bose and Janes, 2013). 
4. Compare the expression of MCP-1 and ICAM-1 between healthy blood 
vessels and atherosclerotic blood vessels by immunohistochemistry and 
compare the results obtained with other cell types. 
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5. Examine the effect of statins on apoE‐ or LDLR‐deficient mice fed with 
an atherosclerotic diet, to elucidate the action on the expression of numerous 
genes in the pathogenesis of atherosclerosis in vivo.  
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